EISSN 2979-9139

Official Journal of
TURKISH
THORACIC SOCIETY

Thoracic
Research & Practice

Formerly Turkish Thoracic Journal



AVES

Volume 24 · Issue 2 · March 2023
thoracrespract.org

Thoracic Research & Practice

Official Journal of the Turkish Thoracic Society

EDITORS in CHIEF

Oğuz KILINÇ
Department of Chest Diseases, Dokuz Eylül University School of Medicine, İzmir, Turkey

İpek Kıvılcım OĞUZÜLGEN
Department of Pulmonary Diseases, Gazi University School of Medicine, Ankara, Turkey

EDITORS

Aylin ÖZGEN ALPAYDIN
Department of Chest Diseases, Dokuz Eylül University School of Medicine, İzmir, Turkey

Ege GÜLEÇ BALBAY
Department of Chest Disease, Düzce University School of Medicine, Düzce, Turkey

İpek ÇAYLI CANDEMİR
Ataturk Chest Diseases and Surgery Education and Research Hospital, Ankara, Turkey

Ufuk ÇAĞIRICI
Department of Chest Surgery, Ege University School of Medicine, İzmir, Turkey

Necati ÇITAK
Department of Thoracic Surgery, İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospita, İstanbul, Turkey

Aslı GÖREK DİLEKTAŞLI
Department of Chest Diseases, Uludağ University School of Medicine, Bursa, Turkey

Zuhal KARAKURT
Respiratory Intensive Care Unit, Süreyyapaşa Chest Diseases and Surgery Training and Research Hospital, İstanbul, Turkey

Leyla PUR ÖZYİĞİT
Department of Allergy and Immunology, University Hospitals of Leicester, Leicester, United Kingdom

Özge YILMAZ
Department of Pediatrics, Celal Bayar University School of Medicine, Manisa, Turkey

BIOSTATISTICAL CONSULTANT

Ahmet Uğur DEMİR
Department of Chest Diseases, Hacettepe University School of Medicine, Ankara, Turkey

Seval KUL
Department of Biostatistics and Medical Informatics, Gaziantep University School of Medicine, Gaziantep, Turkey

PUBLICATION COORDINATOR

Begüm ERGAN
Department of Chest Diseases, Dokuz Eylül University School of Medicine, İzmir, Turkey

AVES

Founder
İbrahim KARA

General Manager
Ali ŞAHİN

Finance Coordinator
Elif YILDIZ ÇELİK

Journal Managers
İrem SOYSAL
Bahar ALBAYRAK
Deniz KAYA
Irmak BERBEROĞLU

Publication Coordinators
Gökhan ÇİMEN
Arzu ARI
Alara ERGİN
Hira Gizem FİDAN
İrem ÖZMEN

Project Coordinators
Doğan ORUÇ
Sinem Fehime KOZ

Contact
Address: Büyükdere Cad. No: 105/9 34394 Mecidiyeköy, Şişli-İstanbul
Phone: +90 212 217 17 00
Fax: +90 212 217 22 92
E-mail: info@avesyayincilik.com

Thoracic Research & Practice
Official Journal of the Turkish Thoracic Society

INTERNATIONAL EDITORIAL BOARD

Ian M. Adcock
Cell and Molecular Biology Airways Disease Section, National Heart and Lung Institute, Imperial College London, United Kingdom

Piergiuseppe Agostoni
Department of Clinical Sciences and Community Health, Cardiovascular Section, Università di Milano, Milano, Italy

M. Selim Arcasoy
Pulmonary, Allergy, and Critical Care Division, Department of Medicine, Columbia University New York, USA

Philippe Astoul
Thoracic Oncology - Pleural Diseases - Interventional Pulmonology, Hôpital Nord - Chemin des Bourrely, Marseille, France

Ülkü Bayındır
Retired Faculty Member, Ege University School of Medicine, İzmir, Turkey

Dominique MA Bullens
Department of Immunology and Microbiology, KU Leuven Laboratory of Pediatric Immunology Division of Pediatrics, Leuven, Belgium

Richard Casaburi
Rehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA

Turgay Çelikel
Department of Chest Diseases, Marmara University School of Medicine, İstanbul, Turkey

Tansu Ulukavak Çiftçi
Department of Chest Diseases, Gazi University School of Medicine, Ankara, Turkey

Lütfi Çöplü
Department of Chest Diseases, Hacettepe University School of Medicine, Ankara, Turkey

Çağlar Çuhadaroğlu
Acıbadem Maslak Hospital, İstanbul, Turkey

Andrew J. Ghio
US Environmental Protection Agency Chapel Hill, North Carolina, USA

James E. Hansen
St. John's Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor- University of California at Los Angeles, Torrance, CA, USA

İlhan İnci
University Hospital Zurich, Department of Thoracic Surgery, Zurich, Switzerland

Oya İtil
Department of Chest Diseases, Dokuz Eylül University School of Medicine, İzmir, Turkey

A. Fuat Kalyoncu
Department of Chest Diseases, Hacettepe University School of Medicine, Ankara, Turkey

Fazilet Karakoç
Department of Child Chest Diseases, Marmara University Pendik Training and Research Hospital, İstanbul, Turkey

Ali Kocabaş
Department of Chest Diseases, Çukurova University School of Medicine, Adana, Turkey

Emel Kurt
Department of Chest Diseases, Osmangazi University School of Medicine, Eskişehir, Turkey

Atul Malhotra
Pulmonary and Critical Care, University of California San Diego, La Jolla, California, USA

Muzaffer Metintaş
Department of Chest Diseases, Osmangazi University School of Medicine, Eskişehir, Turkey

Zeynep Mısırlıgil
Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey

Nesrin Moğulkoç
Department of Chests Diseases, Ege University School of Medicine, İzmir, Turkey

Türk Toraks Derneği
Turkish Thoracic Society

Thoracic Research & Practice

Official Journal of the Turkish Thoracic Society

Dilşad Mungan
Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey

Gökhan M. Mutlu
Division of Pediatric Critical Care Medicine, Nortwestern University, Chicago, USA

Gül Öngen
Department of Chest Surgery, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey

Kent E. Pinkerton
University of California, Davis, Center for Health and the Environment, Davis, USA

Kannan Ramar
Division of Pulmonary and Critical Care Medicine, Center for Sleep Medicine, Mayo Clinic, Rochester, MN, USA

Joseph Roca
Instituto de Biología Molecular de Barcelona, CSIC, Baldiri Reixac, Barcelona, Spain

Israel Rubinstein
Section of Pulmonary, Critical Care, Sleep and Allergy Medicine, Department of Medicine, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA

Abdullah Sayıner
Department of Chest Diseases, Ege University School of Medicine, İzmir, Turkey

Z. Toros Selçuk
Department of Chest Diseases, Hacettepe University School of Medicine, Ankara, Turkey

Nadja Triller
Department of Pulmonary Medicine, University Pulmonary Clinic Golnik, Golnik, Slovenia

Haluk Türktaş
Department of Chest Diseases, Gazi University School of Medicine, Ankara, Turkey

E. Sabri Uçan
Department of Chest Diseases, Dokuz Eylül University School of Medicine, İzmir, Turkey

Karlman Wasserman
Respiratory and Critical Care Physiology and Medicine, Los Angeles Biomedical Research Institute Harbor-UCLA Medical Center, Torrance, California, USA

Mark Woodhead
Honorary Clinical Professor of Respiratory Medicine, Department of Respiratory Medicine, Manchester Royal Infirmary, Manchester, England

Thoracic Research & Practice
Official Journal of the Turkish Thoracic Society

ABOUT

About the Thoracic Research and Practice

Thoracic Research and Practice is a peer reviewed, open access, online-only journal published by the Turkish Thoracic Society.

Thoracic Research and Practice is a bimonthly journal that is published in English in January, March, May, July, September, and November.

Journal History

Thoracic Research and Practice started its publication life following the merger of two journals which were published under the titles "Turkish Respiratory Journal" and "Toraks Journal" until 2008. From 2008 to 2022, the journal was published under the title "Turkish Thoracic Journal". Archives of the journals were transferred to Thoracic Research and Practice.

Aims, Scope, and Audience

Thoracic Research and Practice aims to publish studies of the highest scientific and clinical value, and encourages the submission of high-quality research that advances the understanding and treatment of pulmonary diseases.

Thoracic Research and Practice covers a wide range of topics related to adult and pediatric pulmonary diseases, as well as thoracic imaging, environmental and occupational disorders, intensive care, sleep disorders and thoracic surgery, including diagnostic methods, treatment techniques, and prevention strategies. The journal is interested in publishing original research that addresses important clinical questions and advances the understanding and treatment of these conditions. This may include studies on the effectiveness of different treatments, new diagnostic tools or techniques, and novel approaches to preventing or managing pulmonary diseases.

Thoracic Research and Practice publishes clinical and basic research articles, reviews, statements of agreement or disagreement on controversial issues, national and international consensus reports, systematic reviews and meta-analyses, letters to the editor and editorials. Conference proceedings may also be considered for publication.

The target audience of the journal includes healthcare professionals and researchers who are interested in or working in the pulmonary diseases field, and related disciplines.

Open Access Policy

Thoracic Research and Practice is an open access publication.

Starting on January 2022 issue, all content published in the journal is licensed under the Creative Commons Attribution-NonCommercial (CC BY-NC) 4.0 International License which allows third parties to use the content for non-commercial purposes as long as they give credit to the original work. This license allows for the content to be shared and adapted for non-commercial purposes, promoting the dissemination and use of the research published in the journal.

The content published before January 2022 was licensed under a traditional copyright, but the archive is still available for free access.

All published content is available online, free of charge at thoracrespract.org.

When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s).

Copyright Policy

A Copyright Agreement and Acknowledgement of Authorship form should be submitted with all manuscripts. By signing this form, authors transfer the copyright of their work to the Turkish Thoracic Society and agree that the article, if accepted for publication by the Thoracic Research and Practice will be licensed under a Creative Commons Attribution-Non Commercial 4.0 International License (CC BY-NC 4.0) which permits third parties to share and adapt the content for non-commercial purposes by giving the appropriate credit to the original work.

When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s).

Authors retain the copyright of their published work in the Thoracic Research and Practice.

Thoracic Research & Practice
Official Journal of the Turkish Thoracic Society

Publication Fee Policy

Thoracic Research and Practice is funded by the the Turkish Thoracic Society. Authors are not required to pay any fees during the evaluation and publication process.

You can find the current version of the Instructions to Authors at *https://turkthoracj.org/en/instructions-to-authors-1013*.

Editors in Chief:
Oğuz KILINÇ
İpek Kıvılcım OĞUZÜLGEN
Address: Turan Güneş Bulvarı, Koyunlu Sitesi No: 175/19 Oran, Ankara, TURKEY
Phone: +90 (312) 490 40 50
Fax: +90 (312) 490 41 42
E-mail: editorial.office@turkthoracj.org

Publisher: AVES
Address: Büyükdere Cad., 105/9 34394 Mecidiyeköy, Şişli, İstanbul, TURKEY
Phone: +90 212 217 17 00
Fax: +90 212 217 22 92
E-mail: info@avesyayincilik.com
Web page: avesyayincilik.com

Thoracic Research & Practice
Official Journal of the Turkish Thoracic Society

CONTENTS

ORIGINAL ARTICLES

53 **Clinical and Laboratory Predictors of Mortality in Severe COVID-19 Pneumonia: A Retrospective Study from India**
Swathi Karanth Marsur Prabhakar, Swapna Ramaswamy, Vanitha Basavarajachar, Anushree Chakraborty, Akshata Shivananjiah, Nagaraja Chikkavenkatappa

61 **Interleukin-28 as a Promising Marker for Predicting Invasive Mechanical Ventilation Requirement and Mortality in COVID-19 Patients**
Alperen Aksakal, Adil Furkan Kılıç, Uğurcan Tanülkü, Taha Tavacı, Nurcan Kılıç Baygutalp

66 **Effect of 2 Different High-Dose Methylprednisolone Treatments on Clinical Outcomes in Severe COVID-19 Patients**
Fatma Eser, Bircan Kayaaslan, Ayşe Kaya Kalem, İmran Hasanoğlu, Zeynep Bilgiç, Dilek Asiltürk, Betül Kaplan, Rahmet Güner

76 **Effect of Continuous Positive Airway Pressure Therapy on Pro-Brain Natriuretic Peptide, C-Reactive Protein, Homocysteine, and Cardiac Markers in Patients with Obstructive Sleep Apnea**
Nejdiye Güngördü, Şermin Börekçi, Hazal Cansu Çulpan, Erkam Coşkun, Faruk Ayan, Birsen Mutlu

85 **Respiratory Outcomes at 5-Year Follow-Up in Children with Mannose-Binding Lectin Deficiency: A Retrospective Cohort Study**
Manisha Ramphul, Anna Poghosyan, Javairiya Afzal, Elizabeth McDermott, Lucy Cliffe, Jayesh M. Bhatt

91 **Can Some Viral Respiratory Infections Observed Before the Pandemic Announcement Be Related to SARS-CoV-2?**
Aylin Özgen Alpaydın, Özgür Appak, Naciye Sinem Gezer, Salih Yiğit, Damla Gündüz Karayazı, Ziya Kuruüzüm, Gökçen Ömeroğlu Şimşek, Oya Özlem Eren Kutsoylu, Ayça Arzu Sayıner, Can Sevinç, Eyüp Sabri Uçan, Yasin Levent Uğur, Ali Necati Gökmen, Nur Yapar

96 **Thoracic Surgeons' Perspective on the Management of Primary Spontaneous Pneumothorax**
Yasser Aljehani, Farouk AlReshaid, Abdulrahman Al-Abduljabbar, Rawan A. Rahman AlHarmi, Naif Alkhaldi, Musa'ad Aljughaiman, Bayan Almusailhi, Nabaa Alhawashim, Hatem Elbawab

103 **Treatment Results of Multidrug-Resistant Tuberculosis Patients in the Aegean Region**
Onur Karaman, Yelda Varol, Tülay Akarca, Çağrı Atasoy, Can Biçmen, Diğdem Özbakır, Mustafa Şevket Dereli

CASE REPORTS

109 **An Important Clinical Condition in Differential Diagnosis of Coronavirus Disease 2019: Crack Lung**
Işıl Kibar Akıllı, Müge Bilge, Ekrem Bilal Karaayvaz

113 **Pseudoaneurysm as an Etiological Cause of Hemoptysis in Extensive Tuberculosis**
Martina Mikanović, Ivona Markelić, Zagorka Boras, Vesna Trkeš, Ana Hećimović, Ante Marušić, Andrea Vukić Dugac

Thorac Res Pract. 2023; 24(2): 53-60 DOI: 10.5152/ThoracResPract.2023.22029

Original Article

Clinical and Laboratory Predictors of Mortality in Severe COVID-19 Pneumonia: A Retrospective Study from India

Swathi Karanth Marsur Prabhakar[1], Swapna Ramaswamy[1], Vanitha Basavarajachar[2], Anushree Chakraborty[1], Akshata Shivananjiah[1], Nagaraja Chikkavenkatappa[3]

[1]Department of Pulmonary Medicine, Shanthabai Devarao Shivaram Tuberculosis Research Center & Rajiv Gandhi Institute of Chest Diseases, Bangalore, Karnataka
[2]The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) Projects, Swami Vivekananda Youth Movement, Bangalore, Karnataka
[3]Shanthabai Devarao Shivaram Tuberculosis Research Center & Rajiv Gandhi Institute of Chest Diseases, Bangalore, Karnataka

Cite this article as: Karanth Marsur Prabhakar S, Ramaswamy S, Basavarajachar V, Chakraborty A, Shivananjiah A, Chikkavenkatappa N. Clinical and laboratory predictors of mortality in severe COVID-19 pneumonia: A retrospective study from India. *Thorac Res Pract.* 2023;24(2):53-60.

Abstract

OBJECTIVE: Wide arrays of laboratory parameters have been proposed by many studies for prognosis in COVID-19 patients. In this study, we wanted to determine if the International Severe Acute Respiratory and Emerging Infections Consortium—Coronavirus Clinical Characterization Consortium score in addition to certain clinical and laboratory parameters would help in predicting mortality. We wanted to determine if a greater severity score on chest x-ray at presentation translated to poor patient outcomes using the COVID-19 chest radiography score.

MATERIAL AND METHODS: This retrospective study was conducted at SDS TRC and Rajiv Gandhi Institute of chest diseases, Bangalore from March 2021 to June 2021. This study included 202 real-time-polymerase chain reaction-positive COVID-19 patients aged above 18 years admitted to the intensive care unit of our hospital. Demographic characteristics and baseline hematological and inflammatory markers (serum C-reactive protein, lactate dehydrogenase, troponin-I, ferritin, and D-dimer) were collected. Radiological severity on a chest x-ray was assessed using the validated COVID-19 chest radiography score. The International Severe Acute Respiratory and Emerging Infections Consortium—Coronavirus Clinical Characterization Consortium score was assigned to each patient within 24 hours of intensive care unit admission. Outcome studied was in-hospital mortality.

RESULTS: The overall mortality was 54.9% (111 cases). Age more than 50 years, >4 days of symptoms, peripheral oxygen saturation/fraction of inspired oxygen ratio less than 200, elevated serum lactate dehydrogenase >398.5 IU/L, and hypoalbuminemia (<2.95 g/dL) were detected as independent predictors of mortality. A significant correlation of risk stratification with mortality ($P = .057$) was seen with International Severe Acute Respiratory and Emerging Infections Consortium—Coronavirus Clinical Characterization Consortium score. There was no significant correlation between the COVID-19 chest radiography score and mortality.

CONCLUSION: Age >50 years, peripheral oxygen saturation/fraction of inspired oxygen ratio <200, mean symptom duration of >4 days, elevated serum lactate dehydrogenase, and hypoalbuminemia are independent predictors of mortality in severe COVID-19 pneumonia. International Severe Acute Respiratory and Emerging Infections Consortium—Coronavirus Clinical Characterization Consortium score was different in the survivors and deceased.

KEYWORDS: COVID-19 mortality, 4C score, CARE score, inflammatory markers, SPO2/FIO2 ratio
Received: *February 11, 2022* ***Accepted:*** *October 5, 2022* ***Publication Date:*** *March 28, 2023*

INTRODUCTION

COVID-19 (SARS-CoV2) disease has had a devastating impact on the world. The wide spectrum of SARS-CoV2 disease has been a great challenge to physicians in medical history in both the waves of this pandemic. Approximately, 15%-30% of patients develop respiratory failure and require intensive care management.[1,2] Managing this pandemic demanded rigorous re-organization and scaling up of the existing healthcare and if unprepared, caused unacceptably high mortality rates due to critical shortage of ventilators and intensive care unit (ICU) all over the world. Mortality due to COVID-19 varies from 61.5% to 94%.[3] India was under the complete grip of the second wave of COVID-19 with lakhs of patients succumbing to this disease, with a considerable younger population being lost. Double and triple variants of the virus have been identified making them more transmissible and pathogenic, thus indicating more waves that we have to be prepared for.[4] Hence, a well-planned and meticulous allotment of health resources is a subject of prime concern.

Scientifically backed triage of COVID-19 patients with careful stratification to handle the different severity of this disease in the right setup was the need of the hour. However, many risk stratification scores are proposed and adopted clinically along with an array of inflammatory markers to guide the management of severe COVID-19 patients in whom refractory hypoxemia remains a hallmark. Several characteristics have been associated with severe COVID-19 disease like advanced age, comorbidities, duration of symptoms, and high levels of inflammatory markers (C-reactive protein (CRP), serum ferritin,

Corresponding author: Swapna Ramaswamy, e-mail: swapnar1209@gmail.com

Copyright@Author(s) - Available online at thoracrespract.org. Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

lactate dehydrogenase (LDH), and D-dimer) thereby directing several therapeutic strategies to counter the cytokine storm. Many guidelines recommend repeated and constant monitoring of these inflammatory markers which is financially very exhausting. In any country, adequate utilization of existing resources is the key to effective management of any emergency. Hence, we aimed to determine the prognostic implications of the inflammatory markers (CRP, LDH, troponin-I, ferritin, and D-dimer) and their utility as mortality predictors in severe COVID-19 patients admitted to the ICU. We also aimed at studying the application of infections Consortium-Coronavirus Clinical Characterization Consortium score (ISARIC 4C mortality score) and if greater COVID-19 chest radiography score (on applying CARE score) at presentation translated to poor patient outcomes in due course.

MATERIAL AND METHODS

Study Design and Study Participants

This retrospective study was conducted at SDSD TRC and Rajiv Gandhi Institute of Chest Diseases, Bangalore from March 2021 to June 2021 after ethical clearance (PDCEC/01/33/2021-22). All real-time-polymerase chain reaction (RT-PCR)-positive COVID-19 patients who were aged above 18 years and admitted to the ICU of our hospital were included in the study. Patients with COVID-like illness (RT-PCR-negative) though managed on similar lines were excluded from the study.

Data Collection

Data from 202 patients who were admitted to ICU during our study period were retrieved and thoroughly scrutinized. Demographic characteristics like age, sex, and clinical data including co-morbidities, symptoms, and duration of symptoms were collected and tabulated.

Baseline hematological investigations like a complete blood picture, renal and liver function tests, serum electrolytes, and arterial blood gas analysis were recorded. Neutrophil lymphocyte ratio and peripheral capillary oxygen saturation / fraction of inspired oxygen (SPO_2/FIO_2) ratio were computed.

MAIN POINTS

- Age more than 50 years, peripheral oxygen saturation/ fraction of inspired oxygen ratio of less than 200, mean symptom duration of >4 days, elevated serum lactate dehydrogenase (LDH) (>398.5 IU/L), and hypoalbuminemia (<2.95 g/dL) were found to be independent predictors of mortality in severe COVID-19 pneumonia.
- International Severe Acute Respiratory and Emerging Infections Consortium—Coronavirus Clinical Characterization Consortium score has good prognostic utility and can be used in all levels of healthcare.
- COVID-19 chest radiography score on a chest x-ray had no significant impact on mortality.
- The sensitivity and specificity of serum LDH at cut-off value of 398.5 IU/L in predicting mortality were 71% and 68%, respectively. At a cut-off of <2.95 g/dL, serum albumin has a sensitivity of 68.6% and specificity of 56.8%.

Baseline inflammatory markers panel included serum CRP, serum LDH, troponin-I, ferritin, and D-dimer. In addition, sputum bacterial culture reports were also recorded.

A chest x-ray (CXR) at baseline was assessed for severity using the validated CARE score. Two pulmonologists with 8 and 4 years of experience performed the chest x-ray scoring. The International Severe Acute Respiratory and Emerging Infections Consortium—Coronavirus Clinical Characterization Consortium (ISARIC-4C) score was assigned to each patient to clinically identify those at a higher risk of having poor outcomes. This risk stratification was done within 24 hours of ICU admission. The treatment protocol followed was strictly in adherence to the Karnataka state guidelines and the same was documented. All patients had received remdesevir, steroids, and anticoagulants along with other supportive measures for appropriate duration. The primary outcome studied was in-hospital mortality. The need for non-invasive ventilator (NIV), invasive mechanical ventilator (IMV), and length of stay in the hospital were other surrogate parameters that were looked for as secondary outcomes.

Operational Definitions

Severe COVID-19 pneumonia was defined as per National guidelines issued by the Ministry of health and family welfare, Government of India.[5] COVID-19 infection diagnosed on the basis of positive RT-PCR testalong with the presence of one of the below characteristics—SPO_2 <90% at room air, respiratory rate of more than 30, or presence of severe respiratory distress.

International Severe Acute Respiratory and Emerging Infections Consortium—Coronavirus Clinical Characterization Consortium was calculated using the following variables: age, gender, number of co-morbidities, respiratory rate, SPO_2 at room air, Glasgow coma scale score, blood urea, and serum creatinine. Scores were assigned for each variable at the time of admission and the total score was calculated. International Severe Acute Respiratory and Emerging Infections Consortium—Coronavirus Clinical Characterization Consortium ranges from 0 to 21with risk groups defined as low (0-3), intermediate (4-8), high (9-14), and very high (≥15).[6]

COVID-19 chest radiography score: To calculate CARE score, each lung was divided into 3 zones. Scores were given separately for the presence of ground-glass opacities (GGO) and consolidation depending on the proportion of the zones affected.[7]

Statistical Analysis

Data were entered in Microsoft excel and were analyzed using Statistical Package for Social Sciences (SPSS) version 24.0 (IBM Corp.; Armonk, NY, USA). Proportion, mean, and standard deviation (SD) were used wherever necessary to describe the population. The comparison of demographics and clinical data between survivors and non-survivors was calculated using chi-square test for categorical variables and *t*-test for continuous variables. Univariate analysis was done to get odds ratio. Those with $P < .2$ were included in the multivariate regression analysis to find adjusted odds ratio. $P < .05$ was considered significant.

RESULTS

Demographic Characteristics

Out of total of 820 COVID-19 cases admitted to our hospital during the specified study period, 202 patients had severe COVID-19 pneumonia mandating ICU management. The mean age was 52 years with a male predominance [129; 63.9%] (Table 1). Older age strongly correlated with mortality (P = .02), whereas gender did not (Table 1).

Clinical Characteristics

Fever was the most common presenting symptom (168; 83.16%) followed by dyspnea (165; 81.68%) and fatigue (145; 71.7%) (Table 1). Co-morbidities were present in 141 patients (73.76%) of which diabetes mellitus was the commonest (118; 58.41%) (Table 1). We observed no statistically significant effect of co-morbidity on mortality (Table 1). The mean duration of symptoms before hospitalization was 5.95 days (SD=3.69) (Table 1).

International Severe Acute Respiratory and Emerging Infections Consortium—Coronavirus Clinical Characterization Consortium Risk Stratification

As per ISARIC-4C score, 83 patients (41.08%) were categorized into intermediate risk group, 80 patients (39.60%) to high risk, 8 (3.96%) to very-high risk, and 2 to low-risk group (0.9%).There was a significant correlation between risk stratification with mortality (P = .057) (Table 2).

Radiological Characteristics

Chest radiograph of these patients revealed lower-zone predilection of either GGO or frank consolidation in all cases (202; 100%). Mid-zone involvement was present in 196 cases (97.02%) and 135 patients (66.83%) had upper-zone involvement as well. The mean CARE score of survivors and the deceased was 20.64 (7.85) and 21.21 (7.64), respectively. There was no statistically significant difference in the mean CARE score among survivors and non-survivors (Table 2).

Table 1. Baseline Demographic and Clinical Characteristics of Severe COVID-19 Patients Admitted to Intensive Care Unit

Variables	Total (n = 202)	Survived (n = 91)	Death (n = 111)	*P**
Age [years]; mean (SD)	52.0 (13.97)	49.65 (15.43)	54.36 (13.14)	**.02**
Male, n [%]	129 (63.9)	53 (58.2)	76 (68.5)	.132
Female	73 (36.1)	38 (41.8)	35 (31.5)	
Symptoms, n (%)				
Dyspnea	165 (81.68)	76 (83.5)	89 (80.2)	.542
Fever	168 (83.16)	75 (82.4)	93 (83.8)	.796
Fatigue	144 (71.3)	70 (76.9)	74 (66.7)	.109
Dry cough	94 (46.53)	38 (41.8)	56 (50.5)	.218
Productive cough	88 (43.56)	44 (48.4)	44 (39.6)	.214
Headache	14 (6.9)	6 (6.6)	8 (7.2)	.864
Loss of appetite	14 (6.9)	8 (8.8)	6 (5.4)	.126
Sore throat	9 (4.4)	4 (4.4)	5 (4.5)	.745
Chills	15 (7.4)	9 (9.9)	6 (5.4)	.226
Vomiting	6 (3.0)	3 (3.3)	3 (2.7)	.805
Diarrhea	6 (3.0)	2 (2.2)	4 (3.6)	.558
Chest pain	5 (2.4)	1 (1.1)	4 (3.6)	.121
Altered sensorium	4 (2.0)	0 (0)	4 (3.6)	.051
Hemoptysis	4 (2.0)	1 (1.1)	3 (2.7)	.416
Loss of taste	3 (1.4)	3 (3.3)	0 (0)	.054
Mean duration of symptoms before hospitalization [SD]	5.95 [3.69]	5.88 [3.144]	6.01[4.107]	.804
Comorbidities [n]	149 (73.76)	65 (71.4)	84(75.7)	.495
Diabetes	118 (58.4)	50 (54.9)	68 (61.3)	.365
Hypertension	61 (30.19)	28 (30.8)	32 (28.8)	.764
Chronic lung disease	27 (13.36)	14 (15.4)	13 (11.7)	.445
Heart disease	19 (9.4)	10 (11.0)	9 (8.1)	.485
Obesity	3 (1.4)	1 (1.1)	2 (1.8)	.210
Hypothyroidism	12 (5.9)	7 (7.7)	5 (4.5)	.340
Old cerebro vascular accident	6 (2.9)			

SD, standard deviation.
*P-value is statistically significant.

Table 2. Baseline Risk Stratification and Course in the Hospital of Severe COVID-19 Patients Admitted to Intensive Care Unit

Variables	Total (n = 202)	Survived (n = 91)	Death (n = 111)	*P**
Risk stratification applying ISARIC 4C score [n]				
Low risk	2 (1.2)	1 (1.1)	1 (1.3)	**.057**
Intermediate risk	83 (48)	47 (58.8)	36 (38.7)	
High risk	80 (46.2)	30 (37.5)	50 (53.8)	
Very-high risk	8 (4.6)	2 (2.5)	6 (6.5)	
CARE score, mean [SD]	20.96 (7.7)	20.65 (7.85)	21.22 (7.64)	.604
Complications [n]	**77 (38.11)**	19 (20.87)	58 (52.25)	**<.0001**
Mean duration of ICU stay [SD]	6.87 [5.88]	6.98 [5.829]	6.48 [5.995]	.55
Mean duration of hospital stay [SD]	19.18 [9.508]	24.2 [8.54]	15.07 [8.225]	**<.001**

ISARIC 4C, International Severe Acute Respiratory and emerging infections Consortium—Coronavirus Clinical Characterization Consortium score; SD, standard deviation. *P* Value in bold indicates its statistical significance.
**P*-value is statistically significant.

Clinical Course in Hospital

Although most of the patients in ICU required NIV support (122; 60.39%) and high-flow nasal cannula (70; 34.65%), only 36 of them (17.82%) eventually mandated IMV support, of whom none survived. The mean duration of ICU and hospital stay was 6.87 ± 5.88 and 19.18 ± 9.5, respectively. Complications were noted in 77 patients with secondary bacterial infection being the commonest (41; 20.29%). The frequently isolated microorganisms were Klebsiella species and coagulase-negative staphylococcus and streptococcus viridians. Other encountered complications were sepsis (20; 9.9%) acute kidney injury (14; 6.9%), diabetic ketoacidosis (7; 3.4%), hypokalemia (4; 1.9%), cerebrovascular accident (3; 1.4%), subacute emphysema with pneumo-mediastinum (2; 0.9%), pneumothorax (1; 0.4%), pulmonary thromboembolism (2; 0.9%), myocardial infarction (1; 0.4%), supraventricular tachycardia (1; 0.4%), and delirium (2; 0.9%). Complications were significantly more among the deceased than survivors (Table 2).

Outcome

The overall mortality was 54.9% (111 cases). Most deaths were observed within 7 days of hospitalization (64; 57.65%) and 29 patients (29.62%) succumbed between 7 and 14 days and 18 patients (16.21%) after 14 days of hospitalization. The mean duration of hospitalization among discharged was 24.2 ± 8.5 days and 28 patients (30.07%) were discharged with short-term oxygen therapy.

Mortality Predictors

On multivariate regression analysis, we found that age of more than 50 years, more than 4 days of symptoms, SPO_2/FIO_2 ratio less than 200, elevated serum LDH, and hypoalbuminemia are the independent predictors of mortality in severe COVID-19 pneumonia (Table 3). The cut-off value of 398.5 IU/L sensitivity and specificity of serum LDH in predicting mortality was 71% and 68%, respectively. For serum albumin as a mortality predictor, with a cut-off of <2.95, a sensitivity of 68.6% and a specificity of 56.8% were noted (Figure 1).

DISCUSSION

The severity of COVID-19 and mortality is influenced by multiple factors like genetics, individual immune response, co-morbidities, type of variant causing the disease, and demographic characteristics of the affected population. The management of COVID-19 has evolved since the beginning of the pandemic and has greatly influenced the mortality rate. Advanced age, smoking, male sex, lymphocytopenia, D-dimer, CRP, co-morbidities, SPO_2/FIO_2 ratio, and serum LDH are a few reported mortality predictors.[8-10] Wide heterogeneity in mortality predictors that are reported by several multivariate analyses from different countries can be observed. Of these diverse variables, advanced age is the single most variable that is consistently reported to have prognostic utility. Advanced age (>60 years) has been shown to behave as an independent mortality predictor in several studies.[9,10] Decreased immunity in elderly secondary to reduced T-cell subset and increased cytokine storm render them prone to severe disease. In our study, it was observed that age more than 50 years acted as an independent mortality predictor as enumerated in Table 3, a finding that resonates with the available evidence.[11,12]

Some studies have proposed male gender as a risk factor for higher mortality[13-15] On the contrary, we failed to notice any such association and our findings are consistent with few other studies.[9,16]

The presence of comorbidities is reported to increase the mortality by 2.85-fold.[9,17] Diabetes , hypertension, and cardiovascular conditions are the most commonly associated co-morbidities with increased mortality.[9,13] However, in our study, no such association was encountered.

A delay in access to healthcare facility especially in times of imposed lockdown was a major concern in COVID-19 management. The mean duration of symptoms of more than 4 days was significantly associated with mortality in our study as depicted in Table 3. Another Indian study has reported

Table 3. Multivariate Regression Analysis of Variables Associated with Mortality in Severe COVID-19 Pneumonia Patients

		Survived	Died	OR (95%CI)	aOR (95%CI)	*P*
Age	<50 years	46 (50.5)	41 (36.9)	-	-	.03
	>50 years	45 (49.5)	70 (63.1)	1.74 (0.9-3.1)	1.99 (1.1-3.6)	
Sex	Male	53 (58.2)	76 (68.5)	-	-	.27
	Female	38 (41.8)	35 (31.5)	0.64 (0.3-1.1)	0.6 (0.3-1.3)	
Comorbidities	No	26 (28.6)	27 (24.3)	-	-	-
	Yes	65 (71.4)	84 (75.7)	1.24 (0.6-2.3)	-	
Duration of symptoms	<4 days	36 (39.6)	52 (46.8)	-	-	.04*
	>4 days	55 (60.4)	59 (53.2)	0.74 (0.4-1.3)	0.5 (0.2-0.9)	
SPO_2/FIO_2	>2	48 (52.7)	32 (28.8)	-	-	.01*
	<2	43 (47.3)	79 (71.2)	2.75 (1.5-4.9)	2.28 (1.1-4.3)	
ISARIC 4C score	<3	1 (1.1)	1 (0.9)	-	-	-
	>3	90 (98.9)	110 (99.1)	1.2 (0.7-19.8)	-	
CARE score	<13	18 (19.8)	20 (18.0)	-	-	-
	>13	73 (80.2)	91 (82.0)	1.12 (0.5-2.2)	-	
N/L		8.53 (6.5)	10.5 (7.5)	1.04 (1.0-1.1)	1.02 (0.9-1.1)	.21
ESR		66.8 (44.5)	55.9 (48.3)	0.99 (0.9-1.1)	-	-
Serum albumin		3.17 (0.9)	2.78 (1.2)	0.72 (0.5-0.9)	0.64 (0.4-0.8)	.005*
Serum CRP		98.23 (83.1)	110.3 (88.2)	1.01 (0.9-1.1)	-	-
D-Dimer		810.7 (1224.7)	1307.4 (2335.2)	1.1 (1.0-1.2)	1.1 (0.9-1.2)	.6
Trop I		0.477 (0.199)	0.1157 (0.524)	1.79 (0.5-5.6)	-	-
Serum LDH		386.57 (251.1)	509.2 (306.6)	1.1 (1.0-1.2)	1.1 (0.9-1.2)	.04*
Serum ferritin		527.28 (546.5)	587.65 (563.3)	1.1 (1.0-1.2)	-	-
AST		48.02 (31.6)	48.3 (38.6)	0.99 (0.9-1.1)	-	-
ALT		38.9 (26.6)	35.7 (34.5)	0.98 (0.8-1.1)	-	-

aOR, adjusted odds ratio; ALT, alanine transaminase; AST, aspartate transaminase; CARE score, COVID-19 chest radiography score; CRP, C-reactive protein; ISARIC 4C, International Severe Acute Respiratory and emerging infections Consortium—Coronavirus Clinical Characterization Consortium score; LDH, lactate dehydrogenase; L/N, neutrophil/lymphocyte; SPO_2/FIO_2, peripheral oxygen saturation-fraction of inspired oxygen; Trop I, troponin I.
**P*-value is statistically significant.




Figure 1. Receiver operating charactestic curve (ROC) of predictors of mortality.

higher mortality in those individuals who present to hospital after 4 days of symptom onset.[13]

Peripheral oxygen saturation/fraction of inspired oxygen ratio is a proxy indicator of oxygenation which can be used as a surrogate of PaO_2/FiO_2 (PaO_2-arterial oxygen pressure) ratio in resource-limited countries. Rice et al[18] observed significant correlation of SpO_2/FiO_2 ratio of 235 and 315 with PaO_2/FiO_2 ratio of 200 and 300, respectively. In our study, a SpO_2/FiO_2 ratio of <200 at admission was found to be an independent mortality predictor as shown in Table 3. Choi [19] reported increased mortality in those with a SpO_2/FiO_2 ratio of <315 at admission. Another study reported an S/F ratio of <400 as an independent predictor of mortality.[13] In resource-limited countries where management of moderate to severe COVID-19 patients is done at every level of health care, this simple non-invasive variable can replace PaO_2/FIO_2 as a mortality predictor.

International Severe Acute Respiratory and Emerging Infections Consortium—Coronavirus Clinical Characterization

Consortium score, a mortality predictor score developed and validated on the UK population, has been shown to have good applicability in other population as well.[20] This simple and easy to calculate score categorizes patients into 4 categories of severity by combining readily available variables upon admission. It reflects patient's demography, comorbidities, physiological characteristics, and lab investigations with the mortality increasing with each category. The mortality rate was 62% with a score of 15 and 1% with a score of 3 or less in the UK population.[6] After its initial development, several studies were conducted to assess its external validity and reported similar results as the original study.[21-23] International Severe Acute Respiratory and Emerging Infections Consortium—Coronavirus Clinical Characterization Consortium score of >9 had sensitivity and specificity of 70.5% and 73.97%, respectively, in predicting mortality as reported by Mumtaz et al.[20] We also observed a statistically significant increase in mortality with higher risk strata as enumerated in Table 2. To the best of our knowledge, this is the first time the ISARIC-4C score has been used to stratify the risk of mortality in COVID-19 patients in India.

Several pre-existing scores have been used and compared to determine the most reliable score to predict the mortality risk in COVID-19 patients. Fan et al[24] in 2019 retrospectively evaluated the role of existing scores in predicting mortality in COVID-19 patients and concluded that the A-DROP score [age, dehydration, respiratory failure, orientation disturbance, and systolic blood pressure] which is a modification of the CURB-65 [confusion, urea, respiratory rate, blood pressure, age] score performed better when compared to CURB-65, PSI [pneumonia severity index], SMART-COP [systolic blood pressure, multi-lobar CXR involvement, albumin, respiratory rate, tachycardia, confusion, oxygen saturation, pH], NEWS2 [National early warning score], CRB-65 [confusion, respiratory rate, blood pressure], and qSOFA [quick sequential Organ failure assessment] for in-hospital death. Age, dehydration, respiratory failure, orientation disturbance, systolic blood pressure presented the highest discrimination (area under curve [AUC] = 0.87) followed by CURB-65 (AUC = 0.85), PSI (AUC = 0.85), SMART-COP (AUC = 0.84), NEWS2 (AUC= 0.85), CRB-65 (AUC=0.80), and qSOFA (AUC =0.73) in predicting in-hospital death, though the difference between A-DROP and CURB-65 and PSI was not significant.[24]

In 2020, the prognostic utility of ISARIC-4C score in all cohorts (n = 606) of community-acquired pneumonia (CAP), invasive pneumococcal disease (IPD), COVID-19 infection, and other fatal common respiratory infections was looked at and its performance was compared to the already existing scores CURB65, CRB65, qSOFA, and NEWS and found that the ISARIC-4C score had the greatest AUC in COVID 19, CAP, and IPD patients (0.83, 0.78, and 0.74, respectively) and found that it was the only score that performed statistically significantly better than chance across all 4 cohorts. They concluded that the ISARIC-4C score performed well in predicting 30-day mortality in COVID-19 and other common respiratory infection populations in comparison to other scores.[25]

In another study on 481 patients by Doğanay and Ak[26] in 2021, CURB-65, ISARIC-4C, and COVID-GRAM scores were assessed and compared in terms of predicting in-hospital mortality and ICU requirement in patients hospitalized with COVID-19 disease. In terms of in-hospital mortality, the AUC of CURB-65, ISARIC-4C, and COVID-GRAM were 0.84, 0.78, and 0.70 respectively, whereas, for ICU requirement, it was 0.89, 0.79, and 0.68, respectively. Confusion, urea, respiratory rate, blood pressure, age-65 score was concluded to perform better in predicting in-hospital mortality and ICU requirement in COVID-19 patients, whereas the ISARIC-4C score was found to be successful in identifying low-risk patients.

In another large study by Artero et al[27] on 10 238 patients, 3 scores were tested for their prognostic accuracy. A new score (MuLBSTA based on 6 parameters—multilobar infiltration, hypo-lymphocytosis, bacterial coinfection, smoking history, hypertension, and age) was tested against the other scores (PSI, CURB-65, qSOFA,), and the authors concluded that PSI and CURB-65 as specific severity scores for pneumonia were better than qSOFA andMuLBSTA at predicting mortality in patients with COVID-19 pneumonia.

On the same line, when APACHE II [acute physiology and chronic health evaluation], CURB-65, and MuLBSTA scores were evaluated on 53 COVID patients, it was found that APACHE II performed better than the other 2 scores in predicting the severity, whereas the MuLBSTA was recommended to be used to determine the death risk.[28]

In resonation with above findings, in another retrospective study on 249 patients, the ISARIC-4C score calculated upon admission to the hospital was compared to the simplified acute physiology score (SAPS), APACHE II, and sequential organ failure assessment (SOFA) calculated upon admission to the ICU. The accuracy of the mortality risk scores was calculated for ICU survivors and ICU non-survivors. The authors concluded that the APACHE II had the best discrimination of mortality in ICU patients and both APACHE II and ISARIC-4C score independently predicted mortality risk and could be used concomitantly.[29]

Though CXR is less sensitive than computed tomography thorax in detecting early changes of COVID-19 pneumonia, it has been proposed to be invaluable in predicting mortality. Few studies have suggested a significant correlation between increased lung involvement on CXR and mortality.[30,31] We attempted to study the same by using the validated CARE score. Each lung was divided into 3 zones (6 in total) and a separate score was assigned to GGO and consolidation. COVID-19 chest radiography score of 17.5 showed 75% sensitivity and 69.9% specificity in predicting mortality.[7] However, we did not notice any statistically significant difference in CARE score among survivors and non-survivors.

Lactate dehydrogenase, an intracellular enzyme, is present in almost all tissues. Multiorgan injury, hypoxia, tissue hypo perfusion, metabolic acidosis, and severe infections can cause elevation in serum LDH. As severe COVID-19 pneumonia is characterized by all of the above, an increase in serum LDH is an expected lab parameter. Elevation of serum LDH at the time of admission is known to have an association with severe COVID and more than 16-fold increase in odds of

mortality.[32] Poor prognosis in those with elevated LDH has been observed in several studies.[33-35] Lactate dehydrogenase has also been identified as a prognostic marker in COVID-19 with positive correlation of time to normalization of serum LDH with radiological resorbtion.[36] In our study, elevated LDH at the time of admission was an independent mortality predictor with value of >398.5 has sensitivity and specificity of 71% and 68%, respectively. Martha et al[37] reported sensitivity and specificity of LDH in predicting mortality as 74% and 69%, respectively. No other inflammatory markers showed any association with mortality in our study (Table 3). As the elevation of inflammatory markers is influenced by multiple factors like severity of disease, presence of comorbidities, different laboratory cut-off points, and variation in laboratory diagnostic methods, heterogeneity in findings can be expected.

Hypoalbuminemia has been observed in severe COVID-19 infection. Increased albumin clearance, consumption of amino acids by viral replication, reduced albumin transcription, and impaired liver protein synthesis are plausible mechanisms explaining hypoalbuminemia in severe COVID-19 infection.[38] We observed hypoalbuminemia as an independent mortality predictor. Huang et al[38] reported an albumin level of <35 g/L at admission as an independent predictor of mortality and also observed increased risk of death by 6-fold in those with hypoalbuminemia. Serial monitoring of serum albumin also has prognostic significance. Improvement in serum albumin has been noted with recovery.[39] However, therapeutic benefits of serum albumin transfusion in severe COVID-19 are still not established.[39]

Our study describes various clinical, demographic, and laboratory predictors of mortality in severe COVID-19 pneumonia. We hope that the findings from our study help in proper prognostication and guide healthcare services to properly utilize resources on salvageable patients. However, our study has some limitations. Data were collected only at the time of hospital admission based on the patient's medical records and some variables were not available. Since it was a retrospective single-center study, selection bias was a major concern.

CONCLUSION

Age of more than 50 years, SpO_2/FiO_2 ratio of less than 200, mean symptom duration of >4 days, elevated serum LDH, and hypoalbuminemia were all independent predictors of mortality in severe COVID-19 pneumonia. International Severe Acute Respiratory and Emerging Infections Consortium—Coronavirus Clinical Characterization Consortium score was different in the survivors and deceased. Given its easy application, optimal usage at all levels of healthcare facility at the time of admission can be done. However, the CARE score failed to demonstrate its prognostic performance.

Ethics Committee Approval: Ethical committee approval was received from the Ethics Committee of Pranav Diagnostic Center Ethics Committe (ECR/1217/Inst/KA/2019) (Approval No: PDCEC/01/M33/2021-22).

Informed Consent: N/A.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – S.K.M.P., S.R., A.C., A.J.S.; Design – S.K.M.P., S.R., A.C., N.C.; Supervision – A.J.S., V.B., N.C.; Materials – S.K.M.P., S.R., A.C., A.J.S., N.C.; Data Collection and/or Processing – S.K.M.P., S.R., A.C.; Analysis and/or Interpretation – V.B., A.J.S., N.C., S.K.M.P.; Literature Review – S.K.M.P., S.R., A.J.S., A.C.; Writing – S.K.M.P., S.R., A.J.S.; Critical Review – N.C., V.B., A.J.S., S.R.

Declaration of Interests: The authors have no conflict of interest to declare.

Funding: This study received no funding.

REFERENCES

1. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *JAMA*. 2020;323(20):2052-2059. [CrossRef]; published correction appears in *JAMA*. 2020;323(20):2098. (https://doi.org/10.1001/jama.2020.7681)
2. Docherty AB, Harrison EM, Green CA, et al. Features of 20133 UK patients in hospital with Covid-19 using the ISARIC WHO Clinical Characterization Protocol: prospective observational cohort study. *BMJ*. 2020;369:m1985. [CrossRef]
3. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med*. 2020;180(7):934-943. [CrossRef]; published correction appears in *JAMA Intern Med*. 2020;180(7):1031.
4. Asrani P, Eapen MS, Hassan MI, Sohal SS. Implications of the second wave of COVID-19 in India. *Lancet Respir Med*. 2021;9(9):e93-e94. [CrossRef]
5. *Revised Covid-19 Treatment for COVID-19 in India. Google Search*. Available at: https:\\covid19.karnataka.gov.in. Accessed November 19, 2020.
6. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with Covid-19 using the ISARIC WHO Clinical Characterization Protocol: development and validation of the 4C Mortality Score. *BMJ*. 2020;370:m3339. [CrossRef]; published correction appears in *BMJ*. 2020;371:m4334.
7. Giraudo C, Cavaliere A, Fichera G, et al. Validation of a composed COVID-19 chest radiography score: the CARE project. *ERJ Open Res*. 2020;6(4). [CrossRef]
8. Albalawi O, Alharbi Y, Bakouri M, et al. Clinical characteristics and predictors of mortality among COVID-19 patients in Saudi Arabia. *J Infect Public Health*. 2021;14(8):994-1000. [CrossRef]
9. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. *Eur Respir J*. 2020:55(5). [CrossRef]; published correction appears in *Eurrespir J*. 2020;56(3).
10. Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of Covid-19: systematic review and critical appraisal. *BMJ*. 2020;369:m1328. [CrossRef]; published correction appears in *BMJ*. 2020;369:m2204.
11. Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. *J Med Virol*. 2020;92(7):797-806. [CrossRef]
12. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J (Engl)*. 2020;133(9):1025-1031. [CrossRef]
13. Mahendra M, Nuchin A, Kumar R, Shreedhar S, Mahesh PA. Predictors of mortality in patients with severe COVID-19 pneumonia - a retrospective study. *Adv Respir Med*. 2021;89(2):135-144. [CrossRef]

14. Jain AC, Kansal S, Sardana R, Bali RK, Kar S, Chawla R. A retrospective observational study to determine the early predictors of in-hospital mortality at admission with COVID-19. *Indian J Crit Care Med*. 2020;24(12):1174-1179. [CrossRef]
15. Kokturk N, Babayigit C, Kul S, et al. The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients.*Respir Med*. 2021;183:106433. [CrossRef]
16. Pandita A, Gillani FS, Shi Y, et al. Predictors of severity and mortality among patients hospitalized with COVID-19 in Rhode Island. *PLoS One*. 2021;16(6):e0252411. [CrossRef]
17. Shi C, Wang L, Ye J, et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. *BMC Infect Dis*. 2021;21(1):663. [CrossRef]
18. Rice TW, Wheeler AP, Bernard GR, et al. Comparison of the SpO_2/FIO_2 ratio and the PaO_2/FIO_2 ratio in patients with acute lung injury or ARDS. *Chest*. 2007;132(2):410-417. [CrossRef]
19. Choi KJ, Hong HL, Kim EJ. The association between mortality and the oxygen saturation and fraction of inhaled oxygen in patients requiring oxygen therapy due to COVID-19-associated pneumonia.*Tuberc Respir Dis (Seoul)*. 2021;84(2):125-133. [CrossRef]
20. Mumtaz SA, Shahzad SA, Ahmed I, et al. External validation of 4C ISARIC mortality score in the setting of a Saudi Arabian ICU. Retrospective study. *SSRN Journal*. 2021. [CrossRef]
21. Van Dam PMEL, Zelis N, van Kuijk SMJ, et al. Performance of prediction models for short-term outcome in COVID-19 patients in the emergency department: a retrospective study. *Ann Med*. 2021;53(1):402-409. [CrossRef]
22. Covino M, De Matteis G, Burzo ML, et al. Predicting in-hospital mortality in COVID-19 older patients with specifically developed scores. *J Am Geriatr Soc*. 2021;69(1):37-43. [CrossRef]
23. Verma AA, Hora T, Jung HY, et al. Characteristics and outcomes of hospital admissions for COVID-19 and influenza in the Toronto area. *CMAJ*. 2021;193(12):E410-E418. [CrossRef]
24. Fan G, Tu C, Zhou F, et al. Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. *Eur Respir J*. 2020;56(3). [CrossRef]
25. Wellbelove Z , Walsh C, Perinpanathan T, Lillie P. Letters to the editor. *J Infect*. 2021;82:414-451.
26. Doğanay F, Ak R. Performance of the CURB-65, ISARIC-4C and COVID-GRAM scores in terms of severity for COVID-19 patients. *Int J Clin Pract*. 2021;75(10):e14759. [CrossRef]
27. Artero A, Madrazo M, Fernández-Garcés M, et al. Severity scores in COVID-19 pneumonia: a multicenter, retrospective, cohort study .*J Gen Intern Med*. 2021;36(5):1338-1345. [CrossRef]
28. Cheng P, Wu H ,Yang J, et al. Pneumonia scoring systems for severe COVID19: which one is better . *Virol J*. 2021;18(1):33. [CrossRef]
29. Vicka V , Januskeviciute E , Miskinyte S, et al. Comparison of mortality risk evaluation tools efficacy in critically ill COVID-19 patients. *BMC Infect Dis*. 2021;21(1):1173. [CrossRef]
30. Mushtaq J, Pennella R, Lavalle S, et al. Initial chest radiographs and artificial intelligence (AI) predict clinical outcomes in COVID-19 patients: analysis of 697 Italian patients. *Eur Radiol*. 2021;31(3):1770-1779. [CrossRef]
31. Al-Smadi AS, Bhatnagar A, Ali R, Lewis N, Johnson S. Correlation of chest radiography findings with the severity and progression of COVID-19 pneumonia. *Clin Imaging*. 2021;71:17-23. [CrossRef]
32. Henry BM, Aggarwal G, Wong J, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. *Am J Emerg Med*. 2020;38(9):1722-1726. [CrossRef]
33. Huang Y, Lyu X, Li D, et al. A cohort study of 676 patients indicates D-dimer is a critical risk factor for the mortality of COVID-19. *PLOS ONE*. 2020;15(11):e0242045. [CrossRef]
34. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol*. 2020;146(1):110-118. [CrossRef]
35. Ramos-Rincon JM, Buonaiuto V, Ricci M, et al. Clinical characteristics and risk factors for mortality in very old patients hospitalized with COVID-19 in Spain. *J Gerontol A Biol Sci Med Sci*. 2021;76(3):e28-e37. [CrossRef]
36. Wu MY, Yao L, Wang Y, et al. Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia. *Respir Res*. 2020;21(1):171. [CrossRef]
37. Martha JW, Wibowo A, Pranata R. Prognostic value of elevated lactate dehydrogenase in patients with COVID-19: a systematic review and meta-analysis. *Postgrad Med J*. 2022;98(1160):422-427. [CrossRef]
38. Huang J, Cheng A, Kumar R, et al. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. *J Med Virol*. 2020;92(10):2152-2158. [CrossRef]
39. Xu Y, Yang H, Wang J, et al. Serum albumin levels are a predictor of COVID-19 patient prognosis: evidence from a single cohort in Chongqing, China. *Int J Gen Med*. 2021;14:2785-2797. [CrossRef]

Thorac Res Pract. 2023; 24(2): 61-65 DOI: 10.5152/ThoracResPract.2023.22146

Original Article

Interleukin-28 as a Promising Marker for Predicting Invasive Mechanical Ventilation Requirement and Mortality in COVID-19 Patients

Alperen Aksakal[1], Adil Furkan Kılıç[2], Uğurcan Tanülkü[1], Taha Tavacı[3], Nurcan Kılıç Baygutalp[4]

[1]Department of Pulmonary Diseases, City Hospital, Erzurum, Turkey
[2]Department of Internal Medicine, City Hospital, Erzurum, Turkey
[3]Department of Medical Pharmacology,Atatürk University Faculty of Medicine, Erzurum, Turkey
[4]Department of Biochemistry, Atatürk University Faculty of Pharmacy, Erzurum, Turkey

Cite this article as: Aksakal A, Kılıç AF, Tanülkü U, Tavacı T, Kılıç Baygutalp N. Interleukin-28 as a promising marker for predicting invasive mechanical ventilation requirement and mortality in COVID-19 patients. *Thorac Res Pract.* 2023;24(2):61-65.

Abstract

OBJECTIVE: The study aimed to evaluate serum interleukin-28 levels in COVID-19 patients and correlate the results with disease severity.

MATERIAL AND METHODS: This study included 90 patients who presented to the COVID-19 outpatient clinics, hospital wards, and intensive care units. Serum interleukin-28, C-reactive protein, lactate dehydrogenase, fibrinogen, D-dimer, and ferritin levels were measured. Patients were divided into 3 groups based on clinical severity to mild, moderate, and severe groups (each group consisted of 30 patients).

RESULTS: There were significant differences in serum C-reactive protein, lactate dehydrogenase, fibrinogen, D-dimer, ferritin, and interleukin-28 levels between all groups. The mean serum interleukin-28 levels of all patients were 383.74 ± 63.58 ng/L. The mean serum interleukin-28 levels were 335.52 ± 42.12 ng/L in the mild group, 366.88 ± 41.27 ng/L in the moderate group, and 453.46 ± 36.78 ng/L in the severe group.

CONCLUSION: There were significant differences in comparisons of all pairs ($P < .05$). Interleukin-28 may be a promising biomarker for detecting disease severity in COVID-19 patients.

KEYWORDS: Health, interleukin-28, marker, Sars-Cov-2
Received: *July 28, 2022* ***Accepted:*** *October 5, 2022* ***Publication Date:*** *March 28, 2023*

INTRODUCTION

Starting in December 2019, the COVID-19 pandemic has caused more than 6 million deaths worldwide, and numbers are increasing continuously. People with documented COVID-19 infections show symptoms ranging from mild to severe, and the course of the disease is widely variable. The disease may start as a mild respiratory tract infection. It can lead to severe viral pneumonia, acute respiratory distress syndrome, multiple organ failure, and even death in the course of infection.[1] Due to the capability of infecting large volumes of people and causing severe illness that requires hospitalization in inpatient clinics or intensive care units, a successful risk classification system is required to prevent unnecessary hospitalizations and lower the burden in healthcare systems worldwide. Age-, gender-, and comorbidity-based scoring system has been tested to predict mortality before.[2] C-reactive protein (CRP), D-dimer, creatinine, ferritin, lactate dehydrogenase (LDH) levels, neutrophil to lymphocyte ratio, and many other biomarkers have been tested to predict mortality and severity of disease in COVID-19 patients.[3-6] While some biomarkers were helpful in risk assessment, more clinical research and new biomarkers are required for a better classification system.

Interleukin 28 (IL-28) is a member of the interferon gamma (IFN-λ) family consisting of IL-28A, IL-28B, and IL-29, with their own class II receptor generally found in epithelial cells.[7] Interleukin -28 cytokine family plays a vital role against viruses by inducing 2',5'-oligoadenylate synthetase which is an antiviral enzyme that counteracts viruses by degrading RNAs of viruses and interferon-stimulated gene factor-3 which is a transcriptional factor that regulates transcription of the interferon-stimulated genes.[8] Interleukin-28 has been shown to enhance adaptive immunity against viruses by promoting antigen-specific interferon-gamma release and increasing the cytotoxic potential of CD8+ T cells.[9] It has also been shown that mutations in the IL-28B gene may affect the viral clearance of the hepatitis C virus and response to antivirals.[10-11] Though IL-28 plays an essential role in viral defense, the potency of IL-28 in infections and immune response shows biological variations due to widely determining single-nucleotide polymorphisms (SNPs) and variable expression rates.[12-13] The role of IL-28 in defense against COVID-19 infection is not clear. However, due to its variable expression rates and its important role in viral immunity, we have hypothesized that blood levels of IL-28 might be an indicator of the course of the disease and be used for risk assessment in COVID-19 patients. Therefore, we have studied the relationship between IL-28 levels in the blood and COVID-19 severity in patients as a risk assessment method.

Corresponding author: Alperen Aksakal, e-mail: alperennaksakal@hotmail.com

Copyright@Author(s) - Available online at thoracrespract.org. Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

MATERIAL AND METHODS

A total of 90 patients who applied to the COVID-19 outpatient clinics and wards in Erzurum City Hospital that met the inclusion criteria and agreed to participate in the study were enrolled. Ethical committee approval was received from the Ethics Committee of Erzurum City Hospital (approval No: 2021/01-04). Written and verbally informed consent was obtained from all patients or legal representatives. Inclusion criteria were to have at least 1 positive COVID-19 real-time polymerase chain reaction (RT-PCR) result within 7 days, male or female gender, and age above 18 years old. Pregnant and breastfeeding women were excluded from the study.

Patients were divided into 3 groups as each group consisting of 30 patients. Patients with normal chest x-ray results, who did not need hospitalization, and who had no hypoxemia were grouped into "mild;" patients with pneumonia on computed tomography (CT) scans or chest x-rays with accompanying dyspnea or hypoxemia who needed to be hospitalized in the wards but did not need high-flow nasal oxygen (HFNO) or mechanical ventilation (invasive or non-invasive) or intensive care were grouped into "moderate;" and patients who needed intensive care due to respiratory failure or shock were grouped in "severe" groups. Venous blood samples were collected on the first day of application to the hospital in the mild group and on first day of hospitalization (ICU or ward) for moderate and severe groups. Death ratios and invasive mechanical ventilation requirement (invasive and non-invasive) ratios were recorded.

Venous blood samples from each patient were collected in a serum tube (without an anticoagulant) and centrifuged for 20 minutes at 2000-3000 rpm. The supernatants formed after centrifugation were collected in microcentrifuge tubes. Obtained serum samples were aliquoted and stored in a freezer at −20°C until the analysis day.

Beckman Coulter AU5800 analyzer measured serum CRP, LDH, and ferritin levels. The STA R Max 3 (Stago) hemostasis and coagulation analyzer measured serum fibrinogen and D-dimer levels. A commercial ELISA kit (BT Lab, Catalog No: E3042Hu 96 T, Lot no: 202101015) measured serum IL-28 levels according to the manufacturer's instructions in an Epoch Microplate Spectrophotometer.

Statistical Analysis

Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) version 25.0 (IBM Corp.; Armonk, NY, USA) package program. The normality of data was determined with Kolmogorov–Smirnov test. Descriptive statistical analyses (mean ± standard deviation) and percentages were used. One-way analysis of variance (ANOVA) test and post hoc Tukey test were performed to compare biochemical values of groups. Chi-square test was used to determine the relationship between 2 variables (groups and gender/mechanical ventilation requirement/mortality) in a cross-tabulation. *P* values less than .05 at the 95% CI were considered statistically significant. Receiver operating characteristic (ROC) analysis was performed to define the optimal IL-28 cut-off values for detecting mortality and mechanical ventilation requirement.

MAIN POINTS

- Interleukin (IL-28) plays an essential role in viral defense.
- The role of IL-28 in defense against SARS-Cov-2 infection is not clear.
- Serum IL-28 levels were higher in the moderate group and the highest in the severe group compared to the mild group, in COVID-19 patients.
- Interleukin-28 levels may be used to predict mortality and mechanical ventilation need, independently of C-reactive protein and other infection markers.

RESULTS

The mean age of all patients was 58.5 ± 13.6 years. There was no significant difference in terms of age between the 3 groups ($P = .149$). Chi-square test results showed that there was no significant difference in terms of gender ($P = .875$); and there were significant differences in terms of death, mechanical ventilation requirement (invasive and non-invasive), and invasive mechanical ventilation requirement ($P < .001$ for all comparisons).

All patients who died and who required mechanical ventilation were in the severe group. The demographic, clinical characteristics, and biochemical values of the patients are summarized in Table 1.

One-way ANOVA test showed significant differences in serum CRP, LDH, fibrinogen, D-dimer, ferritin, and IL-28 levels between all groups ($P < .05$ for all comparisons). All patients' mean serum IL-28 levels were 383.74 ± 63.58 ng/L (Table 1). There were significant differences in terms of serum IL-28 levels between mild, moderate, and severe groups, being higher in the moderate group (366.88 ± 41.27 ng/L) and the highest in the severe group (453.46 ± 36.78 ng/L) compared to the mild group (335.52 ± 42.12 ng/L) (Figure 1).

Receiver operating characteristic curve analysis for predicting mechanical ventilation requirement (both invasive and non-invasive) results in the area under the ROC curve (AUC) of 0.84 (95% CI: 0.75-0.93). The cut-off value of IL-28 to predict mechanical ventilation needs with high sensitivity was 391.71 ng/L (100% sensitivity and 60.0% specificity, likelihood ratio (LR): 2.47) (Figure 2A).

Receiver operating characteristic curve analysis for predicting the need for invasive mechanical ventilation resulted in AUC of 0.87 (95% CI: 0.79-0.96). The cut-off value of IL-28 to predict the need for invasive mechanical ventilation with high sensitivity was 401.23 ng/L (100% sensitivity and 70.0% specificity, LR: 3.29) (Figure 2).

Receiver operating characteristic curve analysis for predicting non-invasive mechanical ventilation requirement resulted in the AUC of 0.80 (95% CI: 0.68-0.92). The cut-off IL-28 value to predict non-invasive mechanical ventilation with moderate sensitivity was 423.95 ng/L (71.4% sensitivity and 77.8% specificity (LR: 3.21) (Figure 2).

Receiver operating characteristic curve analysis for predicting mortality resulted in AUC of 0.86 (95% CI: 0.76-0.97).

Table 1. Demographic, Clinical Characteristics, and Biochemical Values of the Patients

	All (n = 90)	Mild (n = 30)	Moderate (n = 30)	Severe (n = 30)
Age (years)	58.5 ± 13.6 (*P* = .149)	54.6 ± 12.0	61.1 ± 14.2	59.9 ± 14.1
Gender, M/F (%)	53/47	50/50 (X^2 = 0.268; *P* = .875)	53/47	57/43
Death, n (%)	6 (6.6)	0 (0 %) (X^2 = 12.8; *P* < .001)	0 (0)	6 (20)
MV req. Inv., n (%)	9 (9.9)	0 (0%) (X^2 = 20.0; *P* < .001)	0 (0)	9 (30)
MV Req. All n (%)	17 (18.7)	0 (0%) (X^2 = 32.9; *P* < .001)	0 (0)	17 (56.7)
CRP (mg/L)	34.46 ± 51.33* (*P* = .011)	11.21 ± 5.42[a] (*P* = .019)	46.57 ± 57.47	44.82 ± 56.70[b] (*P* = .028)
LDH (U/L)	380.43 ± 221.86* (*P* < .001)	212.83 ± 67.69[a] (*P* = .01)	383.07 ± 168.88[c] (*P* = .003)	539.80 ± 249.10[b] (*P* < .001)
Fibrinogen (mg/dL)	393.37 ± 165.50* (*P* = .018)	357.07 ± 105.41[a] (*P* = .037)	462.20 ± 154.60[c] (*P* = .036)	358.43 ± 201.21
D-Dimer (ng/mL)	1941.09 ± 1130.20* (*P* = .028)	386.89 ± 136.52	2082.90 ± 1051.32	3249.87 ± 1275.34[b] (*P* = .021)
Ferritin (ng/mL)	680.15 ± 282.52* (*P* < .001)	166.15 ± 69.57[a] (*P* < .001)	836.96 ± 389.08	1037.33 ± 576.51[b] (*P* < .001)
IL-28 (ng/L)	383.74 ± 63.58* (*P* < .001)	335.52 ± 42.12[a] (*P* = .009)	366.88 ± 41.27[c] (*P* < .001)	453.46 ± 36.78[b] (*P* < .001)

Results are expressed as mean ± standard deviation and n (%); *P:* one-way analysis of variance (ANOVA) test statistics *P* value for group comparisons of numerical variables (age, CRP, LDH, fibrinogen, D-dimer, ferritin, and IL-28) and chi-square test statistics *P* value for group comparisons of categorical variables (gender, death, intubation, and mechanical ventilation); X^2: Pearson chi-square value; *$P < .05$ for one-way ANOVA test; a,b,c show one-way ANOVA post hoc Tukey test *P* values ([a]Significant difference between mild and moderate patients; [b]Significant difference between mild and severe patients; [c]Significant difference between moderate and severe patients).
M/F, male/female; MV req Inv., invasive mechanical ventilation requirement; MV Req. all, mechanical ventilation requirement invasive and non-invasive.

The cut-off IL-28 value to predict mortality with high sensitivity was 401.23 ng/L (100% sensitivity and 67.5% specificities, LR: 3.03). (Figure 2).

DISCUSSION

In this study, we tested whether IL-28 from the IFN-λ family can be used as a marker to show the severity of the disease in COVID-19 patients. There were significant differences in terms of serum IL-28 levels between mild, moderate, and severe groups, being higher in the moderate group (366.88 ± 41.27 ng/L) and the highest in the severe group (453.46 ± 36.78 ng/L) compared to the mild group (335.52 ± 42.12 ng/L). Various studies have shown the effect and role of the classical interferon family members in viral infections and sepsis.[14] The IFN-λ family, also known as type 3 interferons, is most effective on epithelial surfaces and is known to be effective in viral defense.[15]




Figure 1. IL-28 values of groups. IL, interleukin.

It was previously shown that there was an increase in IL-28 levels in chronic Hepatitis C Virus (HCV) and dengue fever.[16] It has also been shown that HCV patients with good response to antiviral treatment used to have lower IL-28 levels.[16] Although IL-28 and the IFN-λ family are generally thought to be having a positive influence in controlling viral infections, higher than normal levels of these cytokines may also be an indicator of an uncontrolled infection or viral response. The effects of the IFN-λ family and IL-28 in sepsis were demonstrated in a mice experiment.[17] In this study, not only the neutralization of the IL-28 pathway decreased mortality due to sepsis in mice but it was also observed that mortality increased in mice administered recombinant IL-28 externally. In contrast, administration of IL-28 to mice without sepsis did not increase mortality. Our study showed that IL-28 levels could be used to predict mortality and mechanical ventilation requirement independent of CRP and other infection markers. Interleukin-28 levels were high in patients who needed invasive mechanical ventilation and died in our study group, which supports the idea of high IL-28 levels being associated with mortality in sepsis due to viral infection.




Figure 2. ROC curve for prediction of (A) mechanical ventilation (invasive and non-invasive) requirement, (B) invasive mechanical ventilation requirement, (C) non-invasive mechanical ventilation requirement, and (D) mortality with IL-28 values. ROC, receiver operating characteristic.

Contrary to the data in our study, in a study conducted on patients with Crimean Congo hemorrhagic fever, it was shown that IL-28-B gene polymorphism did not have a significant effect on mortality.[18] However, there is no evaluation of IL-28 serum levels in this study. These data suggest that IFN-λ family member interleukins may have different effects on different types of viral infections.

The fact that the blockade of the IL-28 pathway in sepsis has produced promising results in terms of mortality in mice experiments is promising as a method that can be used in severe COVID-19 patients with limited treatment opportunities, and more scientific studies are needed on this subject.

An animal study has demonstrated that the upper airway microbiota of IL-28 receptor-negative mutant mice exposed to influenza virus was less affected than normal mice with IL-28 receptor, and secondary *Staphylococcus aureus* infection is less common in non-receptor mice.[19] This study shows that the immune response induced by IL-28 in viral infections may also increase the susceptibility to secondary bacterial infections. There were no data on the frequency of secondary bacterial infections in patients who required mechanical ventilation and who died in our study. Considering these results, future studies may be helpful to show whether excessive IL-28 secretion in viral infections increases secondary bacterial infections.

This study has some limitations. First of all, the study did not have a control group without COVID-19 infection. Second, we could not determine the mRNA expression of IL-28 due to technical inadequacy. Third, COVID-19 infection may lead to some degree of renal dysfunction and concentrations of serum metabolites such as amino acids, bile acids, nucleotides and their metabolites, glycerophospholipids, fatty acids, oxidized lipids, and organic acids due to altered filtration capacity of kidneys and thus, the levels of IL28 in serum samples might be affected. Fourth, since the patients in the severe group had serious clinical conditions and were administered multiple treatments at the same time, the linearity of biochemical parameters may have been impaired.

In conclusion, IL-28 may be a candidate biomarker for determining the disease severity of COVID-19 patients. Further studies are needed to determine the optimal cut-off values.

Ethics Committee Approval: Ethical committee approval was received from the Ethics Committee of Erzurum City Hospital (Ministry of Health) (approval No: 2021/01-04).

Informed Consent: Written and verbally informed consent was obtained from all patients or legal representatives.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – A.A., U.T.; Design – A.A., U.T.; Supervision – A.F.K.; Funding – A.A., U.T, A.F.K., T.T.; Materials – A.A., U.T.; Data Collection and/or Processing – A.A., U.T., T.T.; Analysis and/or Interpretation – N.K.B, U.T.; Literature Review – N.K.B, U.T.; Writing – A.A, T.T, U.T.; Critical Review – N.K.B, A.F.K.

Acknowledgments: The authors would like to thank to all Erzurum City Hospital health workers in ICU and patient wards for COVID, due to their helps during the outbreak and the duration of this research.

Declaration of Interests: The authors have no conflict of interest to declare.

Funding: This study received no funding.

REFERENCES

1. Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVID-19 or SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents*. 2020;34(2):327-331. [CrossRef]
2. King JT Jr, Yoon JS, Bredl ZM, et al. Accuracy of the Veterans Health Administration COVID-19 (VACO) Index for predicting short-term mortality among 1307 US academic medical centre inpatients and 427 224 US Medicare patients. *J Epidemiol Community Health*. 2022;76(3):254-260. [CrossRef]
3. Rahman T, Al-Ishaq FA, Al-Mohannadi FS, et al. Mortality prediction utilizing blood biomarkers to predict the severity of COVID-19 using machine learning technique. *Diagnostics (Basel)*. 2021;11(9):1582. [CrossRef]
4. Tiscia G, Favuzzi G, De Laurenzo A, et al. The prognostic value of ADAMTS-13 and von Willebrand factor in COVID-19 patients: prospective evaluation by care setting. *Diagnostics (Basel)*. 2021;11(9):1648. [CrossRef]
5. Uranga A, Villanueva A, Lafuente I, et al. Risk factors for clinical deterioration in patients admitted for COVID-19: a case-control study.*Rev Clinesp (Barc)*. 2022;222(1):22-30. [CrossRef]
6. Cihakova D, Streiff MB, Menez SP, et al. High-value laboratory testing for hospitalized COVID-19 patients: a review.*Future Virol*. 2021;16(10):691-705. [CrossRef]
7. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. *Nat Immunol*. 2003;4(1):63-68. [CrossRef]
8. Kempuraj D, Donelan J, Frydas S, et al. Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with anti-viral activities.*Int J Immunopathol Pharmacol*. 2004;17(2):103-106. [CrossRef]
9. Morrow MP, Pankhong P, Laddy DJ, et al. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. *Blood*. 2009;113(23):5868-5877. [CrossRef]
10. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL-28B predicts hepatitis C treatment-induced viral clearance.*Nature*. 2009;461(7262):399-401. [CrossRef]
11. Junaid K, Rasool H, Ul Mustafa A,et al. Association of IL-28 B and IL10 polymorphism with HCV infection and direct antiviral treatment.*Ann Clin Lab Sci*. 2021;51(4):512-520.
12. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet*. 2009;41(10):1105-1109. [CrossRef]
13. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL-28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. *Gastroenterology*. 2010;138(4):1338-1345.e7. [CrossRef]
14. Malmgaard L. Induction and regulation of IFNs during viral infections. *J Interferon Cytokine Res*. 2004;24(8):439-454. [CrossRef]
15. Lazear HM, Nice TJ, Diamond MS. Interferon-λ: immune functions at barrier surfaces and beyond. *Immunity*. 2015;43(1):15-28. [CrossRef]
16. Abe H, Hayes CN, Ochi H, et al. IL-28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. *J Hepatol*. 2011;54(6):1094-1101. [CrossRef]
17. Luo Q, Liu Y, Liu S, Yin Y, Xu B, Cao J. Interleukin 28 is a potential therapeutic target for sepsis. *Clin Immunol*. 2019;205:29-34. [CrossRef]
18. Aytekin FY, Barut HŞ, Rüstemoğlu A, Atay A, Günal Ö, Duygu F. Factors related to fatalities and clinical progression of Crimean-Congo hemorrhagic fever patients and the effects of il 28-B gene polymorphism. *Arch Virol*. 2019;164(2):547-557. [CrossRef]
19. Planet PJ, Parker D, Cohen TS, et al. Lambda interferon restructures the nasal microbiome and increases susceptibility to Staphylococcus aureus superinfection. *mBio*. 2016;7(1):e01939-e01915. [CrossRef]

Thorac Res Pract. 2023; 24(2): 66-75 DOI: 10.5152/ThoracResPract.2023.22050

Original Article

Effect of 2 Different High-Dose Methylprednisolone Treatments on Clinical Outcomes in Severe COVID-19 Patients

Fatma Eser[1], Bircan Kayaaslan[1], Ayşe Kaya Kalem[1], İmran Hasanoğlu[1], Zeynep Bilgiç[2], Dilek Asiltürk[2], Betül Kaplan[2], Rahmet Güner[1]

[1]Department of Infectious Diseases and Clinical Microbiology, Yıldırım BeyazıtUniversity, Faculty of Medicine, Ankara City Hospital, Ankara, Turkey
[2]Department of Infectious Diseases and Clinical Microbiology,Ankara City Hospital, , Ankara, Turkey

Cite this article as: Eser F, Kayaaslan B, Kaya Kalem A, et al. Effect of 2 different high-dose methylprednisolone treatments on clinical outcomes in severe COVID-19 patients. *Thorac Res Pract.* 2023;24(2):66-75.

Abstract

OBJECTIVE: The present study aimed to evaluate and compare the use of 2 different high-dose methylprednisolone posology in treating severe coronavirus disease 2019 pneumonia regarding mortality and recovery time between themselves and against steroidal/non-steroidal treatment.

MATERIAL AND METHODS: Severe coronavirus disease 2019 patients followed up between March 2020 and January 2021 were included. The steroid-free treatment protocol was applied before August 2020 (non-pulse group) and a treatment algorithm containing normal and high doses of methylprednisolone was applied after August 2020 (pulse group). Patients with clinical deterioration under the normal dose of methylprednisolone were administered 250 mg or 1000 mg of methylprednisolone for 3 days. We compared the pulse and non-pulse groups, in addition to pulse subgroups with each other, for clinical outcomes.

RESULTS: A total of 138 patients were included, including 36 patients in the non-pulse group and 102 in the pulse group. In the pulse group, 70 patients received 1000 mg/day and 32 received 250 mg/day of high-dose methylprednisolone therapy. In the comparison of pulse and non-pulse patient groups, mortality rate was lower in the pulse group ($P < .001$), and the time to discharge without oxygen support was shorter. Although the patients in the 250 mg subgroup were older, there was no difference between the 250 mg and 1000 mg subgroups in terms of end of oxygen requirement, discharge with oxygen support, and mortality. In addition, the required time to reach the oxygen-free period in patients discharged without oxygen support was similar in the 2 subgroups, and the majority of patients in both subgroups reached the oxygen-free period on the 20th day after initiating methylprednisolone.

CONCLUSION: Since there was no difference in clinical improvement between the use of 250 mg or 1000 mg methylprednisolone in patients with severe coronavirus disease 2019 infection, 1000 mg methylprednisolone was not required.

KEYWORDS: Methylprednisolone, corticosteroid, treatment, anakinra, COVID-19
Received: *March 3, 2022* ***Accepted:*** *October 6, 2022* ***Publicaiton Date:*** *February 6, 2023*

INTRODUCTION

Fourteen percent of coronavirus disease 2019 (COVID-19) cases progress to severe COVID-19 pneumonia. Anti-inflammatory and anti-cytokine drugs, especially corticosteroid therapy, constitute the backbone of treating such severe COVID-19 infection.[1-3] The severe clinical course in COVID-19 is associated with an excessive and uncontrolled immune response. Severe lung injury and acute respiratory distress syndrome (ARDS) develop in relation to excessive immune response, and the disease may progress to a fatal course.[4] It has been demonstrated that immunomodulatory and immunosuppressive therapies and interleukin-blocking agents used to suppress the excessive immune response in COVID-19 disease reduce hospital stay and increase survival.[5]

Corticosteroids positively contribute to the treatment when administered with appropriate timing in ARDS and sepsis cases.[6] In addition, the benefit of using corticosteroid therapies in patients who need oxygen support in COVID-19 disease has been proven to be effective in clinical trials designed as randomized controlled.[7,8] Recent studies report that the short-term use of methylprednisolone (MTP) at a dose of 250 mg/day in severe COVID-19 pneumonia reduces mortality and the need for oxygen support and improves inflammation markers.[9,10] Although not yet clearly supported by randomized controlled studies, it has been reported in a case series that short-term treatments of 500 mg/day and 1000 mg/day MTP also reduce mortality and contribute to lung recovery.[2,11] In a multicenter retrospective cohort, Cusacovich et al[12] reported that corticosteroid pulses reduce the mortality in severe COVID-19 patients.

The present study firstly aimed to investigate the impact of the treatment regimens containing low- and high-dose steroids on reducing mortality and shortening recovery time in patients who were followed up with severe COVID-19 pneumonia and deteriorated clinically. Secondly, if steroid treatment had an impact, we aimed to evaluate whether there was a

Corresponding author: Fatma Eser, e-mail: fatmacivelekeser@hotmail.com

Copyright@Author(s) - Available online at thoracrespract.org. Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

difference between the 250 mg/day and 1000 mg/day posology regarding clinical outcomes, recovery time, and mortality.

MATERIAL AND METHODS

Study Design and Setting

This retrospective observational study was performed in one of the country's reference hospitals for COVID-19 infection between March 2020 and January 2021. Patients over 18 years of age who were admitted to the hospital with COVID-19-related pneumonia (progressed to severe pneumonia during hospitalization), severe pneumonia, and critical illness were reviewed. Among these patients, those with clinical deterioration under standard therapy during their hospitalization period were included in the study.

An informed consent form was obtained from all patients included in the study. Ethical approval was provided by the Turkish Ministry of Health and the Ankara City Hospital Ethical Committee 2 with the number E2-21-31.

Patient Population

All included patients were those whose follow-up was started in the wards. Patients who needed intensive care support during their follow-up were transferred to the intensive care unit (ICU) and admitted back to the wards when the need for intensive care was ended. Disease severity was based on the WHO guideline classification. Patients with any oxygen saturation of <90% in room air, respiratory rate of >30/min, or examination finding indicating respiratory distress were categorized as having severe COVID-19 pneumonia. Those patients with ARDS, sepsis, and septic shock and those needing mechanical ventilation or vasopressor support were categorized as critically ill patients.[13]

Standard of care was constituted based on the recommendations of the Ministry of Health of the Turkish Republic COVID-19 guidelines, which includes treatment protocols that are regularly updated depending on the achievements in the literature.[14] Based on this public guideline, the time-varying treatment algorithms applied for COVID-19 patients in our center before and after August 2020 are presented in Figure 1. Before August 2020, all patients received favipiravir and anticoagulant therapy as the standard of care 1 (SOC 1). Low- or high-dose steroid treatment was not used during this period, so these patients were accepted as the non-pulse group. In case of clinical deterioration in these patients in this period, basic life support and/or tocilizumab, anakinra, intravenous immunoglobulin (IVIG), and stem cell transfusion were applied to the patients.

MAIN POINTS

- High-dose methylprednisolone (MTP) reduces mortality and shortens recovery time in severe coronavirus disease 2019 (COVID-19) infection.
- There is no difference between mortality and recovery time in the use of methylprednisolone at a dose of 250 mg/day or 1000 mg/day.
- There is no need to use a higher dose of methylprednisolone than 250 mg/day in severe COVID-19 infection.

In the updated ministry guideline, it was recommended to use 0.5-1 mg/kg of prednisolone or equivalent corticosteroid in patients who needed oxygen support due to respiratory distress and to use high-dose (≥250 mg/day) MTP in case of no response to this treatment within 24 hours. In addition, it was advised that anti-cytokine therapy should be used in patients with clinical progression under high-dose MTP therapy.[14] Based on our updated treatment algorithm, after August 2020, patients received favipiravir, anticoagulant therapy, and 0.5-1 mg/kg/day MTP (or equivalent) as the standard of care 2 (SOC 2). In case of clinical deterioration under SOC 2, firstly, patients were administered high-dose MTP therapy for 3 days. Therefore, patients with clinical deterioration during this second period were defined as the pulse group. We used 2 different MTP high doses for the pulse group, a dose of 250 mg/day and 1000 mg/day. The high dose of MTP used in patients was determined by the team of specialist physicians who followed up the patient. The MTP dose was continued as 1 mg/kg/day as of the fourth day for patients whose need for oxygen support and acute-phase reactants regressed under 3 days of high-dose MTP treatment.

If the patients' need for oxygen support did not regress and/or acute-phase reactants continued to increase after the third day of high-dose MTP, we added anakinra to the therapy. Anakinra was used at a dose of 2-10 mg/kg, divided into 4 doses.

Clinical deterioration was defined as persistent high fever, increase in oxygen support requirement within 24 hours, deepening of lymphopenia and thrombocytopenia, and increase in acute-phase response under SOC 1 and SOC 2 presented in Figure 1.

Follow-up Characteristics and Clinical Outcomes

Demographic characteristics and comorbid diseases of patients, time from symptom onset to admission, and time from symptom onset to clinical deterioration were obtained from the patient files and hospital electronic database. Fever (>38.0°C), oxygen support level [percent of fraction of inspired oxygen (FiO_2) required to keep oxygen saturation (SpO_2)>93%, and SpO_2/FiO_2 ratio were recorded. The low SpO_2/FiO_2 ratio reveals the need for higher oxygen support, which is expected to increase under treatment. The following laboratory parameters were also recorded: white blood cell, lymphocyte and platelet counts, creatine kinase, lactate dehydrogenase (LDH), C-reactive protein (CRP), procalcitonin, interleukin-6, ferritin, and D-dimer. Antiviral and anti-cytokine therapies, complications of COVID-19 disease, and the need for ICU follow-up were noted for all patients.

In order to evaluate the clinical course, fever, SpO_2/FiO_2 ratio, and laboratory parameters listed above were evaluated on the following days: (i) the day of hospital admission, (ii) the day of clinical deterioration/first day of high-dose pulse or other additional therapies, (iii) the third day of pulse therapy, (iv) the fifth day of pulse therapy, and (v) the day free of oxygen support.

Any clinical conditions, including thromboembolic events, acute renal failure under treatment, blood sugar dysregulation, or increased blood pressure, were considered the development of complications of COVID-19 disease.




Figure 1. (A) Treatment protocol for coronavirus disease 2019 (COVID-19) infection (March-August 2020). (B) Treatment protocol for COVID-19 infection (August 2020-January 2021)

We compared the pulse and non-pulse groups in terms of primary clinical outcomes consisting of death, discharge without oxygen support, discharge with oxygen support, and time to reach period without oxygen support in patients who were discharged without oxygen. As a secondary outcome, the requirement of ICU follow-up and the development of complications were evaluated for the pulse and non-pulse groups. The need for anakinra treatment in patients unresponsive to high-dose MTP was also compared as a secondary outcome. In the same way, we compared 2 different high-dose steroid

dose subgroups within themselves for all primary and secondary outcomes.

Statistical Analysis

Statistical analysis was performed using IBM Statistical Package for Social Sciences Statistics for Windows version 25.0 (IBM Inc., Armonk, NY, USA). Descriptive statistics were presented using median and interquartile range (25th-75th percentiles) for continuous variables and frequency and percentage values for categorical variables. The Mann–Whitney *U*-test compared age, duration of symptom onset to admission and initial clinical deterioration, and clinical and laboratory findings on admission day and the initial day of MTP between pulse and non-pulse groups (absent and exist) and 250 mg versus 1000 mg. The relationship between pulse steroid use and categorical variables (gender, presence of comorbid disease, clinical severity parameters, clinical outcomes, development of complication, and requirement of hospitalization in the ICU) was investigated using the Pearson chi-square test when the test assumptions were satisfied. Otherwise, Fisher's exact test was used. Time after high-dose methylprednisolone therapy to reach an oxygen-free condition was compared between non-pulse and pulse steroid groups using Kaplan–Meier curves. Statistical significance was regarded as a *P*-value <.05 in overall comparisons.

RESULTS

One hundred thirty-eight patients with severe COVID-19 pneumonia who had clinical deterioration during hospitalization were enrolled in the study. Thirty-six patients who met the inclusion criteria before August 2020 were included in the non-pulse group, while 102 patients who met the inclusion criteria after August 2020 formed the pulse group.

Comparison of Pulse and Non-pulse Groups

Demographic and clinical characteristics of patients and laboratory findings of the pulse and non-pulse groups on the day of admission and the day of clinical deterioration are given in Table 1. Age, gender, comorbid diseases, and duration of symptom onset to initiation of clinical deterioration were similar in the 2 groups. The duration of symptom onset to admission was longer and the need for oxygen support (SpO_2/FiO_2 ratio) on the day of hospital admission was higher in the pulse group compared to the non-pulse group (*P* = .003, <.001, respectively). C-reactive protein, ferritin, and LDH values on the day of hospital admission were also higher in the pulse dose group than in the non-pulse group (*P* = .004, .004, and <.001, respectively).

In the non-pulse group, in case of clinical deterioration, 4 patients were treated with tocilizumab, 3 with anakinra, 1 with IVIG, and 2 with stem cell therapy. In the pulse group, all patients received pulse therapy in case of clinical deterioration, and 26 patients unresponsive to pulse dose MTP therapy were administered anakinra treatment.

The comparison of the patient group according to administration of pulse steroid therapy regarding primary clinical outcomes revealed that those receiving high-dose steroid therapy had lower mortality rates, higher rates of discharge without oxygen support, and a shorter time to reach oxygen-free condition (*P* < .001 for each) (Table 4, Figure 2).

Comparison for 250 mg Versus 1000 mg Subgroups

A total of 102 patients with clinical deterioration had received 2 different high doses of MTP treatment. Of them, 32 received 250 mg/day MTP and 70 had 1000 mg/day MTP. Those 2 patient subgroups administered different high doses were compared for clinical outcomes within themselves. Demographic and clinical characteristics of the patient subgroups and laboratory findings on the day of admission and the day of clinical deterioration/initial day of high doses are presented in Table 2. The patients in the 250 mg subgroup were older (*P* < .001) and had more comorbid diseases (at least 1), hypertension, and pulmonary disease compared with the 1000 mg subgroup (*P* = .02, .04, .03, respectively). Duration of symptom onset to hospital admission and duration of symptom onset to initiation of high-dose MTP (clinical deterioration) were longer in the 250 mg subgroup. Laboratory and clinical parameters were similar between the 2 subgroups, except for the leukocyte count taken on the day of clinical deter ioration/initial day of high doses, which was higher in the 250 mg/day subgroup compared to the 1000 mg/day MTP group (*P* < .001). The comparison of laboratory values on the third, fifth, and the day when the patient could breathe without oxygen support under high-dose MTP treatment is given in Table 3.

The rates of patients who required anakinra treatment due to being unresponsive to high-dose MTP were not statistically different in the 250 mg/day and 1000 mg/day subgroups (31.3% and 22.9%, respectively, *P* = .136) (Table 4).

In the non-pulse group, 9 (25%) patients underwent mechanical respiratory support, and the median duration of mechanical ventilation was 10 (2-27) days. In the pulse group, 10 (10%) patients received mechanical ventilation support, and the median duration was 5 (1-10) days. Two (6.2%) of 32 patients in the 250 mg subgroup and 8 (11.4%) of 70 patients in the 1000 mg subgroup had mechanical ventilation support, and the median duration of mechanical ventilation in these subgroups was 7 (5-9) and 5 (1-10) days, respectively. When the 2 groups were compared in terms of clinical outcomes, there was no difference in mortality and discharge rates with or without oxygen support (Table 2 and Figure 2). No difference was observed between the 250 mg/day and 1000 mg/day MTP subgroups in terms of time to reach the oxygen-free day in patients discharged without oxygen support. Most patients in both groups reached the oxygen-free period on the 20th day after starting MTP (Figure 2).

DISCUSSION

In this study, the use of low- and high-dose MTP was detected to be a significant contribution to clinical recovery and survival. The survival or oxygen-free discharge rates were significantly higher, and the time to reach the oxygen-free period was shorter in patients who received high-dose MTP than in those who did not receive it. A second critical result of our study was that this positive effect was achieved even

Table 1. Clinical and Demographic Characteristics of the Patients Based on Pulse and Non-pulse Group

	Pulse Group (n = 102)	Non-pulse Group (n = 36)	*P*
Age, median (IQR)	61 (50–70)	63.5 (52-71.5)	.52
Gender (male), n (%)	82 (80.4)	22 (61.1)	.02*
Comorbid disease (at least 1), n (%)	60 (58.8)	24 (66.7)	.41*
Coronary artery disease	21 (20.6)	10 (27.8)	.37*
Hypertension	42 (41.2)	14 (38.9)	.81*
Diabetes mellitus	26 (25.5)	10 (27.8)	.79*
Pulmonary disease	3 (2.9)	5 (13.9)	.03*
Clinical severity, n (%)			.86*
Pneumonia	27 (26.5)	9 (25)	
Severe pneumonia—critical disease	75 (73.5)	27 (75)	
Duration of symptom onset to admission (day), median (IQR)	7 (5-10)	3 (2.5-7.5)	.003
Duration of symptom onset to initial clinical deterioration (day), median (IQR)	9 (7–11)	9 (5.5-13.5)	.86
Clinical and laboratory findings on admission day, median (IQR)			
Fever, °C, n (%)	44 (43.1)	21 (58.3)	.12*
SpO_2/FiO_2 ratio	2.5 (1.9-3.1)	4.3 (2.6-4.5)	<.001
White blood cell, 10^9/L	7.1 (4.9-9.2)	5.5 (4.6-7.9)	.09
Lymphocyte, 10^9/L	0.7 (0.5-1)	0.9 (0.6-1.1)	.08
Platelet, 10^9/L	195 (164–265)	193 (142.5-235)	.21
C-reactive protein, g/L	0.1 (0.1-0.2)	0 (0-0.1)	.004
IL-6, pg/mL	30.6 (14.8-61.9)	35.3 (23.5-41.7)	.44
Procalcitonin, µg/L	0.1 (0-0.2)	0.1 (0-0.3)	.74
Ferritin, µg/L	530.5 (269–1132)	245 (77.5-495)	.004
D-dimer, mg/L	0.8 (0.5-1.4)	0.9 (0.4-1.9)	.94
Creatine kinase, U/L	147.5 (75–281)	87.5 (59.5-183.5)	.06
Lactate dehydrogenase, U/L	392.5 (317-525.5)	286.5 (234-417)	.000
Clinical and laboratory findings on the initial day of MTP, median (IQR)			
Fever (>38.0°C), n (%)	22 (21.6)	21 (58.3)	<.001*
SpO_2/FiO_2 ratio	2 (1.5-2.6)	2.3 (1.8-2.6)	.22
White blood cell, 10^9/L	8.7 (6.2-12.3)	6.4 (5.1-9.3)	.01
Lymphocyte, 10^9/L	0.6 (0.4-0.8)	0.7 (0.6-1.1)	.007
Platelet, 10^9/L	250.5 (198.5–314)	215 (163.5-277)	.03
C-reactive protein, g/L	0.1 (0.1-0.2)	0.1 (0-0.2)	.80
IL-6, pg/mL	28.3 (12.5-61)	55.1 (31.5-95.5)	.03
Procalcitonin, µg/L	0.1 (0-0.2)	0.1 (0.1-0.6)	.06
Ferritin, µg/L	634.5 (354.5-1361.5)	626 (161.1-1240)	.24
D-dimer, mg/L	0.7 (0.5-1.3)	1.1 (0.6-2.4)	.02
Creatine kinase, U/L	122 (67-276)	111 (64-258.5)	.87
Lactate dehydrogenase, U/L	431 (336-571)	398 (300.5-519.5)	.12

IL, interleukin; IQR, interquartile range; MTP, methylprednisolone.
*Comparison from chi-square test, if not indicated Mann–Whitney *U*-test.

with a relatively low dose of pulsed MTP of 250 mg/day. We determined no differences between 250 mg/day and 1000 mg/day doses of MTP in terms of primary or secondary outcomes and treatment failure.

Randomized controlled clinical studies demonstrated that corticosteroid treatments used at 0.5-1.0 mg/kg/day doses reduce mortality. This result has been supported by several meta-analysis studies.[7,8] In addition, comparing the use of 6




Figure 2. Time to reach free of oxygen support day.

mg dexamethasone equivalent with 250 mg MTP (3 days), it was reported that it would be a successful option in patients who did not respond to the initial low-dose corticosteroid treatment.[15] In the studies of Cusacovich et al and Edalatifard et al.[12,9] 250 mg/day (3 days) pulse therapies were administered to 124 and 34 patients, respectively, and the results were compared with the standard therapy. The authors reported that MTP pulse therapy was an effective therapeutic agent in severe COVID-19 patients and reduced mortality. Although Fernández-Cruz et al reported that the in-hospital mortality rate was similar between the patients administered low-dose or high-dose corticosteroids, a current meta-analysis in which randomized controlled studies were included concluded that high-dose MTP therapy may be a promising treatment alternative in severely ill patients.[16,17] The results of our study also support the effectiveness of high-doses steroids detected in the meta-analysis. In the present study, all the patients in the pulse group were treated with low dose (0.5-1 mg/kg/day) of MTP at the beginning of hospitalization and received high-dose MTP due to clinical deterioration. More than 90% of the patients responded well to high-dose MTP and only 8.8% died in the pulse group, whereas 52.8% died in the non-pulse group.

Pulse and non-pulse group patients were included in the study in different periods. However, their demographic characteristics, clinical features, and laboratory values on admission were not different. Moreover, the patient in the pulse group had higher CRP, LDH, and ferritin levels on the day of clinical deterioration and needed a higher level of oxygen support (lower SpO_2/FiO_2 ratio). The current literature and our centers' results indicate an association between higher levels of LDH, CRP, and ferritin and severe COVID-19 infection.[16,18] Although the patients in the pulse group had the characteristics associated with a more severe clinical course, a better clinical response was achieved by pulse therapy. Lower rates of the requirement of ICU and mortality and a shorter time to reach the oxygen-free period were detected in the pulse group. The study of López Zúñiga et al[19] reported that high-dose (1.5 mg/kg/day) corticosteroid treatment was effective in increasing survival. In addition, Ikeda et al[20] revealed that the duration of mechanical ventilator support was shorter in those who received corticosteroids than in those who did not. In the same study, it was concluded that the duration of mechanical ventilation support was shorter in patients receiving high-dose corticosteroids than in patients receiving low-dose corticosteroids. There is no consensus in the literature on the optimal type and dose of steroids that should be used in severe patients. Doses of 125-500 mg/day MTP have been used as posology in clinical studies.[9,10,12] There are no studies comparing different high doses of steroids with each other. Reports on using 1000 mg/day MTP in severe COVID-19 are limited to case series.[2,11] The fact that a high dose of 1000 mg/day of MTP was used in 70 patients in our study provides a notable experience about the results of using such a high-dose MTP in severe COVID-19 patients.

Although the patients in the 250 mg/day subgroup were older and had more comorbid diseases, their laboratory parameters were not different at admission and at the time of clinical deterioration. In addition, there were no significant differences between 32 patients treated with 250 mg/day MTP and 70 patients treated with 1000 mg/day MTP for these parameters on the third and the fifth day of pulse treatment and the day free of oxygen support. Correspondingly, the course of laboratory values was similar on the third and the fifth day of pulse treatment and the day free of oxygen support.

Anakinra treatment was used in 26 of 102 patients who received pulse therapy due to clinical failure based on the treatment algorithm. In comparison of the 250 mg/day and 1000 mg/day MTP subgroups, there was no significant difference in terms of clinical unresponsiveness and the need for

Table 2. Clinical and Demographic Characteristics of the Patients Based on the Methylprednisolone Dose

	250 mg Subgroup (n = 32)	1000 mg Subgroup (n = 70)	*P*
Age, median (IQR)	67.5 (59.5-72)	57.5 (46-66)	<.001
Gender (male)	23 (71.9)	59 (84.3)	.14*
Comorbid disease (at least 1)	24 (75)	36 (51.4)	.02*
Coronary artery disease, n (%)	7 (21.9)	14 (20)	.83*
Hypertension, n (%)	18 (56.3)	24 (34.3)	.04*
Diabetes mellitus, n (%)	10 (31.3)	16 (22.9)	.37*
Pulmonary disease, n (%)	3 (9.4)	0 (0)	.03*
Clinical severity, n (%)			.23*
Pneumonia	6 (18.8)	21 (30)	
Severe pneumonia—critical disease	26 (81.3)	49 (70)	
Duration of symptom onset to admission, median (IQR) days	7 (6-10)	7 (4-9)	.03
Duration of symptom onset to initial high-dose MTP, median (IQR) days	11 (8-12)	8.5 (6-11)	.02
Clinical and laboratory findings on admission, median (IQR) days			
Fever, °C, n (%)	12 (37.5)	32 (45.7)	.44*
SpO_2/FiO_2 ratio	2.2 (1.5–3)	2.8 (2.2-3.2)	.11
White blood cell, 10^9/L	8.6 (6.2-13.2)	5.9 (4.7-8.8)	.006
Lymphocyte, 10^9/L	0.69 (0.4-1.0)	0.75 (0.57-0.95)	.42
Platelet, 10^9/L	213.5 (162.5–261)	189.5 (164–271)	.46
C-reactive protein, g/L	0.1 (0.1-0.2)	0.1 (0.1-0.2)	.60
IL-6, pg/mL	23 (14-40)	36.9 (18-68.3)	.23
Procalcitonin, µg/L	0.1 (0-0.1)	0.1 (0-0.3)	.24
Ferritin, µg/L	400.5 (226-739.5)	600 (287–1200)	.16
D-dimer, mg/L	1 (0.5-1.8)	0.7 (0.5-1.2)	.56
Creatine kinase, U/L	110 (55–199)	163 (81–310)	.07
Lactate dehydrogenase, U/L	417 (348–494)	371 (305–528)	.24
Clinical and laboratory findings on initial pulse, median (IQR) days			
Fever, °C, n (%)	6 (18.8)	16 (22.9)	.64*
SpO_2/FiO_2 ratio	1.7 (1.4-2.4)	2.2 (1.5-2.6)	.29
White blood cell, 10^9/L	10.49 (8.18-16.83)	7.8 (5.31-11.4)	<.001
Lymphocyte, 10^9/L	0.59 (0.38-0.85)	0.63 (0.485-0.835)	.36
Platelet, 10^9/L	244 (207-331)	258 (195.5-312)	.78
C-reactive protein, g/L	0.1 (0.1-0.2)	0.1 (0.1-0.2)	.66
IL-6, pg/mL	26.5 (15.4-64.1)	29 (12.5-55.2)	.89
Procalcitonin, µg/L	0.1 (0-0.2)	0.1 (0-0.2)	.39
Ferritin, µg/L	562 (402-–1016)	709 (316.5-1413)	.54
D-dimer, mg/L	0.9 (0.5-1.6)	0.7 (0.5-1.2)	.41
Creatine kinase, U/L	100 (61-268)	127 (74-289)	.34
Lactate dehydrogenase, U/L	476 (366-571)	417 (313-572)	.16

IL, interleukin; IQR, interquartile range; MTP, methylprednisolone.
*Comparison from chi-square test, if not indicated Mann–Whitney *U*-test.

anakinra treatment. Anakinra treatment has been reported to be a safe and effective alternative treatment in severe COVID-19 patients that reduces the need for mechanical ventilation and mortality rates.[21,22]

Due to their potential anti-inflammatory effects, corticosteroids effectively suppress lung inflammation by reducing proinflammatory cytokines and excessive cytokine response in the severe phase of the disease.[23]It is known that

Table 3. Improvement of Oxygen Requirement and Laboratory Parameters After Pulse Therapy in 250 mg and 1000 mg Subgroups

	250 mg Subgroup (n = 32)	1000 mg Subgroup (n = 70)	*P**
FiO_2/SpO_2 ratio			
Third day	1.52 (1.13-2.27)	2.04 (1.19-3.14)	.16
Fifth day	1.68 (1.18-2.69)	2.09 (1.13-3.14)	.84
White blood cell, 10^9/L			
Third day	11.1 (8.22-15.94)	10.415 (8.34-12.88)	.25
Fifth day	9.33 (7.7-12.31)	9.725 (7.3-13.36)	.07
Free of oxygen support day	8.57 (6.72-11.42)	9.41 (6.58-12.83)	.63
Lymphocyte, 10^9/L			
Third day	0.525 (0.320-0.86)	0.53 (0.43-0.78)	.75
Fifth day	0.57 (0.41-1.05)	0.7 (0.46-1.09)	.16
Free of oxygen support day	1.09 (0.86-1.74)	1.34 (0.77-1.98)	.95
Platelet, 10^9/L			
Third day	270 (237–377)	306 (230–381)	.20
Fifth day	302 (262–360)	312 (251–408)	.73
Free of oxygen support day	287 (224–374)	338 (245–394)	.31
C-reactive protein, g/L			
Third day	0.04 (0.03-0.12)	0.05 (0.03-0.1)	.88
Fifth day	0.03 (0.02-0.05)	0.02 (0.01-0.06)	.96
Free of oxygen support day	0.01 (0-0.02)	0.01 (0-0.03)	.18
Interleukin-6, pg/mL			
Third day	14.1 (59-26.2)	8.03 (4.3–23)	.19
Fifth day	12.65 (9-30.65)	13.55 (5.38–29)	.28
Free of oxygen support day	12 (5.3–19)	5.96 (3.9-15.3)	.13
Procalcitonin, µg/L			
Third day	0.05 (0.03-0.28)	0.05 (0.03-0.11)	.97
Fifth day	0.07 (0.03-0.12)	0.06 (0.03-0.13)	.15
Free of oxygen support day	0.03 (0.03-0.03)	0.04 (0.03-0.08)	.007
Ferritin, µg/L			
Third day	592 (374-1188)	703 (382-1462)	.78
Fifth day	453 (316-991)	652 (372-1517)	.41
Free of oxygen support day	373.5 (122-746)	581 (286-928)	.3
D-dimer, mg/L			
Third day	0.83 (0.67-1.58)	0.58 (0.37-0.95)	.017
Fifth day	0.99 (0.66-1.93)	0.92 (0.55-1.71)	.66
Free of oxygen support day	0.44 (0.3–1)	0.55 (0.35-1.45)	.25
Creatine kinase, U/L			
Third day	75 (45–133)	73.5 (43.5-174.5)	.44
Fifth day	51 (31-70)	53 (37-117)	.15
Free of oxygen support day	33.5 (21-60)	39 (29-73)	.10
Lactate dehydrogenase, U/L			
Third day	502.5 (384-618)	401.5 (328-527)	.010
Fifth day	432 (384-520)	388 (313-533)	.61
Free of oxygen support day	321 (275-386)	317 (258-402)	.83

*All comparisons: Mann–Whitney *U*-test.

Table 4. Primary and Secondary Outcomes for Pulse and Non-pulse Groups and 250 mg and 1000 mg Subgroups

	Pulse Group (n = 102)	Non-pulse Group (n = 36)	*P**		250 mg Subgroup (n = 32)	1000 mg Subgroup (n = 70)	
	n (%)	n (%)			n (%)	n (%)	*P**
Clinical outcomes, n (%)			<.001	Clinical outcomes, n (%)			.25
Discharged without oxygen support	85 (83.3)	17 (47.2)		Discharged oxygen support free	27 (84.4)	58 (82.9)	
Discharged with oxygen support	8 (7.8)	0 (0)		Discharged with oxygen support	4 (12.5)	4 (5.7)	
Exitus	9 (8.8)	19 (52.8)		Exitus	1 (3.1)	8 (11.4)	
				Requirement of anakinra therapy, n (%)	10 (31.3)	16 (22.9)	.14
Development of complication, n (%)	17 (16.7)	16 (44.4)	<.001	Development of complication, n (%)	7 (21.9)	10 (14.3)	.34
Requirement of intensive care unit, n (%)	44 (43.1)	29 (80.6)	<.001	Requirement of intensive care unit, n (%)	16 (50)	28 (40)	.34

*All comparisons: chi-square test.

corticosteroids regulate excessive immune response in case of sepsis[24], and are similarly effective in the severe period of COVID-19 infection.[3] The use of corticosteroids has some controversial issues regarding its short- and long-term adverse effects and disease progression capacity.[25] In our study, we could not present a result on this issue because it was a retrospective design, and the records were insufficient. However, it was reported that high-dose MTP shortens the length of ICU stays without significant side effects.[15]

This study has some limitations. In our center, there was an expert consensus that the clinical response to pulse steroid therapy was successful. Therefore, there was no patient group who was not given pulse therapy when clinical worsening occurred. We could not compare the use of high-dose MTP treatment with low-dose MTP in clinical deterioration. Due to the retrospective nature of the study, the records of adverse effects associated with corticosteroid use were insufficient. Therefore, the side effects of different high doses could not be evaluated.

In conclusion, the use of high-dose MTP in severe COVID-19 patients reduces mortality and shortens recovery time. There is no difference between the use of pulse therapy at a dose of 250 mg/day or 1000 mg/day (for 3 days) in terms of mortality, recovery time, and clinical course. A dose of 250 mg/day of MTP is as effective as 1000 mg/day dose MTP in severe COVID-19 patients, and there is no additional contribution of a higher dose than 250 mg/day in clinical recovery.

Ethics Committee Approval: Ethical committee approval was received from the Ethics Committee of Ankara City Hospital Ethical Committee 2 (Approval No: E2-21-31, Date: 13.01.2021).

Informed Consent: Verbal/Written informed consent was obtained from the patients who agreed to take part in the study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – F.E., B.Kayaaslan., R.G.; Design – F.E., B.Kayaaslan; Supervision – F.E., A.K.K.; Funding – None; Materials – Z.B., D.A., B.Kaplan.; Data Collection and/or Processing – F.E., B.Kaplan., Z.B., D.A.; Analysis and/or Interpretation – F.E., B.Kayaaslan., İ.H.; Literature Review – F.E., İ.H., A.K.K.; Writing – F.E, B.Kayaaslan.; Critical Review – B.Kayaaslan., R.G.

Declaration of Interests: The authors have no conflict of interest to declare.

Funding: The authors declared that this study has received no financial support.

REFERENCES

1. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance - United States, January 22-May 30, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(24):759-765. [CrossRef]
2. Dolci G, Cassone G, Venturelli F, et al. High-dose glucocorticoids pulse-therapy for beta-Coronaviridae pneumonia: a systematic literature review and case-series of coronavirus disease-2019. *Clin Exp Rheumatol*. 2021;39(5):1119-1125. [CrossRef]
3. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-immunomodulatory therapy in COVID-19. *Drugs*. 2020;80(13):1267-1292. [CrossRef]
4. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. *Lancet Respir Med*. 2020;8(6):e46-e47. [CrossRef]
5. Aomar-Millán IF, Salvatierra J, Torres-Parejo Ú, et al. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study. *Intern Emerg Med*. 2021;16(4):843-852. [CrossRef]
6. Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. *Expert Rev Respir Med*. 2020;14(11):1149-1163. [CrossRef]
7. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med*. 2021;384(8):693-704. [CrossRef]

8. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al.Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA*. 2020;324(13):1330-1341. [CrossRef]
9. Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. *Eur Respir J*. 2020;56(6):2002808. [CrossRef]
10. Ruiz-Irastorza G, Pijoan JI, Bereciartua E, et al. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: an observational comparative study using routine care data. *PLoS One*. 2020;15(9):e0239401. [CrossRef]
11. So C, Ro S, Murakami M, Imai R, Jinta T. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series. *Respirol Case Rep*. 2020;8(6):e00596. [CrossRef]
12. Cusacovich I, Aparisi Á, Marcos M, et al. Corticosteroid pulses for hospitalized patients with COVID-19: effects on mortality. *Mediators Inflammm*. 2021;2021:6637227. [CrossRef]
13. World Health Organization. *Clinical management of COVID-19: interim guidance*; 2020. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1. Accessed September 1, 2021.
14. Republic of Turkey Ministry of Health. COVID-19 (SARS-CoV-2 infection) adult patient treatment, Scientific advisory committee study. Available at: https://covid19.saglik.gov.tr/Eklenti/40719/0/covid-19rehberieriskinhastayonetimivetedavipdf.pdf.
15. Batirel A, Demirhan R, Eser N, Körlü E, Tezcan ME. Pulse steroid treatment for hospitalized adults with COVID-19. *Turk J Med Sci*. 2021;51(5):2248-2255. [CrossRef]
16. Fernández-Cruz A, Ruiz-Antorán B, Muñoz-Gómez A, et al. A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality. *Antimicrob Agents Chemother*. 2020;64(9):e01168-20. [CrossRef]
17. Hasan SS, Kow CS, Mustafa ZU, Merchant HA. Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? A meta-analysis of randomized control trials. *Expert Rev Respir Med*. 2021;15(8):1049-1055. [CrossRef]
18. Güner R, Hasanoğlu İ, Kayaaslan B, et al. COVID-19 experience of the major pandemic response center in the capital: results of the pandemic's first month in Turkey. *Turk J Med Sci*. 2020;50(8):1801-1809. [CrossRef]
19. López Zúñiga MÁ, Moreno-Moral A, Ocaña-Granados A, et al. High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response. *PLOS ONE*. 2021;16(1):e0243964. [CrossRef]
20. Ikeda S, Misumi T, Izumi S, et al. Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study. *Sci Rep*. 2021;11(1):10727. [CrossRef]
21. Pasin L, Cavalli G, Navalesi P, et al. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. *Eur J Intern Med*. 2021;86:34-40. [CrossRef]
22. Erden A, Ozdemir B, Karakas O, et al. Evaluation of 17 patients with COVID-19 pneumonia treated with anakinra according to Hscore, SOFA, MuLBSTA, and Brescia-COVID respiratory severity scale (BCRSS) scoring systems. *J Med Virol*. 2021;93(3):1532-1537. [CrossRef]
23. Montón C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. *Eur Respir J*. 1999;14(1):218-220. [CrossRef]
24. Franchimont D, Kino T, Galon J, Meduri GU, Chrousos G. Glucocorticoids and inflammation revisited: the state of the art. NIH clinical staff conference. *Neuroimmunomodulation*. NIH clin staff conference. 2002-2003;10(5):247-260. [CrossRef]
25. Akter F, Araf Y, Hosen MJ. Corticosteroids for COVID-19: worth it or not?. *Mol Biol Rep*. 2021:1-10. [CrossRef]

Thorac Res Pract. 2023; 24(2): 76-84 DOI: 10.5152/ThoracResPract.2023.22130

Original Article

Effect of Continuous Positive Airway Pressure Therapy on Pro-Brain Natriuretic Peptide, C-Reactive Protein, Homocysteine, and Cardiac Markers in Patients with Obstructive Sleep Apnea

Nejdiye Güngördü[1], Şermin Börekçi[1], Hazal Cansu Çulpan[2], Erkam Coşkun[3], Faruk Ayan[4], Birsen Mutlu[1]

[1]Department of Pulmonary Diseases, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey
[2]Altındağ District Health Directorate, Ankara, Turkey
[3]Department of Biochemistry, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey
[4]Department of Cardiology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey

Cite this article as: Güngördü N, Börekçi Ş, Çulpan HC, Coşkun E, Ayan F, Mutlu B. Effect of continuous positive airway pressure therapy on pro-brain natriuretic peptide, C-reactive protein, homocysteine, and cardiac markers in patients with obstructive sleep apnea. *Thorac Res Pract.* 2023;24(2):76-84.

Abstract

OBJECTIVE: Obstructive sleep apnea is associated with increased morbidity and mortality, especially cardiovascular and cerebrovascular, and affects a significant proportion of the population. The study was aimed to determine the levels of pro-brain natriuretic peptide, C-reactive protein, homocysteine, and cardiac markers (creatine kinase, creatine kinase isoenzyme MB, troponin T) and evaluate the effectiveness of continuous positive airway pressure therapy in patients with obstructive sleep apnea.

MATERIAL AND METHODS: Pro-brain natriuretic peptide, C-reactive protein, homocysteine, and cardiac markers (creatine kinase, creatine kinase isoenzyme MB, troponin T) were assessed in blood samples collected before and after continuous positive airway pressure treatment from the 30 patients included in the study, and their results were compared.

RESULTS: There was a significant decrease between the baseline pro-brain natriuretic peptide and the 6-month pro-brain natriuretic peptide values after continuous positive airway pressure therapy ($P < .05$). There was a significant increase in creatine kinase-MB and troponin T values 6 months after continuous positive airway pressure therapy compared to baseline values ($P < .05$).

CONCLUSIONS: A significant decrease was observed in pro-brain natriuretic peptide values after continuous positive airway pressure therapy in obstructive sleep apnea patients without cardiac failure, while a more significant decrease was especially observed among hypertension patients. This finding suggests that pro-brain natriuretic peptide may be used as an early indicator of cardiac dysfunction in obstructive sleep apnea patients without any heart diseases except for hypertension.

KEYWORDS: Obstructive sleep apnea, pro brain natriuretic peptide, continuous positive airway pressure

Received: *July 21, 2022* ***Accepted:*** *October 7, 2022* ***Publication Date:*** *March 28, 2023*

INTRODUCTION

Obstructive sleep apnea (OSA) is a disease characterized by recurrent episodes of partial or complete upper airway obstruction resulting in hypoxia and arousals during sleep.[1] This disease is associated with increased morbidity and mortality, especially cardiovascular and cerebrovascular, and affects a significant proportion of the population.[2] Recurrent apnea in OSA can cause nocturnal hypoxemia and sympathetic hyperactivity; sympathetic hyperreactivity may lead to an increase in systemic blood pressure followed by endothelial dysfunction due to this increase, while endothelial dysfunction causes systemic inflammation. Therefore, cardiovascular diseases (CVDs) such as congestive heart failure, hypertension, arrhythmia, and coronary artery diseases (CADs) are prevalent among these patients.[3] Obstructive sleep apnea is considered to be a risk factor for progressive heart failure. Continuous positive airway pressure (CPAP) therapy forms the basis of a treatment to eliminate obstructive events and prevent daytime sleepiness and cardiovascular complications.

Brain natriuretic peptide (BNP) is a cardiac neurohormone secreted by myocytes after myocardial hypoxemia and ventricular volume expansion. Since ventricular load in the apneic period results in ventricular strain, increased BNP level is regarded as a prognostic marker in patients with OSA. Studies have revealed increased secretion of N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) in cardiac problems such as heart failure, CAD, and cardiac hypertrophy and is associated with poor prognosis. Studies have also shown that BNP levels are affected in different ways in OSA patients.[2,4-7] Serum C-reactive protein (CRP) is an inflammatory marker and is reported to be elevated in patients with OSA.[8,9] Various studies have reported that homocysteinemia due to intermittent hypoxia may be observed in OSA patients.[10,11] Elevated levels of cardiac biomarkers in serum are expected following ischemia or damage/necrosis of myocytes. Studies investigating troponin levels in the blood of patients with OSA have reported varying results.[7,12,13]

Corresponding author: Nejdiye Güngördü, e-mail: nejdiyegungordu@gmail.com

Copyright@Author(s) - Available online at thoracrespract.org. Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

In this study, we aimed to evaluate the effects of recurrent apnea and hypoxia on pro-BNP, CRP, homocysteine, and cardiac biomarker levels in OSA patients and the responses of these effects to CPAP therapy.

MATERIAL AND METHODS

This study was conducted as a prospective study in the sleep laboratory of an accredited university. Approval was obtained from the Ethics Committee of the Cerrahpaşa Faculty of Medicine at İstanbul University (No: 20908). Informed consent was obtained from each recruited participant.

Study Participants

Thirty-three patients who were diagnosed with moderate and severe OSA by polysomnography (PSG) and received CPAP treatment were prospectively followed up for 6 months. Inclusion criteria were diagnosis of OSA and recommendation of a CPAP device, an average daily CPAP use ≥4 h/day during the 6-month follow-up period, consent to study participation, normal pulmonary function test (PFT) and chest radiography, and ejection fraction (EF) of ≥60% on echocardiography. Exclusion criteria were refusal to participate in the study, previous diagnosis of heart failure or detection of heart failure, diastolic failure or right heart failure on echocardiography, abnormal PFT, and recent facial trauma/operation. Two patients with signs of heart failure on echocardiography and 1 patient who did not show up to follow-up were excluded from the study.

Demographic and Clinical Characteristics

A data collection form was developed to evaluate the age, gender, additional diseases, and medications of each patient. In addition to physical examination, neck circumference, weight, and height were measured. Body mass index was calculated as kilograms per square meter. Posteroanterior chest radiography, electrocardiography (ECG), and respiratory function tests were performed. The EF was used to exclude >60% cardiac failure. Complete blood count, routine biochemical analysis, and thyroid hormone levels were studied.

Polysomnography and Continuous Positive Airway Pressure Therapy

Polysomnography was performed using the SOMNOscreen™ Plus PSG device. Measurements were taken and recorded during nocturnal sleep for 5-8 hours. Polysomnography consisted of 2 electroencephalography (C3A2-O2A1), 2 electrooculogram, 1 chin and 1 leg electromyogram, 1 ECG recording, oronasal thermistor, hemoglobin oxygen saturation with fingertip pulse oximetry, position evaluation, and thoracic and abdominal movements. Synchronous video recording was taken during sleep with the help of a body position sensor and nasal pressure sensor. The sleep scores of the patients were scored in 30-second epochs according to the 2012 American Academy of Sleep Medicine guidelines. Apnea was defined as cessation of the airflow for at least 10 seconds, while hypopnea was defined as ≥50% decrement in airflow with accompanying arousal and/or ≥3% arterial oxygen desaturation.[14] Patients were classified as having mild, moderate, and severe OSA by apnea–hypopnea index (AHI) 5-15, 15-30, and ≥30, respectively. Patients who were recommended CPAP therapy were instructed on how to use the device and summoned to 1-month, 3-month, and 6-month outpatient follow-ups; patients living outside the city were interviewed over the phone. In these follow-ups, patients were asked whether they had any difficulties with the devices, whether they were comfortable with the pressure settings, and how many hours they used the device. Patients who did not regularly use the device or who could not be reached over phone were excluded from the study.

Analysis of Blood Samples

A total of 6 cc of blood was drawn from the patients before the PSG when CPAP titration was performed and after 6 months of CPAP treatment. Blood samples were collected between 9:30 AM and 11:00 AM after 12 hours of fasting using the standard venipuncture technique. After the blood samples were centrifuged at 5000 rpm for 5 minutes, the separated serum was stored at −80°C to study pro-BNP, CRP, homocysteine, and cardiac markers (CK, CK-MB, troponin T). The serum samples were removed from −80°C storage on the day of study. Pro-brain natriuretic peptide was studied with the electrochemiluminescence method in the Cobas E170 modular system device, homocysteine with the immunonephelometric method in the Siemens BN ProSpec device, CK with the enzymatic (N-acetyl-L-cysteine) method in the Cobas Hitachi-modular DPP device, CK-MB with the immunoinhibition method in the Cobas Hitachi-modular DPP device, and troponin T was studied with the electrochemiluminesc ence method in the Cobas e 411 device.

Statistical Analysis

Number Cruncher Statistical System 2007 and Power Analysis and Sample Size 2008 Statistical Software (Utah, USA) were used for statistical analysis of the data. Descriptive statistical methods (mean, standard deviation, median, frequency, 25th-75th percentile, frequency, percentage) were used to analyze and present the data. Shapiro–Wilk was used to test normality distribution of the data. Wilcoxon signed-rank test was used for the evaluation of the non-normally distributed parameters to compare 6-month follow-up values to the baseline values. Mann–Whitney *U*-test was used for comparing continuous parameters between 2 groups. Categorical parameters were compared by using Fisher exact test. McNemar-Bowker test was used for comparing OSA groups before and after the CPAP treatment. Results were evaluated at significance level of $P < .05$.

RESULTS

Demographic, clinical, and anthropometric characteristics of the 30 patients are presented in Table 1.

Twenty-four patients had severe OSA and 6 patients had moderate OSA. Of 30 patients with OSA, 7 (23%) had hypertension while 5 (16.7%) had diabetes mellitus. Demographic, clinical, and anthropometric characteristics of the 30 patients with moderate and severe OSA are presented in Table 2.

Demographic data are shown in Table 3 according to the presence of hypertension in OSA patients.

Mean AHI was 51.4 at baseline and 5.9 after CPAP therapy. The decrease after treatment was statistically significant (Table 4).

Table 1. Patient Characteristics

Characteristics	(n = 30) Mean ± SD Median (25th-75th Percentile)
Age (years)	46.5 ± 9.8
	47.5 (38.8-53.3)
Height	168.1 ± 10.2
	167.5 (159.8-177.3)
Weight	96.5 ± 17.5
	94.5 (84.8-105)
Body mass index	34.2 ± 5.8
	94.5 (84.8-105)
Apnea–hypopnea index	51.43 ± 25.1
FVC (%)	101.3 ± 12.5
	102.5 (90.8-107.3)
FEV1 (%)	98.4 ± 12.8
	97.5 (87.8-110)
FEV1/FVC	80.3 ± 4.3
	97.5 (87.8-110)
	n (%)
Gender	
Male	24 (80)
Female	6 (20)
Smoking history	
No	19 (63.3)
Yes	5 (16.7)
Quit	6 (20)

FEV, forced expiratory flow; FEV1, forced expiratory flow in 1 second; FVC, forced vital capacity; SD, standard deviation.

Table 2. Characteristics of the 30 Patients with Moderate and Severe OSA

Characteristics	Moderate OSA (n = 6) Mean ± SD Median (25th-75th Percentile)	Severe OSA (n = 24) Mean ± SD Median (25th-75th Percentile)	*P* *
Age	49 ± 7.6	45.9 ± 10.3	.561
	47.5 (43.5-55.8)	47.5 (37.3-53)	
Height	171.5 ± 8	167.3 ± 10.7	.347
	172 (164.5-177.8)	165.5 (159-17.8)	
Weight	97 ± 12.6	96.4 ± 18.8	.667
	97.5 (84.8-108.5)	94.5 (81.5-104.8)	
BMI	33 ± 3.7	34.5 ± 6.3	.743
	32.5 (30-36.9)	33.4 (30.9-37.1)	
FVC (%)	98.8 ± 7	101.9 ± 13.6	.667
	99.5 (93.3-104.3)	105 (90.3-108.5)	
FEV1 (%)	97.8 ± 8.6	98.5 ± 13.8	.820
	96 (92-106.3)	98 (87.3-110)	
FEV1/FVC	80.8 ± 4.8	80.1 ± 4.3	.781
	81 (78.3-83.5)	80 (77.3-84)	
	n (%)	n (%)	*P* **
Gender			
Male	6 (100)	18 (75)	.302
Female	0	6 (25)	
Smoking history			
No	4 (66.7)	15 (62.5)	1
Yes	1 (16.7)	4 (16.7)	
Quit	1 (16.7)	5 (20.8)	

BMI, body mass index; FEV, forced expiratory flow; FEV1, forced expiratory flow in 1 second; FVC, forced vital capacity; OSA, obstructive sleep apnea; SD, standard deviation.
*Mann–Whitney *U*-test.
**Fisher exact test.

There was a statistically significant difference between baseline and post-CPAP AHI groups; while 73% of patients were in the severe OSA group at baseline, they were in the moderate obstructive sleep apnea syndrome (OSAS) group after treatment, while 17% of the patients were in the moderate OSA group at baseline and were in the mild OSA group after treatment (Table 5).

Pro-brain natriuretic peptide, CRP, homocysteine, and cardiac biomarkers before and after CPAP treatment are presented in Table 4. An average decrease of 0.4 units was detected in 6-month follow-up CRP values after CPAP therapy, though the difference was not statistically significant ($P > .05$). There was a significant increase in creatine kinase-MB (CK-MB) and troponin T values 6 months after CPAP therapy compared to baseline values ($P < .05$). A statistically significant correlation was not observed between homocysteine and creatine kinase (CK) values at 6-month follow-up compared to baseline values ($P > .05$). There was a statistically significant decrease in pro-BNP values 6 months after CPAP therapy compared to baseline values ($P < .05$). Patients who had hypertension had significantly higher baseline pro-BNP levels ($P < .05$) compared to patients without hypertension; however, this difference disappeared after 6 months of CPAP therapy ($P > .05$). There was a significant difference in pro-BNP values both before and after treatment between patients with hypertension and without hypertension (Table 6, Figures 1 and 2).

DISCUSSION

According to the results of our study, a significant decrease was observed in pro-BNP and a significant increase in troponin T and CK-MB values after 6 months of CPAP treatment compared to baseline values in patients with moderate and severe OSA without heart failure. No statistically significant difference was observed between CRP, homocysteine, and CK values after 6 months of CPAP treatment compared to baseline values.

Kita et al[6] demonstrated increased serum BNP levels between 02:00 and 06:00 at night in OSAS patients, and this improved after effective CPAP therapy. In another study by Møller

Table 3. Presence of Hypertension in OSA Patients

Characteristics	Hypertension (+) (n = 7) Mean ± SD Median (25th-75th Percentile)	Hypertension (–) (n = 23) Mean ± SD Median (25th-75th Percentile)	*P**
Age	52.6 ± 10.4	44.7 ± 9	.077
	51 (48-64)	45 (38-53)	
Height	163 ± 14.8	169.7 ± 8.2	.245
	159 (150-180)	169 (162-177)	
Weight	99 ± 21.4	95.8 ± 16.7	.886
	93 (80-105)	96 (86-105)	
BMI	37.3 ± 6.2	33.2 ± 5.5	.144
	37.5 (31.6-43.8)	33.3 (28.6-35.1)	
FVC (%)	101.1 ± 15.2	101.3 ± 12	.962
	103 (90-116)	102 (91-107)	
FEV1 (%)	98.1 ± 19.3	98.4 ± 10.7	1
	105 (86-110)	97 (89-110)	
FEV1/FVC	79.9 ± 4.1	80.4 ± 4.4	.811
	80 (79-82)	81 (77-84)	
	n (%)	n (%)	*P***
Gender			
Male	3 (42.9)	21 (91.3)	.016
Female	4 (57.1)	2 (8.7)	
Smoking history			
No	5 (71.4)	14 (60.9)	1
Yes	1 (14.3)	4 (17.4)	
Quit	1 (14.3)	5 (21.7)	

BMI, body mass index; FEV, forced expiratory flow; FEV1, forced expiratory flow in 1 second; FVC, forced vital capacity; OSA, obstructive sleep apnea; SD, standard deviation.
*Mann–Whitney *U*-test.
**Fisher exact test.

et al.[15] a significant difference in BNP levels was observed after 14 months of CPAP therapy in patients with moderate OSA. Cifçi et al[7] did not observe a significant change in pro-BNP levels after 6-month CPAP treatment and reported that pro-BNP levels in serum were not associated with the severity of OSA. Colish et al[12] did not find a significant change in pro-BNP levels after 1 year of CPAP therapy compared to baseline values in 47 OSA patients. In another study by Chang et al.[13] CPAP therapy was found to decrease NT-pro-BNP but had a significant effect on troponin-T in patients with moderate and severe OSA. Xu et al[16] demonstrated that CPAP treatment was associated with reduced NT-pro-BNP in nonobese participants with OSA. The results of our study are consistent with the results of studies by Kita et al.[6] Xu et al.[16] and Chang et al[13] but differed from the results of Møller et al.[15] Cifçi et al.[7] and Colish et al.[12]

In a study by Sharma et al.[17] in which the effects of CPAP treatment on serum pro-BNP levels were investigated in acute decompensated heart failure patients with OSA, no significant improvement was found in NT-pro-BNP levels after PAP treatment. In a study by Zhao et al.[18] in which the effects of positive pressure mechanical ventilation treatment on serum pro-BNP levels were investigated in congestive heart failure patients with OSA, plasma pro-BNP levels were found to be significantly decreased in the group treated with CPAP compared to the group receiving only medical treatment, and it was demonstrated that positive pressure mechanical ventilation treatment may be effective in decreasing BNP levels in patients with OSA. As for our study, we observed a significant decrease in pro-BNP with CPAP therapy, despite the fact that participants were OSA patients without heart disease other than hypertension.

Tasci et al[5] demonstrated that there was a significant decrease in serum NT-pro-BNP levels with nasal CPAP treatment in patients with hypertensive OSA compared to normotensive patients. In our study, although patients with hypertension had significantly higher baseline pro-BNP levels ($P < .05$); however, this difference disappeared after 6 months of CPAP treatment. This suggests that CPAP therapy is more effective in lowering pro-BNP levels in OSAS patients

Table 4. OSA Classification

Parameters	Overall (n = 30)	Moderate OSA (n = 6)	Severe OSA (n = 24)	Hypertension (n = 7)	No Hypertension (n = 23)
	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
	Median (25th-75th Percentile)	Median (25th-75th Percentile)	Median (25th-75th Percentile)	Median (25th-75th Percentile)	Median (25th-75th Percentile)
AHI	51.4 ± 25.1	19.7 ± 4.1	59.4 ± 21.5	59.6 ± 22.3	48.9 ± 25.8
	50.4 (33.7-66.8)	19.1 (15.6-24.4)	54.3 (44.6-69)	66.7 (44.6-79.8)	50.2 (32-57.6)
Pressure	7.4 ± 1.8	6.3 ± 2.1	7.7 ± 1.6	6.6 ± 1.4	7.7 ± 1.8
	4.3 (1.9-7.3)	6.5 (4-8.3)	4.6 (2.2-7.5)	4.5 (2.7-7.2)	3.9 (1.8-7.6)
Post-CPAP AHI	5.9 ± 7.5	5.1 ± 9.8	6.1 ± 7.1	4.4 ± 2.6	6.4 ± 8.5
	8 (6-8)	0.8 (0.2-9.2)	8 (6-8)	7 (6-8)	8 (6-9)
*P**	<.001	.046	<.001	.018	<.001

AHI, apnea–hypopnea index; CPAP, continuous positive airway pressure; OSA, obstructive sleep apnea; SD, standard deviation.
*Wilcoxon signed-rank test (comparison of AHI and post-CPAP AHI).

Table 5. OSA Groups After the CPAP Treatment

Baseline	Post-CPAP AHI			
AHI	**Mild**	**Moderate**	**Severe**	***P****
Mild	0	0	0	<.001
Moderate	5 (17%)	1 (3%)	0	
Severe	22 (73%)	1 (3%)	1 (3%)	

AHI, apnea–hypopnea index; CPAP, continuous positive airway pressure; OSA, obstructive sleep apnea.
*McNemar-Bowker test.

with hypertension, thus providing better hypertension management. Msaad et al[19] found that BNP levels significantly decreased in normotensive and especially hypertensive OSAS patients after CPAP treatment, which was consistent with our findings. Brain natriuretic peptide seems to be sensitive enough to detect myocardial stress caused by OSA. As such, it is a potential marker for screening preclinical cardiovascular damage in patients with untreated OSA. This finding suggests that pro-BNP can be used as an early marker of cardiac dysfunction in patients with OSA without any heart disease and can be used in the risk management of patients

Table 6. Comparison of Baseline and 6-Month Pro-BNP, CRP, Homocysteine, and Cardiac Biomarkers After CPAP Treatment

	Overall (n = 30)	**Moderate (n = 6)**	**Severe (n = 24)**	**Hypertension (n = 7)**	**No Hypertension (n = 23)**	
	Mean ± SD	**Mean ± SD**	**Mean ± SD**	**Mean ± SD**	**Mean ± SD**	
	Median (25th-75th Percentile)	**Median (25th-75th Percentile)**	**Median (25th-75th Percentile)**	**Median (25th-75th Percentile)**	**Median (25th-75th Percentile)**	***P*****
Baseline CRP	3.8 ± 2.9	1.8 ± 1	4.3 ± 3	4.4 ± 1.9	3.7 ± 3.2	.311
	3.2 (1.4-5.8)	2.1 (0.6-2.5)	4.3 (1.4-6.3)	4.3 (3.2-5.7)	2.2 (1.3-6)	
Control CRP	3.4 ± 2.3	4 ± 3.4	3.2 ± 2	3.8 ± 1.8	3.3 ± 2.5	.471
	3.3 (1.3-5.3)	3.3 (1.3-6.4)	3.3 (1.2-5.3)	3.4 (2.8-5.3)	2.5 (1.3-5.2)	
*P**	.252	.345	.061	.735	.270	
Baseline CK	120.8 ± 71.8	121.5 ± 48.7	120.7 ± 77.4	93.9 ± 37.7	129 ± 78.2	.413
	104 (72.8-138)	128.5 (75.3-147.8)	87.5 (70.3-140)	79 (74-119)	120 (69-141)	
Control CK	127.9 ± 62.5	138 ± 41.8	125.4 ± 67.1	112.6 ± 51.9	132.6 ± 65.7	.532
	118.5 (78.8-157.5)	141.5 (99-178.3)	112.5 (78.3-153)	106 (65-153)	121 (85-162)	
*P**	.136	.249	.271	.090	.420	
Baseline troponin T	4.5 ± 2.6	5.4 ± 2.8	4.2 ± 2.6	5.2 ± 3.9	4.2 ± 2.1	.962
	3 (3-5.2)	4.6 (3-8.3)	3 (3-4.3)	3 (3-9.1)	3 (3-5)	
Control troponin T	5.4 ± 2.6	5.8 ± 2.4	5.3 ± 2.7	6.1 ± 3.7	5.2 ± 2.3	.564
	4.8 (3-6.8)	5.1 (4.3-7.4)	4.6 (3-6.8)	4.9 (3.4-7.6)	4.8 (3-6.8)	
*P**	.027	.917	.006	.116	.112	
Baseline CK-MB	13.1 ± 5.1	13 ± 4	13.2 ± 5.4	8.6 ± 2.1	14.5 ± 4.9	.003
	12 (8.8-17.3)	12.5 (10-17.3)	12 (8.3-17.8)	8 (7-11)	13 (11-18)	
Control CK-MB	15.7 ± 5.4	13.7 ± 2.7	16.3 ± 5.9	14.1 ± 4.6	16.2 ± 5.7	.360
	14 (11.8-18.3)	14 (11.5-15)	15 (11.3-19.8)	13 (11-17)	15 (12-19)	
*P**	.006	.786	.004	.018	.152	
Baseline homocysteine	13.7 ± 3.7	14.6 ± 1.6	13.5 ± 4.1	13.7 ± 4.4	13.7 ± 3.6	.598
	14.1 (11.5-15.7)	14.2 (13.5-16.4)	13.7 (10.6-15.5)	15.3 (12.2-16.7)	14 (11.3-15.6)	
Control homocysteine	13.8 ± 4.6	15.8 ± 4.1	13.3 ± 4.7	12.8 ± 4.9	14.1 ± 4.7	.471
	12.6 (11.1-17.2)	17.4 (11.2-18.9)	12.1 (10-15.3)	11.5 (9.5-18.1)	13.6 (11.6-17)	
*P**	.845	.249	.864	.397	.594	
Baseline pro-BNP	26.8 ± 30.6	21.8 ± 11	28.1 ± 33.9	56.6 ± 48.5	17.7 ± 14.9	.025
	15.7 (7.8-33.8)	22.8 (13.4-30.8)	12.9 (6.7-33.9)	34 (18.5-94.9)	12.8 (6.1-28.5)	
Control pro-BNP	16.7 ± 17.5	15 ± 10.5	17.1 ± 19	27.9 ± 27.6	13.2 ± 12	.245
	7.7 (5-24.3)	12.3 (5-25.9)	5.4 (5-22.8)	12.2 (5-64.4)	5 (5-18.5)	
*P**	.004	.080	.014	.046	.044	

CK, creatine kinase; CK-MB, creatine kinase-MB; CPAP, continuous positive airway pressure; CRP, C-reactive protein; Pro-BNP, pro-B-type natriuretic peptide.
*Wilcoxon signed-rank test (comparison of baseline and post-CPAP values).
**Mann–Whitney *U*-test (comparison of hypertension and non-hypertension).




Figure 1. Comparison of baseline and 6-month pro-brain natriuretic peptide, C-reactive protein, homocysteine, and cardiac biomarkers after continuous positive airway pressure treatment by apnea–hypopnea index groups.

with OSA before the occurrence of clinical manifestations, mortality, and morbidity.

In a study by Shamsuzzaman et al.[20] CRP levels were found to be significantly higher in patients with OSA compared to the healthy control group; CRP level was significantly correlated with the severity of OSA, and significantly lower CRP levels were observed after effective CPAP treatment. Yokoe et al[8] demonstrated that CRP levels were associated with both AHI and BMI and decreased after 1 month of CPAP treatment. Improvement in AHI with CPAP treatment was found to be associated with a decrease in CRP. In our study, we observed that there was an average 0.43 unit decrease in CRP levels at the 6-month follow-up, but this decrease was not statistically significant. Köktürk et al[21]investigated CRP levels and increased risk of CVD in OSAS patients and found that CRP levels were significantly higher in the group that had both OSAS and CVD compared to the other 2 groups; there was no significant difference between the OSAS group without CVD and the group that only had CVD in terms of CRP.[21] In a study by Chu et al.[22] it was observed that CRP was significantly higher in the OSA group than in the control group, and after 6 months of CPAP treatment, CRP levels were significantly lower than baseline.[22] In another study by Wang et al.[23] it was observed that the level of CRP was significantly lower after CPAP treatment. In a study by Panoutsopoulos et al.[24] it was observed that CRP significantly decreased after 3 months of CPAP treatment in OSA patients,[24] whereas in our study, as well as in some other studies,[25-27] no significant decrease was found in CRP levels after CPAP treatment. Conflicting results regarding CRP may be attributed to population differences; some studies have included participants with more comorbid diseases or have not reported data regarding comorbid diseases or smoking/alcohol use, whereas it is known that CRP levels are affected by age, smoking, gender, and presence of atherosclerotic diseases.[28]

In a study by Can et al.[11] OSA patients with CAD were found to have higher homocysteine levels compared to OSAS patients without CAD; however, in our study, no comment can be made since no CAD patients were included. Kokturk et al[29] found that homocysteine levels were significantly higher in both OSA patients with and without CVD compared to patients with only CVD and reported that the severity of OSA was associated with homocysteine levels. Svatikova et al[30] compared patients newly diagnosed with moderate and severe OSA to a healthy control group matched in terms of age and BMI without OSA and did not find a significant difference between the groups in terms of homocysteine levels. Li et al[31] found that changes in homocysteine levels in different OSA patient groups were not proportional to disease




Figure 2. Comparison of baseline and 6-month pro-brain natriuretic peptide, C-reactive protein, homocysteine, and cardiac biomarkers after continuous positive airway pressure treatment by the presence of hypertension.

severity and CPAP treatment did not affect homocysteine levels. Kumor et al[32] did not observe a significant change in homocysteine and leptin levels in OSAS patients after 3 months of CPAP treatment but found a significant decrease in lipid levels in OSA patients without ischemic heart disease. In terms of homocysteine, the results of the aforementioned study were consistent with our results. In our study, the 0.1 unit increase in homocysteine levels at 6 months compared to baseline homocysteine levels was not statistically significant, and this finding is consistent with studies by Svatikova et al and Kumor et al. The fact that the homocysteine level is affected by many nonstandardized factors and the insufficient number of cases may have led to varying results regarding homocysteine in studies.

Gami et al[33] found that nocturnal hypoxia that occurred in OSA patients caused myocyte damage which increased troponin levels in the blood. They also reported that troponin levels in the blood in the morning and at night did not increase in patients with moderate and severe OSA who also had CAD. Cifçi et al[7] reported that serum CK-MB and troponin I levels did not change after 6 months of CPAP treatment and were not associated with the severity of OSA. Colish et al[12] conducted a prospective study on 47 OSA patients and did not find a significant change in troponin T levels after CPAP treatment compared to baseline. Strehmel et al[34] found that CPAP treatment had no effect on high-sensitive troponin T (hs-Trop T) levels. In our study, we observed a significant increase in troponin T and CK-MB levels after treatment. Chang et al[13] reported that CPAP therapy had no significant effect on hs-Trop T levels. Randby et al[35] found that OSA severity increased as troponin T levels increased. In contrast, Barceló et al[36] observed a significant increase in high-sensitive cardiac troponin T (hs-cTnT) levels after effective CPAP, which was consistent with our findings. It also indicates that treatment with CPAP is followed by a rise in hs-cTnT concentrations. It is reasonable to suggest that CPAP therapy may induce a potential degree of cardiac stress, resulting in detrimental consequences for the heart. Zhang et al[37] observed elevated hs-cTnT levels in patients with severe OSA and that CPAP treatment had no effect on these levels. In the present study, a statistically significant difference was found in CK-MB and troponin T values, except for CK after 6 months of CPAP treatment, compared to baseline values.

The limitations of our study were the low number of patients in our study group, the subjective evaluation of patient compliance to CPAP, and the lack of a healthy control group.

The strength of our study is important in terms of showing the effect of CPAP therapy on cardiac biomarkers in OSA patients without heart failure.

CONCLUSION

While there was no statistically significant change in CRP, homocysteine, and CK levels, there was a significant change in pro-BNP, troponin T, and CK-MB levels after 6 months of CPAP therapy in patients with moderate and severe OSAS without heart failure. A more significant decrease in pro-BNP levels was observed in hypertension patients. This finding suggests that pro-BNP may be used as an early indicator of cardiac dysfunction in OSA patients without any heart diseases except for hypertension.

Ethics Committee Approval: Ethical committee approval was received from the Ethics Committee of the Cerrahpaşa Faculty of Medicine at İstanbul University University (Approval No: 20908).

Informed Consent: Written informed consent was obtained from all patients who participated in this study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – N.G., Ş.B.; Design – N.G., Ş.B.; Supervision – Ş.B., B.M.; Materials – N.G., Ş.B., H.C.Ç., E.C., F.A., B.M.; Data Collection and/or Processing – N.G., Ş.B, H.C.Ç., E.C., F.A., B.M.; Analysis and/or Interpretation – H.C.Ç.; Literature Review – N.G., Ş.B.; Writing – N.G.; Critical Review – N.G., Ş.B., B.M.

Declaration of Interests: The authors have no conflict of interest to declare.

Funding: This study received no funding.

REFERENCES

1. American Academy of Sleep Medicine. *International Classification of Sleep Disorders. Diagnostic and Coding Manual (ICSD-2)*. 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005.
2. Jennum P, Tønnesen P, Ibsen R, Kjellberg J. All-cause mortality from obstructive sleep apnea in male and female patients with and without continuous positive airway pressure treatment: a registry study with 10 years of follow-up. *Nat Sci Sleep*. 2015;7:43-50. [CrossRef]
3. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). *Circulation*. 2008;118(10):1080-1111. [CrossRef]
4. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med*. 2004;350(7):655-663. [CrossRef]
5. Tasci S, Manka R, Scholtyssek S, et al. NT-pro-BNP in obstructive sleep apnea syndrome is decreased by nasal continuous positive airway pressure. *Clin Res Cardiol*. 2006;95(1):23-30. [CrossRef]
6. Kita H, Ohi M, Chin K, et al. The nocturnal secretion of cardiac natriuretic peptides during obstructive sleep apnoea and its response to therapy with nasal continuous positive airway pressure. *J Sleep Res*. 1998;7(3):199-207. [CrossRef]
7. Cifçi N, Uyar M, Elbek O, Süyür H, Ekinci E. Impact of CPAP treatment on cardiac biomarkers and pro-BNP in obstructive sleep apnea syndrome. *Sleep Breath*. 2010;14(3):241-244. [CrossRef]
8. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. *Circulation*. 2003;107(8):1129-1134. [CrossRef]
9. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. *JAMA*. 1999;282(22):2131-2135. [CrossRef]
10. Mazza A, Bossone E, Mazza F, Distante A. Homocysteine and cardiovascular risk. *Monaldi Arch Chest Dis*. 2004;62(1):29-33.
11. Can M, Açıkgöz Ş, Mungan G, et al. Serum cardiovascular risk factors in obstructive sleep apnea. *Chest*. 2006;129(2):233-237. [CrossRef]
12. Colish J, Walker JR, Elmayergi N, et al. Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI. *Chest*. 2012;141(3):674-681. [CrossRef]
13. Chang YS, Yee BJ, Hoyos CM, et al. The effects of continuous positive airway pressure therapy on troponin-T and N-terminal pro B-type natriuretic peptide in patients with obstructive sleep apnoea: a randomised controlled trial. *Sleep Med*. 2017;39:8-13. [CrossRef]
14. Berry RB, Budhiraja R, Gottlieb DJ, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. *J Clin Sleep Med*. 2012;8(5):597-619. [CrossRef]
15. Møller DS, Lind P, Strunge B, Pedersen EB. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. *Am J Hypertens*. 2003;16(4):274-280. [CrossRef]
16. Xu L, Keenan BT, Maislin D, et al. Effect of obstructive sleep apnea and positive airway pressure therapy on cardiac remodeling as assessed by cardiac biomarker and magnetic resonance imaging in nonobese and obese adults. *Hypertension*. 2021;77(3):980-992. [CrossRef]
17. Sharma S, Fox H, Aguilar F, et al. Auto positive airway pressure therapy reduces pulmonary pressures in adults admitted for acute heart failure with pulmonary hypertension and obstructive sleep apnea. The ASAP-HF Pilot Trial. *Sleep*. 2019;42(7):zsz100. [CrossRef]
18. Zhao ZH, Liu ZH, Luo Q, et al. Positive pressure ventilation treatment reduces plasma levels of amino terminal-pro brain natriuretic peptide in congestive heart failure patients with sleep apnea. *Circ J*. 2006;70(5):572-574. [CrossRef]
19. Msaad S, Marrakchi R, Grati M, et al. How does serum brain natriuretic peptide level change under nasal continuous positive airway pressure in obstructive sleep apnea-hypopnea syndrome? *Libyan J Med*. 2016;11:31673. [CrossRef]
20. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. *Circulation*. 2002;105(21):2462-2464. [CrossRef]
21. Kokturk O, Ciftci TU, Mollarecep E, Ciftci B. Elevated C-reactive protein levels and increased cardiovascular risk in patient with obstructive sleep apnea syndrome. *Int Heart J*. 2005;46(5):801-809. [CrossRef]
22. Chu AA, Yu HM, Yang H, et al. Evaluation of right ventricular performance and impact of continuous positive airway pressure therapy in patients with obstructive sleep apnea living at high altitude. *Sci Rep*. 2020;10(1):20186. [CrossRef]
23. Wang X, Yue Z, Liu Z, et al. Continuous positive airway pressure effectively ameliorates arrhythmias in patients with obstructive sleep apnea-hypopnea via counteracting the inflammation. *Am J Otolaryngol*. 2020;41(6):102655. [CrossRef]
24. Panoutsopoulos A, Kallianos A, Kostopoulos K, et al. Effect of CPAP treatment on endothelial function and plasma CRP levels

in patients with sleep apnea. *Med Sci Monit*. 2012;18(12):CR747-CR751. [CrossRef]
25. Dorkova Z, Petrasova D, Molcanyiova A, Popovnakova M, Tkacova R. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. *Chest*. 2008;134(4):686-692. [CrossRef]
26. Burioka N, Koyanagi S, Endo M, et al. Clock gene dysfunction in patients with obstructive sleep apnoea syndrome. *Eur Respir J*. 2008;32(1):105-112. [CrossRef]
27. Chung S, Yoon IY, Lee CH, Kim JW. The effects of nasal continuous positive airway pressure on vascular functions and serum cardiovascular risk factors in obstructive sleep apnea syndrome. *Sleep Breath*. 2011;15(1):71-76. [CrossRef]
28. Lear SA, Chen MM, Birmingham CL, Frohlich JJ. The relationship between simple anthropometric indices and C-reactive protein: ethnic and gender differences. *Metabolism*. 2003;52(12):1542-1546. [CrossRef]
29. Kokturk O, Ciftci TU, Mollarecep E, Ciftci B. Serum homocysteine levels and cardiovascular morbidity in obstructive sleep apnea syndrome. *Respir Med*. 2006;100(3):536-541. [CrossRef]
30. Svatikova A, Wolk R, Magera MJ, Shamsuzzaman AS, Phillips BG, Somers VK. Plasma homocysteine in obstructive sleep apnoea. *Eur Heart J*. 2004;25(15):1325-1329. [CrossRef]
31. Li J, Yu LQ, Jiang M, Wang L, Fang Q. Homocysteine level in patients with obstructive sleep apnea/hypopnea syndrome and the impact of continuous positive airway pressure treatment. *Adv Clin Exp Med*. 2018;27(11):1549-1554. [CrossRef]
32. Kumor M, Bielicki P, Przybyłowski T, Rubinsztajn R, Zieliński J, Chazan R. Three month continuous positive airway pressure (CPAP) therapy decreases serum total and LDL cholesterol, but not homocysteine and leptin concentration in patients with obstructive sleep apnea syndrome (OSAS). *Pneumonol Alergol Pol*. 2011;79(3):173-183.
33. Gami AS, Svatikova A, Wolk R, et al. Cardiac troponin T in obstructive sleep apnea. *Chest*. 2004;125(6):2097-2100. [CrossRef]
34. Strehmel R, Valo M, Teupe C. Natriuretic peptide and high-sensitive troponin T concentrations correlate with effectiveness of short-term CPAP in patients with obstructive sleep apnea and coronary artery disease. *Clin Med Insights Circ Respir Pulm Med*. 2016;10:33-39. [CrossRef]
35. Randby A, Namtvedt SK, Einvik G, et al. Obstructive sleep apnea is associated with increased high-sensitivity cardiac troponin T levels. *Chest*. 2012;142(3):639-646. [CrossRef]
36. Barceló A, Esquinas C, Bauçà JM, et al. Effect of CPAP treatment on plasma high sensitivity troponin levels in patients with obstructive sleep apnea. *Respir Med*. 2014;108(7):1060-1063. [CrossRef]
37. Zhang XB, Zeng HQ, Du YP, Lyu Z, Zhan FF. High-sensitivity cardiac troponin T in obstructive sleep apnea patients without cardiovascular diseases: efficacy of CPAP treatment. *Chron Respir Dis*. 2018;15(2):157-164. [CrossRef]

Thorac Res Pract. 2023; 24(2): 85-90 DOI: 10.5152/ThoracResPract.2023.22121

Original Article

Respiratory Outcomes at 5-Year Follow-Up in Children with Mannose-Binding Lectin Deficiency: A Retrospective Cohort Study

Manisha Ramphul[1], Anna Poghosyan[1], Javairiya Afzal[1], Elizabeth McDermott[2], Lucy Cliffe[1], Jayesh M. Bhatt[1]

[1]Department of Paediatric Respiratory Medicine, Nottingham Children's Hospital, Nottingham University Hospitals, Nottingham, United Kingdom of Great Britain and Northern Ireland
[2]Department of Immunology, Nottingham University Hospitals, Nottingham, United Kingdom of Great Britain and Northern Ireland

Cite this article as: Ramphul M, Poghosyan A, Afzal J, McDermott E, Cliffe L, Bhatt JM. Respiratory outcomes at 5-year follow-up in children with mannose-binding lectin deficiency: A retrospective cohort study. *Thorac Res Pract.* 2023;24(2):85-90.

Abstract

OBJECTIVE: Mannose-binding lectin deficiency may predispose children to having increased infection susceptibility. However, there is no conclusive evidence that mannose-binding lectin deficiency is associated with adverse respiratory consequences in children. We aimed to evaluate the effects of mannose-binding lectin deficiency (defined as a level of less than 0.6 mg/L) on clinical, radiological, and microbiological characteristics in children presenting with troublesome respiratory symptoms, as compared to those who are mannose-binding lectin-sufficient.

MATERIAL AND METHODS: We conducted a retrospective cohort study to investigate the association between mannose-binding lectin deficiency and respiratory outcomes in children over a period of 10 years in a large teaching hospital. Children presenting with frequent or persistent respiratory symptoms such as a chronic wet cough lasting more than 4 weeks, recurrent lower respiratory tract infections (≥4 infections in a year), or severe respiratory tract infections requiring admission to intensive care or to high dependency unit were included in the study.

RESULTS: The study showed no significant difference in clinical outcomes with mannose-binding lectin deficiency and sufficiency. Thirty-two percent of children with mannose-binding lectin deficiency and 30% of those with mannose-binding lectin sufficiency had positive respiratory microbiology. Twenty-three percent of children with mannose-binding lectin deficiency and 24% of those with mannose-binding lectin sufficiency had radiological changes on plain radiographs; also the prevalence of bronchiectasis was similar in both groups. The rates of admission to pediatric intensive care unit were comparable in the 2 groups.

CONCLUSIONS: Children with mannose-binding lectin deficiency and sufficiency showed similar clinical, radiological, and microbiological characteristics. Our study suggests that there are no childhood adverse respiratory consequences with mannose-binding lectin deficiency.

KEYWORDS: Child, pediatric, pneumonia, respiratory distress, viruses
Received: *July 7, 2022* ***Accepted:*** *October 11, 2022* ***Publication Date:*** *March 28, 2023*

INTRODUCTION

The innate immune system orchestrates immediate defense against infections. It includes mannose-binding lectin (MBL), which is a liver-produced acute-phase protein and an important first-line defense molecule largely involved in antimicrobial recognition and clearing responses.[1,2] It activates the lectin pathway of the complement system, namely cleaving factor C4 through MBL-associated serine proteases.[3]

The levels of MBL vary in the population, with a level of less than 0.6 mg/L defined as MBL deficiency.[4] At birth, the level is two-thirds of the adult level, which increases to the adult level at 1 month of life, after which the level of MBL within each individual is relatively static and there is a small decrease in later life.[5]

The gene encoding MBL, MBL2, is located on chromosome 10q11.2-q21, consisting of 4 exons.[6] Mannose-binding lectin-2 gene polymorphism is very common; variability is greatly influenced by a type of mutation altering complement activation mechanism involved in the opsonization process making bacterial clearance less effective.[7]

Investigation of MBL deficiency can be performed by the quantification of serum MBL or by genotyping for the MBL status.[8] A dilemma with the interpretation of genotyping is that individuals with identical genotypes may differ by 10-fold in MBL levels.[6]

Changes in MBL gene expression associated with low MBL protein levels have been found in healthy individuals commonly and may vary when measured in disease as an acute-phase protein.[9] Emerging studies identified no existing

Corresponding author: Jayesh M Bhatt, e-mail: jayesh.bhatt@nuh.nhs.uk

Copyright@Author(s) - Available online at thoracrespract.org. Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

association between MBL deficiency and recurrent URTI such as otitis media in children. These data suggest that low MBL concentration does not necessarily indicate a propensity to disease and low levels have to be interpreted alongside clinical features and existing symptoms.[10]

Mannose-binding lectin deficiency is reportedly common, with more than 10% of the general population being MBL-deficient.[8]

The European Society for Immunodeficiencies guideline[11] lists MBL deficiency under complement deficiencies and states that data regarding the clinical impact of MBL deficiency are contradictory and possible effects include susceptibility to bacterial infections and to autoimmunity.

A recent meta-analysis shows that MBL deficiency is associated with death in patients with pneumococcal infection after adjusting other confounders.[12] Neonates with low MBL levels have been deemed to be at higher risk of early-onset sepsis and pneumonia,[13] and children with low MBL levels have often been reported to be at higher risk of severe infections.[14]

Mannose-binding lectin deficiency in children has been reported to lead to decreased opsonizing activity, hence predisposing children to infection.[15] It has been reported to be associated with a severe respiratory infection, due to impaired host response to infective agents.[12,16] Mannose-binding lectin deficiency is especially relevant during the vulnerable period of infancy between 6 and 17 months of age, when maternal antibodies wane and the adaptive immune system is still developing.[17] It has also been associated with more severe lung disease in cystic fibrosis (CF)[18] and also in bronchiectasis not related to CF in adults.[19] In children with bronchiectasis not related to CF, there were no significant differences in growth, annual pulmonary exacerbation rates, pulmonary function tests, radiologic scores, and microbiologic findings between low, intermediate, and high-expressing MBL genotypes over the 1-year follow-up.[20]

However, in another recent study, MBL levels had no association with infection status or with progression from systemic inflammatory response syndrome to sepsis or septic shock in children admitted with a severe or life-threatening illness.[21] It has also been shown that MBL deficiency is not associated with susceptibility to influenza-related critical illness in children.[21] The literature equally reports no link between MBL deficiency and severe lower respiratory tract infection caused by respiratory syncytial virus.[22]

MAIN POINTS

- The current literature is divided about whether mannose-binding lectin (MBL) deficiency predisposes children to having increased infection susceptibility.
- We showed that there are no associations of MBL deficiency with childhood adverse respiratory consequences.
- Children with MBL deficiency and sufficiency showed similar radiological and microbiological characteristics.

So controversy exists as to when MBL deficiency leads to disease. Additionally, there is no conclusive evidence that MBL deficiency is associated with adverse respiratory consequences at follow-up.

The aim of our study was to evaluate any differences in clinical, radiological, and microbiological characteristics in children with MBL deficiency (defined as a level of less than 0.6 mg/L) presenting with troublesome respiratory symptoms (frequent, recurrent, persistent, or very severe), as compared to those who are MBL-sufficient.

MATERIAL AND METHODS

We performed a retrospective cohort study looking at the quantification of serum MBL in children over a period of 10 years from 2004 to 2014 at the Nottingham's Children Hospital.

This study was approved locally as a service evaluation project and ethics approval was not deemed necessary. All the retrospective data collected were anonymized and there was no active intervention for patients; hence, informed consent was not mandated.

We defined a minimum follow-up period of 5 years or more from the time of the MBL measurement.

The inclusion criteria for the study were as follows:

(i) Age less than 18 years and
(ii) Troublesome respiratory symptoms such as

   (a) frequent or persistent respiratory symptoms such as a chronic wet cough lasting more than 4 weeks or
   (b) recurrent lower respiratory tract infections (≥4 infections in a year) or
   (c) severe respiratory tract infections requiring admission to intensive care or to the high dependency unit.

The MBL level was checked as part of baseline immunology testing to exclude a primary immune deficiency.

Mannose-binding lectin deficiency was defined as a serum level <0.6 mg/L. We followed up with a cohort of children with MBL deficiency and compared their respiratory outcomes to those with MBL sufficiency.

The primary outcome was the difference in clinical outcomes in the 2 groups, which included number of admissions to the pediatric intensive care unit (PICU) and responses to childhood immunizations.

We defined a suboptimal response to primary vaccinations based on antibody titers, which were below the laboratory-quoted ranges for *Haemophilus influenzae* B and tetanus. For the pneumococcal conjugate vaccine (Prevenar13), the response was deemed as a suboptimal response when fewer than 8 serotypes were at the desired level.

Secondary outcomes studied were differences in the 2 groups in radiology findings (chest x-ray (CXR) and computed

Table 1. Baseline Characteristics of Study Population

	MBL-Deficient (<0.6 mg/L)	MBL-Sufficient
Number of children	43 (21%)	163 (79%)
Male (%)	22 (51%)	72 (44%)
Median age in years (range)	8 (3.2 to 11)	8 (4 to 11.8)

MBL, mannose-binding lectin.

tomography (CT) of the chest), as well in microbiology findings in respiratory samples for positive viral and bacterial yields.

Statistical Analysis

The data were analyzed using GraphPad Prism 9 software. We tested for normality, and non-normally distributed data were expressed as median and interquartile ranges. The chi-square test was used to compare the follow-up parameters of MBL-deficient and MBL-sufficient children. The odds ratio, the 95% confidence intervals, and the *P*-values were calculated. $P < .05$ was considered statistically significant.

RESULTS

A total of 206 patients undergoing MBL testing were included in the study, out of whom 43 (21%) were MBL-deficient.

The baseline characteristics of the study population are shown below in Table 1.

The clinical, radiological, and microbiological characteristics of the MBL-deficient and MBL-sufficient children are summarized in Table 2. There were no clinical or statistical differences between the 2 groups.

The various follow-up parameters are depicted in Figure 1.

The percentage of children requiring admission to the PICU was small and similar in the 2 groups. Twenty-eight percent of children with MBL deficiency and 33% of those with MBL sufficiency had suboptimal vaccine responses to primary immunizations.




Figure 1. Bar chart showing follow-up features of mannose-binding lectin (MBL)-deficient and MBL-sufficient children.

Thirty-two percent of children with MBL deficiency and 30% of those with MBL sufficiency had positive microbiology (respiratory viruses, bacteria, or both).

Twenty-three percent of children with MBL deficiency and 24% of those with MBL sufficiency had changes on plain radiographs. We performed a subgroup analysis to look at the presence of bronchiectasis in children undergoing a CT chest. Five MBL-deficient children and 10 MBL-sufficient children underwent a CT scan, and the proportion of bronchiectasis was similar in both groups, as shown in Figure 2.

Subgroup Analysis-Booster Immunizations

Our data did not show a difference in the adequacy of response to primary immunizations in the MBL-deficient cohort, compared to the MBL-sufficient cohort. Further subgroup analysis noted that children with MBL deficiency were clinically less likely to respond well to booster immunizations (67% of the MBL-deficient children compared to 40% of MBL-sufficient children), as shown in Figure 3. However,

Table 2. Clinical, Radiological, and Microbiological Parameters over Follow-Up Period

	MBL-Deficient (<0.6 mg/L)	MBL-Sufficient	OR	95% CI	*P*
Number of children needing emergency PICU admissions during follow-up (%)	1 (2.3%)	6 (3.7%)	0.62	0.05 to 4	.66
Suboptimal vaccine responses to primary immunizations, either to Prevenar, *Haemophilus influenzae* B, tetanus, or a combination: N1 (%)	12 (28%)	53 (33%)	0.92	0.43 to 1.97	.83
Suboptimal vaccine responses to booster immunizations: N2/N1 (%)	8/12 (67%)	21/53 (40%)	3.05	0.86 to 9.86	.08
Abnormal imaging at any point during 5-year follow-up (%)	10 (23%)	39 (24%)	0.96	0.45 to 2.16	.96
Bronchiectasis on CT chest	3 out of 5	7 out of 10	0.64	0.08 to 5.21	.64
Any positive respiratory microbiology (respiratory viruses, bacterial pathogens, or both)	14 (32%)	49 (30%)	1.12	0.53 to 2.27	.75

CT, computed tomography; MBL, mannose-binding lectin; OR, odds ratio; PICU, pediatric intensive care unit.




Figure 2. Chart showing risk of bronchiectasis in the 2 groups.




Figure 3. Adequacy of response to booster immunizations in mannose-binding lectin (MBL)-deficient and MBL-sufficient children.

the difference was not statistically significant ($P = 0.08$) due to small numbers.

DISCUSSION

Different studies have explored the relationship between MBL deficiency and increased susceptibility to respiratory infections both in children and adults, with different conclusions.[17,23] Our study did not find adverse clinical, radiological, or microbiological consequences in MBL-deficient children at 5-year follow-up.

Previous studies have shown an association between MBL gene polymorphism and more severe upper respiratory tract infections in children with homozygous mutation of the MBL2 gene over a 2-year follow-up.[24] However, our findings did not reveal a link between MBL deficiency and increased positivity of viral or bacterial respiratory samples.

Even though the literature suggests that children with MBL deficiency are susceptible to infection by specific pathogens such as *Streptococcus pneumoniae*,[25] we did not find an association between MBL deficiency and susceptibility to pneumococcal community-acquired pneumonia and invasive pneumococcal disease, which could have required PICU admissions.

The association between MBL protein levels and recurrent respiratory infections in children remains debatable. Confounders such as atopy, parental smoking, and environmental factors, as well as small sample sizes of the studies, make it difficult to attribute the cause solely to MBL deficiency.

It is increasingly recognized that MBL genetic polymorphisms may have an impact on the serum level and function of the molecule. It has been reported that 3 single nucleotide exonal substitutions in the MBL2 gene lead to a decrease in functional circulating MBL; the structural variant alleles interfere with the assembly of MBL trimers and lead the degradation of the protein. Promoter variants may also influence the expression of MBL, hence impacting MBL serum concentrations.[26]

Low MBL levels, as well as low-producing MBL2 variants, are described to lead to an increased susceptibility to infections and also to worse severity of illness.[27] This is especially relevant when in cases of an existing weak immune system, for instance, for infants and young children and patients with CF, or on immunosuppressive treatment.

We advocate that MBL testing performed as part of baseline immunology testing in children is unnecessary, as the results seem to guide neither the management nor the prognosis. This recommendation would be in line with the recommendations of the recent evidence-based European Respiratory Society (ERS) guidelines[28] and result in more cost-effective practice, given that each MBL level assay costs £24.[29] The International Union of Immunological Societies Expert Committee has in fact not included MBL deficiency in their recently updated classification of inborn errors of immunity.[30]

While our study showed that children with MBL deficiency were more likely to respond inadequately to appropriate booster immunizations, a previous study did not find an association between MBL deficiency and response to pneumococcal vaccination.[31] Equally, MBL polymorphisms have been shown not to affect the production and persistence of antibodies for acellular pertussis.[32] Longer-term prospective studies may shed more light on this area.

The most important strength of the study is the size of the cohort, with the inclusion of a large number of children, and a substantial period of follow-up of 5 years or longer. Our study is hence a robust addition to the existing evidence regarding the specifics of respiratory infections in children with MBL deficiency.

Our study had a number of limitations. It was a retrospective study, which may introduce selection and recall bias. While undertaking the subgroup analyses, our subgroup numbers were relatively low. Also, we did not include a symptom score and hence could not quantify the degree of symptoms that children with MBL deficiency and sufficiency subjectively experienced.

Finally, we defined MBL deficiency on biochemical values, rather than by genetic polymorphisms. Most MBL-disease association studies to date have assessed MBL2 genotypes with or without MBL levels, with MBL insufficient genotypes being XA/O or O/O.[11] This is different to our study, where we looked at serum MBL protein levels, rather than the genotype and ideally both measures could have been included. We note that the literature reports that variant alleles can lead to increased MBL serum levels, but the variant MBL is of a lower molecular weight and is dysfunctional when compared to normal MBL.[26]

CONCLUSION

To conclude, we showed no difference at 5-year follow-up in clinical, radiological, and microbiological characteristics between children who are MBL-deficient, compared to those who have sufficient levels. The rates of admission to PICU were comparable in the 2 groups. About a quarter of the children in both groups had long-term pulmonary changes on the CXR and the prevalence of bronchiectasis was similar. Children with MBL deficiency in our cohort are more likely to respond poorly to appropriate booster immunization, but the significance of this is unclear.

The study found no adverse respiratory consequences with MBL deficiency in childhood. This adds to the existing body of literature that shows no statistically significant association between MBL deficiency and susceptibility to recurrent respiratory tract infection in children.

Ethics Committee Approval: This study was approved locally as a service evaluation project and ethics approval was not deemed necessary.

Informed Consent: All the retrospective data collected were anonymized and there was no active intervention for patients; hence, informed consent was not mandated.

Peer-review: Externally peer-reviewed.

Author Contributions: Design - J.M.B., M.R.; Data Collection - M.R., A.P., J.A.; Data Analysis - M.R.; Writing the Manuscript - M.R., A.P., J.M.B.; Critical Review - M.R., A.P., E.M., L.C., J.M.B.

Declaration of Interests: The authors have no conflict of interest to declare.

Funding: This study received no funding.

REFERENCES

1. Jack DL, Turner MW. Anti-microbial activities of mannose-binding lectin. *Biochem Soc Trans*. 2003;31(4):753-757. [CrossRef]
2. Takahashi K, Ezekowitz RAB. The role of the mannose-binding lectin in innate immunity. *Clin Infect Dis*. 2005;41(suppl 7): S440-S444. [CrossRef]
3. Thiel S, Møller-Kristensen M, Jensen L, Jensenius JC. Assays for the functional activity of the mannan-binding lectin pathway of complement activation. *Immunobiology*. 2002;205(4-5): 446-454. [CrossRef]
4. Mannose binding lectin. Available at: https://www.ouh.nhs.uk/immunology/diagnostic-tests/tests-catalogue/mbl.aspx. Accessed November 22, 2020.
5. Ip WK, To YF, Cheng SK, Lau YL. Serum mannose-binding lectin levels and mbl2 gene polymorphisms in different age and gender groups of Southern Chinese adults. *Scand J Immunol*. 2004;59(3):310-314. [CrossRef]
6. Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. *J Immunol Methods*. 2000;241(1-2):33-42. [CrossRef]
7. Summerfield JA, Sumiya M, Levin M, Turner MW. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. *BMJ*. 1997;314(7089): 1229-1232. [CrossRef]
8. Thiel S, Frederiksen PD, Jensenius JC. Clinical manifestations of mannan-binding lectin deficiency. *Mol Immunol*. 2006;43 (1-2):86-96. [CrossRef]
9. Dean MM, Minchinton RM, Heatley S, Eisen DP. Mannose binding lectin acute phase activity in patients with severe infection. *J Clin Immunol*. 2005;25(4):346-352. [CrossRef]
10. Homøe P, Madsen HO, Sandvej K, Koch A, Garred P. Lack of association between mannose-binding lectin, acute otitis media and early Epstein-Barr virus infection among children in Greenland. *Scand J Infect Dis*. 1999;31(4):363-366. [CrossRef]
11. Brodszki N, Frazer-Abel A, Grumach AS, et al. European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune diseases (ERN RITA) complement guideline: deficiencies, diagnosis, and management. *J Clin Immunol*. 2020;40(4):576-591. [CrossRef]
12. Eisen DP. Mannose-binding lectin deficiency and respiratory tract infection. *J Innate Immun*. 2010;2(2):114-122. [CrossRef]
13. Frakking FNJ, Brouwer N, van Eijkelenburg NKA, et al. Low mannose-binding lectin (MBL) levels in neonates with pneumonia and sepsis. *Clin Exp Immunol*. 2007;150(2):255-262. [CrossRef]
14. Taras R, Stefan M, Derewicz D, Ionescu M, Cinteza E, Balgradean M. Characteristics of mannose-binding lectin deficiency in pediatric septic patients – case presentation. *Maedica*. 2019;14(1):49-52. [CrossRef]
15. Super M, Lu J, Thiel S, Levinsky RT, Turner MW. Association of low levels of MANNAN-binding protein with a common

defect of opsonisation. *Lancet*. 1989;334(8674):1236-1239. [CrossRef]
16. Cedzynski M, Szemraj J, Swierzko AS, et al. Mannan-binding lectin insufficiency in children with recurrent infections of the respiratory system. *Clin Exp Immunol*. 2004;136(2):304-311. [CrossRef]
17. Koch A, Melbye M, Sørensen P, et al. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. *JAMA*. 2001;285(10):1316-1321. [CrossRef]
18. Chalmers JD, Fleming GB, Hill AT, Kilpatrick DC. Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: a review and meta-analysis. *Glycobiology*. 2011;21(3): 271-282. [CrossRef]
19. Chalmers JD, McHugh BJ, Doherty C, et al. Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study. *Lancet Respir Med*. 2013; 1(3):224-232. [CrossRef]
20. Dogru D, Polat SE, Tan Ç, et al. Impact of mannose-binding lectin 2 gene polymorphisms on disease severity in noncystic fibrosis bronchiectasis in children. *Pediatr Pulmonol*. 2020;55(5): 1190-1198. [CrossRef]
21. Madsen EC, Levy ER, Madden K, et al. Mannose-binding lectin levels in critically ill children with severe infections. *Pediatr Crit Care Med*. 2017;18(2):103-111. [CrossRef]
22. Kristensen IA, Thiel S, Steffensen R, Madhi S, Sorour G, Olsen J. Mannan-binding lectin and RSV lower respiratory tract infection leading to hospitalization in children: a case–control study from Soweto, South Africa. *Scand J Immunol*. 2004;60(1-2):184-188. [CrossRef]
23. García-Laorden MI, Rodríguez de Castro F, Solé-Violán J, et al. The role of mannose-binding lectin in pneumococcal infection. *Eur Respir J*. 2013;41(1):131-139. [CrossRef]
24. Ruskamp JM, Hoekstra MO, Rovers MM, Schilder AGM, Sanders EAM. Mannose-binding lectin and upper respiratory tract infections in children and adolescents: a review. *Arch Otolaryngol Head Neck Surg*. 2006;132(5):482-486. [CrossRef]
25. Darmawan AB, Soesatyo MHNE, Restuti RD, Surono A. The role of mannose-binding lectin serum level in tubotympanic chronic suppurative otitis media. *Int J Otolaryngol*. 2018; 2018:6178159-6178159. [CrossRef]
26. Garred P, Larsen F, Madsen HO, Koch C. Mannose-binding lectin deficiency--revisited. *Mol Immunol*. 2003;40(2-4):73-84. [CrossRef]
27. Worthley DL, Bardy PG, Mullighan CG. Mannose-binding lectin: biology and clinical implications. *Intern Med J*. 2005; 35(9):548-555. [CrossRef]
28. Chang AB, Fortescue R, Grimwood K, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. *Eur Respir J*. 2021;58(2): 2002990. [CrossRef]
29. Sheffield Teaching Hospital NHS Trust. *Mannose Binding Lectin*. Sheffield: Directorate of Laboratory Medicine; 2019.
30. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. *J Clin Immunol*. 2022. [CrossRef]
31. van Kessel DA, Hoffman TW, van Velzen-Blad H, Zanen P, Rijkers GT, Grutters JC. Response to pneumococcal vaccination in mannose-binding lectin-deficient adults with recurrent respiratory tract infections. *Clin Exp Immunol*. 2014;177(1):272-279. [CrossRef]
32. Gröndahl-Yli-Hannuksela K, Vuononvirta J, Peltola V, Mertsola J, He Q. Lack of association between mannose binding lectin and antibody responses after acellular pertussis vaccinations. *PLoS One*. 2014;9(2):e88919. [CrossRef]

Thorac Res Pract. 2023; 24(2): 91-95 DOI: 10.5152/ThoracResPract.2023.22187

Original Article

Can Some Viral Respiratory Infections Observed Before the Pandemic Announcement Be Related to SARS-CoV-2?

Aylin Özgen Alpaydın[1], Özgür Appak[2], Naciye Sinem Gezer[3], Salih Yiğit[1], Damla Gündüz Karayazı[1], Ziya Kuruüzüm[4], Gökçen Ömeroğlu Şimşek[1], Oya Özlem Eren Kutsoylu[4], Ayça Arzu Sayıner[2], Can Sevinç[1], Eyüp Sabri Uçan[1], Yasin Levent Uğur[5], Ali Necati Gökmen[6], Nur Yapar[4]

[1]Department of Pulmonary Diseases, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
[2]Department of Medical Microbiology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
[3]Department of Radiology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
[4]Department of Infectious Diseases and Clinical Microbiology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
[5]Department of Intensive Care Unit, Mehmet Akif Ersoy State Hospital, Çanakkale,Turkey
[6]Department of Anesthesiology and Reanimation, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey

Cite this article as: Özgen Alpaydın A, Appak Ö, Gezer NS, et al. Can some viral respiratory infections observed before the pandemic announcement be related to SARS-CoV-2? *Thorac Res Pract.* 2023;24(2):91-95.

Abstract

OBJECTIVE: There have been doubts that SARS-CoV-2 has been circulating before the first case was announced. The aim of this study was to evaluate the possibility of COVID-19 in some cases diagnosed to be viral respiratory tract infection in the pre-pandemic period in our center.

MATERIAL AND METHODS: Patients who were admitted to our hospital's pulmonary diseases, infectious diseases, and intensive care clinics with the diagnosis of viral respiratory system infection within a 6-month period between October 2019 and March 12, 2020, were screened. Around 248 archived respiratory samples from these patients were analyzed for SARS-CoV-2 ribonucleic acid by real-time-quantitative polymerase chain reaction. The clinical, laboratory, and radiological data of the patients were evaluated.

RESULTS: The mean age of the study group was 47.5 (18-89 years); 103 (41.5%) were female and 145 (58.4%) were male. The most common presenting symptoms were cough in 51.6% (n = 128), fever in 42.7% (n = 106), and sputum in 27.0% (n = 67). Sixty-nine percent (n = 172) of the patients were pre-diagnosed to have upper respiratory tract infection and 22.0% (n = 55) had pneumonia, one-third of the patients (n = 84, 33.8%) were followed in the service. Respiratory viruses other than SARS-CoV-2 were detected in 123 (49.6%) patients. Influenza virus (31.9%), rhinovirus (10.5%), and human metapneumovirus (6.5%) were the most common pathogens, while none of the samples were positive for SARS-CoV-2 RNA. Findings that could be significant for COVID-19 pneumonia were detected in the thorax computed tomography of 7 cases.

CONCLUSION: The negative SARS-CoV-2 real-time-quantitative polymerase chain reaction results in the respiratory samples of the cases followed up in our hospital for viral pneumonia during the pre-pandemic period support that there was no COVID-19 among our cases during the period in question. However, if clinical suspicion arises, both SARS and non-SARS respiratory viral pathogens should be considered for differential diagnosis.

KEYWORDS: 2019 novel coronavirus disease, polymerase chain reaction, non-severe acute respiratory syndrome, pandemic, severe acute respiratory syndrome coronavirus 2

Received: *October 3, 2022* ***Accepted:*** *October 14, 2022* ***Publication Date:*** *March 28, 2023*

INTRODUCTION

Coronaviruses (CoVs) have been well-known as a causative agent of animal diseases. They were reported to cause upper respiratory tract infections in humans in 1960s and mortal outbreaks of human diseases have emerged such as severe acute respiratory syndrome coronavirus (SARS-CoV-1) and The Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) in the last 20 years.[1] SARS-CoV-2 is the third highly pathogenic coronavirus in the 21st century, which appeared in December 2019 in China[2] following a cluster of viral pneumonia cases soon after resulting a pandemic globally.[3] The World Health Organization (WHO) named the disease caused by the SARS-CoV-2 as coronavirus disease-2019 (COVID-19).

Turkey has announced the first case on March 11, 2020, and subsequently, new cases have been reported one after another. On March 18, 2020, the first COVID-19 patient was determined by a positive real-time-quantitative polymerase chain reaction (RT-qPCR) for SARS-CoV-2 in Dokuz Eylül University Hospital in İzmir, Turkey. The clinical and radiological signs of COVID-19 in the early stages of the disease are like other viral pneumonia; therefore, the differential diagnosis is not easy. Therefore, there may be possible COVID-19 cases among the viral pneumonia treated before the date of March 11, 2020, when the first case was detected in Turkey. Thus, there are reports that SARS-CoV-2 emerged and circulated earlier than previous announcement of the first case, scientists explained. There are studies that have reported SARS-CoV-2 in the USA, Europe, and Brazil prior to the identification of the first case.[4-7]The aim of this study was to evaluate the

Corresponding author: Aylin Özgen Alpaydın, e-mail: aylin.alpaydin@deu.edu.tr

Copyright@Author(s) - Available online at thoracrespract.org. Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

possibility of some cases considered as viral respiratory tract infections in the close pre-pandemic period to be COVID-19.

MATERIAL AND METHODS

Study Population

Patients who were admitted to our hospital's pulmonary diseases, infectious diseases, and clinical microbiology and intensive care clinics within a 6-month period from October 2019 to March 12, 2020, and treated for the diagnosis of viral pneumonia were screened. There were 394 patients sampled for respiratory pathogens, and 248 samples analyzed for SARS-CoV-2 were included in the study. The clinical, laboratory, and radiological data of these patients related to COVID-19 were retrospectively scanned and evaluated through the records of the hospital database system after obtaining an non-interventional research ethics committee approval of Dokuz Eylül University Faculty of Medicine.

Clinical features (symptoms and vital signs; fever, respiratory rate, blood pressure, pulse), laboratory findings (leukocyte and lymphocyte count, C-reactive protein, procalcitonin, ferritin, lactate dehydrogenase, D-dimer), radiological features, and prognosis (recovery, intensive care transport, exitus) were the parameters that were analyzed.

Respiratory Viruses and Severe Acute Respiratory Syndrome Coronavirus 2 Testing

Real-time-quantitative polymerase chain reaction for SARS-CoV-2 RNA was performed blindly on samples collected from the patients with suspected viral pneumonia and stored at –80˚C. Nucleic acid extraction was done by EZ-1 virus mini kit using EZ-1Advanced XL platform (Qiagen, Hilden, Germany). Severe acute respiratory syndrome coronavirus 2 RNA was tested by a 1-step RT-PCR assay targeting viral RdRp (Biospeedy SARS CoV-2 qPCR detection kit, Bioeksen, Turkey). The test was performed on the RotorGene Q 5plex HRM. Human RNase P gene amplification was used as an internal control.

Each sample was tested by a syndromic panel-based multiplex RT-PCR assay for the detection of the following respiratory pathogens as a part of the routine diagnostics: Influenza A/B virus, rhinovirus, coronaviruses (NL63, 229E, OC43, HKU1), parainfluenza viruses,[1-4] human metapneumoviruses (hMPV) (A/B), bocavirus, RSV (A/B), adenovirus, enterovirus, parechovirus, and *Mycoplasma pneumonia* (Fast Track Diagnostics [FTD]respiratory pathogens-21 Assay, Siemens Healthcare GmbH, Erlangen, Germany).

MAIN POINTS

- Viruses other than SARS-CoV-2 were circulating in the pre era of COVID-19.
- There are studies on the existence of COVID-19 before its detection in other countries.
- When we evaluated our own local data, we could not show the presence of SARS-COV-2 during the pre-COVID-19 period.

Statistical Analysis

For descriptive findings, categorical variables were indicated by numbers and percentages, and variables determined by measurement will be indicated by mean ± standard deviation, (SD) median, minimum value, and maximum value. The distribution property of the variables specified in the measurement will be evaluated with the Kolmogorov–Smirnov test. The chi-square test will be used for the categorical variables specified by counting to evaluate the relationship between the independent variables and the dependent variable. In cases where the values observed in the cells do not satisfy the chi-square test assumptions, the differences in frequencies between the groups will be compared using Fisher's exact test. The *t*-test or Mann–Whitney *U* test will be used to evaluate the relationship between the variables specified in the measurement and the dependent variable, considering the normal distribution of the data. Data were evaluated with Statistical Package for Social Sciences (SPSS) version 22.0 package program (IBM Corp.; Armonk, NY, USA). Significance level $P < .05$ will be accepted.

RESULTS

The mean age of 248 patients whose SARS-CoV-2 RT-qPCR test could be analyzed was 47.5 (18-89 years); 103 (41.5%) were female and 145 (58.4%) were female. Respiratory viruses were isolated in 123 (49.6%) patients.

The presenting symptoms were cough in 51.6% (n = 128), fever in 42.7% (n = 106), sputum in 27.0% (n = 67), fatigue in 25.4% (n = 63), and sore throat in 25% (n = 62). Dyspnea (19.4%, n = 48), myalgia (13.7%, n = 34), headache (10.1%, n = 25), and nausea—vomiting (6.5%, n = 16) were the least common symptoms.

About 63% percentage (n = 158) of the patients were treated in the outpatient clinic, 33.8% (n = 84) in the service, and 2.4% (n = 6) in the intensive care unit. Sixteen cases (6.5%) were transferred from the ward to the intensive care unit. Sixty-nine percent (n = 172) of the patients were pre-diagnosed to have upper respiratory tract infection and 22.0% (n = 55) had pneumonia. Six percent (n = 15) of the patients died during the treatment period.

Non-SARS-CoV-2 respiratory viruses detected in nasal swab samples of the patients are presented in Table 1 And none of them were found to be SARS-CoV-2-positive in PCR test. Findings that could be significant for COVID-19 pneumonia were detected in the thorax computed tomography (CT) of 7 cases. The data of these cases are presented in Figure 1 and Table 2.

DISCUSSION

When the pandemic emerged soon after COVID-19 was identified in China, doubt about the existence of cases that could be COVID-19 before the detection of the first case in each country has been a matter of curiosity. Therefore, we reviewed the viral pneumonia cases in our clinic that may be associated with COVID-19 just before March 11, 2020, when the first COVID-19 case was announced in Turkey. Samples collected for the respiratory virus panel with a preliminary

Table 1. The Distribution of the Respiratory Pathogens Obtained from Nasal Swabs of the Study Population

Respiratory Pathogens	n (%)
Respiratory viruses	123 (49.6)
Non-severe acute respiratory syndrome coronavirus	11 (4.4)
Influenza	79 (31.9)
Rhinovirus	26 (10.5)
Metapneumovirus	16 (6.5)
Parainfluenza	5 (2)
Respiratory syncytial virus	5 (2)
Adenovirus	4 (1.6)
Mycoplasma pneumonia	3 (1.2)
Influenza + *Mycoplasma pneumonia*	1 (0.4)
Influenza + metapneumovirus	1 (0.4)
Parainfluenza + rhinovirus	1 (0.4)

diagnosis of viral pneumonia were then re-examined for SARS-CoV-2 PCR and none were found positive. Another viral agent was detected in 4 of 6 cases with radiological findings, suggestive of COVID-19.

The mean age of our study population was relatively young (47.5), and gender distribution was in favor of women. There were respiratory viruses in 49.6% of the patients. In a prospective study of European primary care including adults with symptoms of lower respiratory tract infection, 45.8% of the patients had microbiologically confirmed common respiratory virus infection (influenza virus, hMPV, respiratory syncytial virus (RSV), coronavirus (CoV) or rhinovirus) with a mean age of 50, mostly consisting of females similarly with our findings.[8] Another study has also reported the mean age of 45.2 with a slight male predominance.[9] On the other hand, the demographic data on COVID-19 reveal that all age groups are at risk of getting COVID-19; however, patients aged > 60 years and males are prone to severe infection in COVID-19.[10]

The presentation of lower respiratory tract infection of viral etiology has been defined as mostly self-limiting, and influenza virus, hMPV, RSV, CoV, or rhinovirus have been reported to have a significantly higher symptom score. Cough, sputum, and rhinorrhea were the most commonly reported symptoms.[8] In another study including 5859 individuals suspected of influenza-like illness, cough, rhinorrhea, and headache were the most common symptoms and dyspnea was especially associated with RSV (odds ratio: 2.33, 95% CI: 1.73-3.12).[11] In our study, cough, fever, and sputum were the most common symptoms. Therefore, although cough was




Figure 1. (A) Consolidated areas of ground-glass density in the upper lobes of both lungs and peripheral ground-glass density infiltrates in the lower lobes. (B) Peripherally located nodular infiltration areas in the upper and lower lobes of both lungs. (C) Peripheral weighted patchy ground-glass densities in both lungs. (D) Peripheral predominantly faintly circumscribed peripheral ground-glass density nodular infiltrates in the lower lobe of both lungs. (E) Peripheral-peribronchovascular consolidations and areas of ground-glass density in the upper and lower lobes of both lungs. (F) Ground-glass areas in both lungs, with focal patchy centrilobular distribution more prominent in the right lung. (G) Infiltration areas of more prominent ground-glass density in the left upper lobe in both lungs.

Table 2. Characteristics of 7 Cases Whose Radiological Findings Were Suggestive of COVID-19 Pneumonia

Case No	Age/Sex	Co-morbidity	Detected Microorganism in Nasal Swab	Lymphocyte Count (10 × 3/μL)	CRP (mg/L)	Procalcitonin (mg/L)	Prognosis
1	70M	+	Influenza A	0.5	434	42	Exitus
2	52/F	–		0.9	22	-	Discharged from service
3	70/M	+		1	97	0.13	Discharged from service
4	59/M	+		1.1	328	-	Discharged from service
5	60/M	+	Influenza A	0.9	360	0.32	Discharged from service
6	65/F	+	Metapneumovirus	0.3	45	0.21	Exitus
7*	68/M	–		1.1	84	-	Discharged from service

All were negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) except *Whose specimen was not adequate for reinvestigation of SARS-CoV-2 polymerase chain reaction.
CRP; C reactive protein.

the most frequent presentation for both SARS-CoV-2 and non-SARS-CoV-2 agents, symptoms like rhinorrhea and headache should be considered in viral pneumonia. Fever and fatigue have been reported more in COVID-19.[10]

Sixty-nine percent (n = 172) of the patients were pre-diagnosed to have upper respiratory tract infection and 22.0% (n = 55) had pneumonia. Six percent (n = 15) of the patients died during the treatment period.

Most of the patients evaluated for viral respiratory tract infection in our study had moderate clinical severity and one-third required hospitalization with a 6% mortality. This may be due to the fact that the study population consisted of patients whose viral respiratory tract specimens were studied without distinction of upper-lower respiratory tract infection. In our study, 22.0% of the patients had pneumonia. In a study including 954 patients suspected to have respiratory viruses, there was 27.5% positivity, and the patients had a mean pneumonia severity index (PSI) score of 42, H1N1 was found to have highest PSI.[9] Viral pneumonia has been reported to account for approximately one-third of community-acquired pneumonia cases, in a wide range of clinical course of mild to severe.[12] Generally, adenovirus, hMPV, para-influenza virus, RSV, and influenza A and B viruses suffer mild symptoms and have a low mortality.[13] Poor outcomes are both associated with viral and host factors including older age, comorbidities, solid organ transplant, and hematopoietic stem cell transplant.[14] The clinical spectrum of SARS-CoV-2 ranges from asymptomatic to moderate or severe disease with multiorgan failure. Asymptotic infections have been reported between 27% and 40% and hospitalization rates were between 4% and 7% depending on the population characteristics.[15]

In our study, the most common viral agents were influenza virus (31.9%), rhinovirus (10.5%), and hMPV (6.5%) of the tested population. In other studies, similarly, influenza was also the most common pathogen (9.9%-48%) depending on the influenza season, followed by rhinovirus (4.3%-7.9%) and hMPV (1.8%-4.1%).[9-11] In a large systemic review of community-acquired pneumonia in European adults, influenza virus A and B were most frequently (9%) identified viruses, followed by rhinovirus, coronavirus, and parainfluenza (2%-7%).[16]

Research is being conducted in many countries to investigate the question marks about the global circulation of SARS-CoV-2 before December 2019. Several studies by different groups retrospectively demonstrated the presence of antibodies and viral RNA in clinical samples, and SARS-CoV-2 community circulation was demonstrated by detecting viral RNA in wastewater at a time inconsistent with November 2019.[17] In USA, antibodies for SARS-CoV-2 were determined in more than 100 blood samples in early December 2019.[4] In France, SARS-CoV-2 antibodies were detected in serum samples and a respiratory sample before December 2019.[5,18] In Brazil, SARS-CoV-2 community spread was demonstrated at the end of November 2019 in wastewater.[7] The presence of SARS-CoV-2 in different parts of the world at an earlier stage than currently accepted will provide basic clues for the assessment of this pandemic and make a very important contribution to future pandemic preparedness.

Findings that could be significant for COVID-19 pneumonia were detected in the thorax CT of 7 cases. The data of these cases are presented in Figure 1 and Table 2. Although some clinical (sputum was less frequent in COVID-19) and laboratory parameters (leukocyte, lymphocyte, and C-reactive protein levels were lower in COVID-19) may guide to distinguish COVID-19 from other viral pathogens, radiological appearance might be more helpful.[19] Peripheral involvement, pure ground-glass opacity, and apicobasal gradient were more likely to be present in COVID-19. On the contrary, thickening of the bronchial walls and micronodules were more frequently associated with other respiratory viruses.[20,21] Of the 7 patients having radiological signs of COVID-19, influenza was positive in 2, and hMPV in 1, C-RP was highest in influenza cases.

CONCLUSION

The absence of positive PCR results for SARS-CoV-2 in the nasal swab samples of the patients who were followed up with a viral pneumonia clinic in the pre-pandemic period in our hospital supports the fact that there was no COVID-19 among our cases at that time. Cases with significant findings in terms of COVID-19 on thorax CT suggest that other viral pneumonia may be confused with COVID-19 clinically and radiologically; when clinical suspicion arises, PCR testing should be performed for both SARS and non-SARS respiratory viral pathogens for differential diagnosis.

Ethics Committee Approval: Ethical committee approval was received from the Ethics Committee of Dokuz Eylül University Faculty of Medicine (approval No: 2020/13-46).

Informed Consent: Informed consent was not obtained due to the retrospective design of the study. Data analysis permission was obtained from the hospital administration, provided that it is used by anonymizing.

Peer-review: Externally peer-reviewed.

Acknowledgments: The authors thank the LabGen, Laboratuvar Sistemleri San ve Tic A.Ş. for providing the consumables of the PCR assays.

Declaration of Interests: The authors have no conflict of interest to declare.

Funding: This study received no funding.

REFERENCES

1. Hui DS, Zumla A. Historical perspective: other human coronavirus infectious diseases, SARS and MERS. In: Fabre A, Hurst JR, Ramjug S, eds. *COVID-19 (ERS Monograph)*. Sheffield: European Respiratory Society; 2021:28-38.
2. El Zowalaty ME, Järhult JD. From SARS to COVID-19: a previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans - Call for a One Health approach. *One Health*. 2020;9:100124. [CrossRef]
3. WHO Novel Coronavirus (2019-nCoV) Situation Reports; 2020. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7c0f7_2.
4. García-García D, Morales E, de la Fuente-Nunez C, Vigo I, Fonfría ES, Bordehore C. Identification of the first COVID-19 infections in the US using a retrospective analysis (REMEDID). *Spat Spatiotemporal Epidemiol*. 2022;42:100517. [CrossRef]
5. Deslandes A, Berti V, Tandjaoui-Lambotte Y, et al. SARS-CoV-2 was already spreading in France in late December 2019. *Int J Antimicrob Agents*. 2020;55(6):106006. [CrossRef]
6. Apolone G, Montomoli E, Manenti A, et al. Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy. *Tumori*. 2021;107(5):446-451. [CrossRef]
7. Fongaro G, Stoco PH, Souza DSM, et al. The presence of SARS-CoV-2 RNA in human sewage in Santa Catarina, Brazil, November 2019. *Sci Total Environ*. 2021;778:146198. [CrossRef]
8. Vos LM, Bruyndonckx R, Zuithoff NPA, et al. Lower respiratory tract infection in the community: associations between viral aetiology and illness course. *Clin Microbiol Infect*. 2021;27(1):96-104. [CrossRef]
9. Qu JX, Gu L, Pu ZH, et al. Viral etiology of community-acquired pneumonia among adolescents and adults with mild or moderate severity and its relation to age and severity. *BMC Infect Dis*. 2015;15:89. [CrossRef]
10. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; 2022.
11. Souty C, Masse S, Valette M, et al. Baseline characteristics and clinical symptoms related to respiratory viruses identified among patients presenting with influenza-like illness in primary care. *Clin Microbiol Infect*. 2019;25(9):1147-1153. [CrossRef]
12. Menchén DA, Vázquez JB, Allende JMB, García GH. Neumonía vírica. Neumonía en la COVID-19. *Medicine (Madr)*. 2022;13(55):3224-3234. [CrossRef]
13. Pagliano P, Sellitto C, Conti V, Ascione T, Esposito S. Characteristics of viral pneumonia in the COVID-19 era: an update. *Infection*. 2021;49(4):607-616. [CrossRef]
14. Li Z, Xie L, Wang H, Wang S, Wu J. Clinical observation of Reduning combined with recombinant human interferon α-2b in the treatment of children with viral pneumonia. *Evid Based Complement Alternat Med*. 2022;2022:1739561. [CrossRef]
15. Salzberger B, Buder F, Lampl B, et al. Epidemiology of SARS-CoV-2. *Infection*. 2021;49(2):233-239. [CrossRef]
16. Alimi Y, Lim WS, Lansbury L, Leonardi-Bee J, Nguyen-Van-Tam JS. Systematic review of respiratory viral pathogens identified in adults with community-acquired pneumonia in Europe. *J Clin Virol*. 2017;95:26-35. [CrossRef]
17. Canuti M, Bianchi S, Kolbl O, et al. Waiting for the truth: is reluctance in accepting an early origin hypothesis for SARS-CoV-2 delaying our understanding of viral emergence? *BMJ Glob Health*. 2022;7(3):e008386. [CrossRef]
18. Carrat F, Figoni J, Henny J, et al. Evidence of early circulation of SARS-CoV-2 in France: findings from the population-based "CONSTANCES" cohort. *Eur J Epidemiol*. 2021;36(2):219-222. [CrossRef]
19. Alpaydin AO, Gezer NS, Simsek GO, et al. Clinical and radiological diagnosis of non-SARS-CoV-2 viruses in the era of COVID-19 pandemic. *J Med Virol*. 2021;93(2):1119-1125. [CrossRef]
20. Jalaber C, Chassagnon G, Hani C, et al. Is COVID-19 pneumonia differentiable from other viral pneumonia on CT scan? *Respir Med Res*. 2021;79:100824. [CrossRef]
21. Koo HJ, Lim S, Choe J, Choi SH, Sung H, Do KH. Radiographic and CT features of viral pneumonia. *RadioGraphics*. 2018;38(3):719-739. [CrossRef]

Thorac Res Pract. 2023; 24(2): 96-102 DOI: 10.5152/ThoracResPract.2023.22022

Original Article

Thoracic Surgeons' Perspective on the Management of Primary Spontaneous Pneumothorax

Yasser Aljehani, Farouk AlReshaid, Abdulrahman Al-Abduljabbar, Rawan A. Rahman AlHarmi, Naif Alkhaldi, Musa'ad Aljughaiman, Bayan Almusailhi, Nabaa Alhawashim, Hatem Elbawab

[1]Department of Surgery, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, AlKhobar, Saudi Arabia

Cite this article as: Aljehani Y, AlReshaid F, Al-Abduljabbar A, et al. Thoracic surgeons' perspective on the management of primary spontaneous pneumothorax. *Thorac Res Pract.* 2023;24(2):96-102.

Abstract

OBJECTIVE: The study aimed to determine the current practice of thoracic surgeons in the management of primary spontaneous pneumothorax in Saudi Arabia and to compare the results with the British Thoracic Society guidelines.

MATERIAL AND METHODS: This is a questionnaire-based study. The questionnaire included 41 questions and was directed to those involved in the management of primary spontaneous pneumothorax in Saudi Arabia; namely thoracic, cardiac, and general surgeons. It was distributed electronically through email. Out of 47 registered surgeons at the time of the study, 47 responses were obtained with a 100% response rate.

RESULTS: Among the participants, 39 were thoracic surgeons. It was noted that all surgeons agreed on ordering an initial chest radiograph and most would order an additional view. Also, approaches varied regarding grading systems used. While 26% of the respondents use the British Thoracic Society grading system, 16% follow the American College of Chest Physicians system, and the rest chose other parameters. The majority of surgeons would choose a chest tube of a size not greater than 28 Fr for initial placement. As for video-assisted thoracoscopic surgery, we noted that 55% of the respondents opted for 3 ports, while 36% would place 2 ports.

CONCLUSION: Primary spontaneous pneumothorax is a common condition managed by thoracic surgeons. Various guidelines were established to guide practice. Our study showed some variability in practice which could result in serious medico-legal consequences and can affect the careers of thoracic surgeons. We hope that our results will shed light upon variabilities to influence proper directed management.

KEYWORDS: Thoracic surgery, pneumothorax, primary spontaneous pneumothorax (PSP), treatment, diagnosis

Received: *February 8, 2022* ***Accepted:*** *October 17, 2022* ***Publication Date:*** *March 28, 2023*

INTRODUCTION

Pneumothorax refers to the accumulation of air in the pleural cavity. Pneumothorax may develop spontaneously or due to trauma. Spontaneous pneumothorax is further divided into primary and secondary subtypes. Primary spontaneous pneumothorax (PSP) occurs in the absence of underlying pulmonary disease, while secondary spontaneous pneumothorax frequently occurs in elderly people with underlying lung conditions.[1] PSP tends to develop in young, thin, and tall males due to rupture of subpleural blebs or bullae. It is more common in men than in women. The incidence varies among different geographical areas, for example, the incidence in the United States is 7.4 per 100 000 population per year.[1,2] Similar results were obtained in Arab countries.[3] The recurrence rate is estimated to be around 25%-50%, mostly occurring within the first year.[4] If non-operative management was opted for a patient presenting with a second attack, 54% of those patients will develop a third recurrence.[5] Risk factors that predispose to the condition include cigarette smoking, family history, Marfan's syndrome, homocystinuria, and meteorological factors.[6]

Management approaches vary, ranging from conservative to surgical therapeutic options. These interventions include bed rest, oxygen supplementation, aspiration, and tube thoracostomy, in addition to thoracoscopic and other surgical modalities.[7]

The British Thoracic Society (BTS) produced guidelines for the management of spontaneous pneumothorax in 1993 which were updated in 2010. A conservative approach was strongly favored, with emphasis on observation without intervention in selected patients. Aspiration was recommended as an initial procedure in all cases of PSP if the patient is symptomatic, irrespective of the size of the pneumothorax. Surgical intervention is recommended in ipsilateral second attack or contralateral pneumothorax.[8] Despite the availability of these guidelines, previous studies have shown poor compliance with the guidelines.[9,10]

The healthcare system in Saudi Arabia is composed of the government and private sectors. The ministry of health is the major government provider of healthcare services in Saudi Arabia, including the provision of primary healthcare services. Other government bodies include referral and teaching hospitals, among others. The private sector also contributes to the

Corresponding author: Rawan A.Rahman AlHarmi, e-mail: Rawan.alhermi@gmail.com

Copyright@Author(s) - Available online at thoracrespract.org. Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

delivery of healthcare services.[11] In Saudi Arabia, PSP patients are mostly managed by thoracic surgeons from the time of admission. At present, there are no national guidelines on the management of PSP in Saudi Arabia. Nevertheless, adherence to any of the international guidelines was not previously reported in our region.

The aim of this work is to determine the current practice of thoracic surgeons in the management of PSP in Saudi Arabia and to compare the results with BTS guidelines.

MATERIAL AND METHODS

The proposal was reviewed by the institutional review board (IRB) of Imam Abdulrahman Bin Faisal University and ethical approval was attained on February 17, 2019 (Number: IRB-PGS-2019-01-120).

Study Design

This is a cross-sectional questionnaire-based study. The questionnaire included 41 questions regarding the management and follow-up of patients with PSP in addition to the demographic data of the participants (Tables 1-3). Questions were divided into those with a binary response (i.e., yes/no) and open-ended questions. The questionnaire was developed following a systemic, scientifically accepted methodology based on previous studies, experts' opinion, validation, and statistical analysis (Cronbach's alpha). The questionnaire was tested for validity and reliability with a value of 0.622 which was obtained and calculated based on the responses. It was distributed electronically either by email or through a professional WhatsApp group.

Participants

The questionnaire targeted thoracic surgeons involved in the management of PSP throughout Saudi Arabia. Other specialties (e.g., pulmonary and emergency physicians) are not involved in the management of PSP in our region and hence were not included in the survey. Participant names were obtained from the Saudi Thoracic Society registry.

Statistical Analysis

Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) version 20 (IBM Corp.; Armonk, NY, USA). For data analysis, we used the Chi-square test for categorical variables and the Mann–Whitney *U* test for continuous variables. $P < .05$ was considered to be significant.

RESULTS

Out of 47 registered thoracic surgeons at the time of the study, 47 responded with a 100% response rate. Table 1 demonstrates the demographic data of all participants. Twenty-eight questions with binary responses, that is, yes/no are shown in Table 2, while 13 are open-ended and are demonstrated in Table 3. Table 4 shows a comparison of responses by thoracic surgeons versus others.

Table 1. Demographic Data of All Participants

Parameter	All Participants n = 47	
Age (years)		
Average 44.9 (33-59)*		
Experience (years)		
Average 13.3 (1-30)*		
Gender (n, %)		
Male	44	94
Female	1	2
Not specified	2	4
Board certification (n, %)		
General Surgery	27	57
Cardiothoracic Surgery	20	43
Current primary position (n, %)		
Thoracic surgeon	39	83
Cardiac surgeon	4	9
General surgeon	2	4
Others (e.g., senior registrar, fellow, administrative)	2	4
Fellowship certificate country (n, %)		
North American	16	34
European	8	17
Saudi	5	11
Arab board	15	32
Others	3	6
Health care institution (n, %)		
Governmental	42	89
Private	5	11
Region (n, %)		
East	20	43
Central	12	26
West	12	26
South	2	4
North	1	2

*min-max.

MAIN POINTS

- Various protocols and guidelines were established to guide primary spontaneous pneumothorax (PSP) management.
- There is a variability in the management of PSP among thoracic surgeons and deviation from the current guidelines.
- Deviation from guidelines may pose medico-legal consequences and financial burdens on hospitals.
- There is a strong need for high-quality studies to reach an international consensus on the management of PSP.

Table 2. Binary Response Questions by All Participants

	Answer			
	Yes		No	
Question	n	%	n	%
1) Ordering an initial CXR	47	100	0	0
2) Further views (lateral)	14	30	33	70
3) Further views (expiratory film)	7	15	40	85
4) Routine radiological grading of PSP	19	40	28	60
5) Routine CT scan for the first attack	28	60	19	40
6) Routine drainage	19	40	28	60
7) Performing simple aspiration	3	6	44	94
8) Using Heimlich valve	19	40.4	28	59.6
9) Operating during the first attack	22	47	25	53
10) Stapling the lung involved	46	98	1	2
11) Release of adhesions routinely	40	85	7	15
12) Exploring each lobe for concomitant pathology routinely	42	89	5	11
13) Performing apical pleurectomy routinely	21	45	26	55
14) Performing mechanical pleurodesis routinely	32	68	15	32
15) Performing chemical pleurodesis routinely	6	13	41	87
16) Insertion of chest tube in the procedure	40	85	7	15
17) Routine use of NSAIDs	22	47	25	53
18) Positive effect of NSAIDs on the outcome	21	45	26	55
19) Performing daily CXR	37	79	10	21
20) Keeping chest tube under continuous suction routinely	40	85	7	15
21) Clamping of chest tube before removal	17	36	30	64
22) Performing CXR following removal of chest tube	37	79	10	21
23) Putting a pre take suture	38	81	9	19
24) Follow-up of patients routinely in the first week	33	70	14	30
25) Follow-up of patients routinely in the first month	40	85	7	15
26) Repeating CT scan	2	4	45	96
27) Instructing patients not to fly within 2-4 weeks	30	64	17	36
28) Is such consensus important?	38	81	9	19

CT, computed tomography; CXR, chest radiograph; NSAIDs, non-steroidal anti-inflammatory drugs; PSP, primary spontaneous pneumothorax.

Initial Radiological Imaging

All participants perform an initial chest radiograph (CXR). Sixty percent of the participant surgeons choose to perform computerized tomography (CT) scans routinely for the first PSP attack. Of those who choose to perform routine CT scan, 79% order plain CT scan, while the rest order CT scan with contrast. Surgeons' decision to perform a CT scan for the first PSP attack was not related to their experiences, type of board certification, type of the hospital or geographical location within Saudi Arabia.

Estimation of the Size of Pneumothorax

Nineteen participants (40.4%) measure the size of PSP radiologically. Five participants (10.6%) measure the size of the pneumothorax in CXR according to BTS guidelines. Other measurement methods, namely, American College of Chest Physicians Delphi Consensus Statement (ACCPDCS), interpleural distance, and percentage measurement methods are used by 6.4%, 4.3%, and 4.3%, respectively. Seven participants (14.9%) use other non-specified methods.

Initial Management of Pneumothoraces

Nineteen participants (40.2%) routinely drain the PSP. However, only 1 participant (2.1%) employs simple aspiration for drainage. Additionally, 29.8% prefer to insert a pigtail for drainage of the PSP and the rest (70.2%) prefer chest tube insertion. Twenty-two participants (46.8%) treat the first attack of PSP by surgical intervention. The indications for surgical intervention (other than the first attack) returned 76 responses (Table 3). Recurrence was the highest indication for surgical intervention according to 23 respondents (30%). Persistent air leak and presence of bullae represented 20% and 17% of responses, respectively.

Table 3. Questions with Open-ended Responses by All Participants

1) PSP grading system used	**System**	**n**	**%**
	BTS	5	26
	ACCPDCS	3	16
	AID	2	10.5
	Percentage	2	10.5
	Others	7	37
2) Type of CT scan done	**Type of CT scan**	**n**	**%**
	Plain CT	22	79
	With contrast	6	21
	Not specified	0	0
3) Method of drainage	**Method**	**n**	**%**
	Chest tube	32	68
	Pigtail catheter	8	17
	Both	6	13
	Not specified	1	2
4) Size of chest tube (if used)	**Size**	**n**	**%**
	20 Fr	3	7
	22-24 Fr	13	28
	26-28 Fr	23	50
	30-32 Fr	3	7
	Not specified (age, body size, etc.)	4	9
5) Indication to operate (other than the first attack)	**Indication**	**n**	**%**
	Recurrence	23	30
	Persistent air leakage	15	20
	Bullae or blebs	13	17
	Failure of conservative treatment or lung expansion	7	9
	High-risk occupation	5	7
	Remote residence	4	5
	First attack in selected cases	4	5
	Illicit drug use or smoking	2	3
	Others	3	4
6) Approach used	**Procedure**	**n**	**%**
	VATS	36	77
	Uniportal VATS	9	19
	Thoracotomy	1	2
	Axillary thoracotomy	0	0
	All	1	2
7) Number of ports (if VATS)	**Ports**	**n**	**%**
	3	23	55
	2	15	36
	1	3	7
	Not specified	1	2
8) Agent used in chemical pleurodesis	**Agent**	**n**	**%**
	Talc powder	4	66.7
	Blood	1	16.7
	Betadine	1	16.7

(*Continued*)

Table 3. Questions with Open-ended Responses by All Participants (*Continued*)

9) Size of chest tube (if used in the procedure)	**Size**	**n**	**%**
	20 Fr	1	2.2
	22-24 Fr	9	20
	26-28 Fr	29	64.2
	30-32 Fr	5	11.2
	Not specified (age, body size, etc.)	1	2.2
10) Primary postoperative analgesia protocol	**Protocol**	**n**	**%**
	PCA	12	25.5
	NSAIDs	14	29.8
	Epidural catheter	3	6.4
	Paravertebral block	4	8.5
	Others (acetaminophen, intercostal block, etc.)	14	29.8
11) Duration of keeping chest tube under suction	**Duration**	**n**	**%**
	24-48 hours	31	77.5
	>48 hours	6	15
	Not specified	3	7.5
12) Duration of chest tube use postoperatively	**Duration**	**N**	**%**
	24-48 hours	15	32
	>48 hours	25	53
	Not specified	7	15
13) Days of sick leave granted	**Duration**	**n**	**%**
	1-2 weeks	39	83
	2-4 weeks	8	17
	Depending on situation	0	0

ACCPDCS, American College of Chest Physicians Delphi Consensus Statement; AID, average interpleural distance; BTS, British Thoracic Society; CT, computed tomography; NSAIDs, non-steroidal anti-inflammatory drugs; PCA, patient-controlled analgesia; PSP, primary spontaneous pneumothorax; VATS, video-assisted thoracoscopic surgery.

Use of Suction

Eighty-five percent of our participants believe that suction should be applied routinely to a chest tube. Nine participants were not certain about the duration of the suction. Thirty participants apply suction for 48 hours or more.

Clamping of the Chest Tube

If the insertion of an intercostal drain results in stopping an air leak and full expansion of the lung, 30 participants (63.8%) would act in accordance with the guidelines and would remove the chest tube without first clamping the tube. Seventeen participants would clamp the tube before removal. It was observed that consultants with an experience of 6-15 years (42.6%) do not clamp the chest tube before removal which was statistically significant at $P = .005$.

Surgical Strategies

Video-assisted thoracoscopic surgery (VATS) is the approach of choice for 46 surgeons (97.9%) to treat PSP. To lower the rate of recurrence, 4 participants (12.8%) would use chemical pleurodesis, mechanical pleurodesis or apical pleurectomy, while 8 participants do not use any of these techniques. Eleven participants may perform apical pleurectomy or mechanical pleurodesis, while 16 and 6 participants perform only mechanical pleurodesis or only apical pleurectomy, respectively.

DISCUSSION

Diagnostic and therapeutic guidelines for PSP do exist, but the significant variations in clinical practice observed worldwide make it difficult for clinicians to feel confident about following the recommendations in those guidelines. Moreover, there is a need for an update to these guidelines since they were suggested around 10 years back. This study showed a variation in both the knowledge of existing international guidelines and management of PSP among thoracic surgeons in Saudi Arabia.

Routine performance of CT scan after the first attack was reported by 60% of the participants. When paralleled with the guidelines, the BTS guidelines stated that there are practical constraints that preclude the general use of CT scans as the initial diagnostic modality. However, CT scan is considered the gold standard in the detection of small pneumothoraces and its size estimation.[8] Sihoe et al[12] highlighted the importance of CT scan to predict the risk of occurrence of PSP by the detection of lung bullae in the contralateral lung, thus allowing preemptive surgical intervention in selected patients.

Table 4. Comparison of Responses by Thoracic Surgeons Versus Others

Question	*P*
1) Ordering an initial CXR	N/A
2) Further views (lateral)	.6005
3) Further views (expiratory film)	.8346
4) Routine radiological grading of PSP	.8531
5) Routine CT scan for the first attack	.8531
6) Routine drainage	.3291
7) Performing simple aspiration	.4372
8) Using Heimlich valve	.1149
9) Operating during the first attack	.1371
10) Stapling the lung involved	.6471
11) Release of adhesions routinely	.3781
12) Exploring each lobe for concomitant pathology routinely	.006828*
13) Performing apical pleurectomy routinely	.6538
14) Performing mechanical pleurodesis routinely	.7099
15) Performing chemical pleurodesis routinely	.255
16) Insertion of chest tube in the procedure	.8346
17) Routine use of NSAIDs	.3289
18) Positive effect of NSAIDs on the outcome	.6538
19) Performing daily CXR	.7776
20) Keeping chest tube under continuous suction routinely	.8346
21) Clamping of chest tube before removal	.3715
22) Performing CXR following removal of chest tube	.1065
23) Putting a pre take suture	.1308
24) Follow-up of patients routinely in the first week	.6005
25) Follow-up of patients routinely in the first month	.3781
26) Repeating CT scan	.001417*
27) Instructing patients not to fly within 2-4 weeks	.9315
28) Is such consensus important?	.1533

*P = .05 is statistically significant.
CT, computed tomography; CXR, chest radiograph; N/A, not applicable; NSAIDs, non-steroidal anti-inflammatory drugs; PSP, primary spontaneous pneumothorax.

Both the BTS and ACCPDCS guidelines use the combination of patient's clinical status and size of pneumothorax to direct the management options. The BTS guidelines divide the size of pneumothoraces into "small" and "large" when the lung surface to the chest wall is <2 cm or >2 cm, respectively. The ACCPDCS, however, uses the apex to cupola distance in which a small pneumothorax is less than 3 cm in collapse and a large pneumothorax >3 cm in collapse.[8,13] Rhea et al[14] use the average interpleural distance which is obtained from 3 linear measurements and closely predicts true pneumothorax size as determined by radiographic thoracic gas volume measurement. For clinically compromised patients, all agree that drainage is required. For clinically well patients, each bases its recommendations on pneumothorax size. The poor agreement between guidelines in the size estimation of pneumothorax explains the management variation, that is, the use of thoracostomy tube drainage and the limited use of conservative management.[10] This disagreement can also be appreciated between our participants and hence the variation in the management strategy of PSP in our region. A randomized controlled trial conducted by Brown et al[15] concluded that conservative management was non-inferior to interventional management for radiographic resolution of moderate-to-large PSP within 8 weeks. However, this study did not provide information about the long-term follow-up and recurrence rate of those patients who were managed conservatively.

The management of the chest tube primarily with water seal or added suction is a subject of debate and the benefits of one versus the other are unclear. In a study by So and Yu[16] on 52 patients with spontaneous pneumothorax, the application of suction did have an effect in shortening the hospital stay. Weissberg and Refaely[17] analyzed 1199 patients with pneumothorax. They recommended the application of suction if the lung does not expand well initially but otherwise should not be used routinely. The BTS guidelines do not recommend the routine use of suction and limit its use to persistent air leak with or without incomplete re-expansion of the lung.[8] Most of our participants apply suction to the chest tube routinely. The presence or absence of air leak or lung collapse does not influence either the application of suction or its duration.

The management of pneumothorax depends on the severity of symptoms, the size of pneumothorax, type of pneumothorax, and whether an air leak is likely to be present.[7] The choice of method for the initial treatment of a PSP remains controversial.[18] Only 6.4% of our participants would attempt simple aspiration to treat the pneumothorax. The BTS guidelines recommend simple aspiration as the first-line treatment for all small (<2 cm) PSPs in minimally breathless patients under the age of 50 years requiring intervention.[8] The ACCPDCS however recommends chest drain insertion as the first line of intervention in such patients as simple aspiration is not effective even in symptomatic PSP patients with small pneumothorax.[13] However, in the lack of prospective randomized studies, many authors support simple aspiration as the initial management of PSP compared to chest drain insertion because of the potential to immediately discharge patients and hence a shorter hospital stay which has cost-saving benefits. Furthermore, the procedure is less invasive with lower complication rates and less analgesic requirements.[19,20] Most of our participants (70.2%) would insert a chest tube as initial management for the first attack of PSP.

Several retrospective studies have shown, unanimously, that VATS has superior outcomes in terms of recurrence rates, duration of chest tube placement, and mean hospital stay with the first episode of PSP.[21] Additionally, the reduced length of stay and decreased recurrence mitigate the increased cost associated with VATS. In addition to the patient's choice, the BTS guidelines outline certain indications for the surgical intervention for the first PSP episode. Fifteen of our participants (20%) would intervene surgically during the first attack of PSP when there is persistent air leak. The BTS guidelines

did not advocate a certain time limit for surgical intervention in the case of prolonged air leak. A period between 5 and 14 days is reported in the literature.[8] Thirteen of our participants (28%) reported that the presence of bullae in the CT scan is an indication for surgical intervention because of higher rates of recurrence in such patients. The BTS has no such recommendation. Nevertheless, many authors believe that bullectomy is justifiable for elimination of the source of air leak and lower rate of recurrence.[5,21]

Several factors might contribute to the deviation from existing guidelines. These include a lack of awareness, personal experience, and academic background.[9] We agree with Soulsby[22] that those guidelines should be incorporated in teaching modules and that adherence should be audited. Additionally, randomized controlled trials evaluating the management options of PSP are deficient. More studies are needed to generate the best evidence-based practice guidelines.

The aim of this study is to initiate a national consensus on PSP management approach among thoracic surgeons in our region that would result in better outcomes in terms of patient safety and satisfaction. However, this study has a potential limitation. The small number of participants included in the survey is due to the fact that thoracic surgeons are the ones solely managing PSP in Saudi Arabia.

CONCLUSION

PSP represents a heterogeneous group of patients with distinctive symptomatology, radiology, and pathological basis of the disease. Various protocols and guidelines were established to guide clinical practice. Our study showed variability in the management of PSP between thoracic surgeons and deviation from the current guidelines. The impact of this deviation may have medico-legal consequences as well as financial burdens on hospitals. There is a strong need for high-quality studies to reach an international consensus on the management of PSP.

Ethics Committee Approval: Ethical committee approval was received from the institutional review board (IRB) of Imam Abdulrahman Bin Faisal University and ethical approval was attained on 17/02/2019 (Number: IRB-PGS-2019-01-120).

Informed Consent: All participants were informed about the purpose of the study and that participation was voluntary.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – Y.A.; Design – Y.A.; Supervision – Y.A., H.E.; Data Collection and/or Processing – A.A., N.A., B.A.; Analysis and/or Interpretation – R.A.; Literature Review – F.A., A.A., R.A., N.A., M.A.; Writing – F.A., A.A., R.A.; Critical Review – H.E.

Declaration of Interests: The authors have no conflict of interest to declare.

Funding: This study received no funding.

REFERENCES

1. Luh SP. Review: Diagnosis and treatment of primary spontaneous pneumothorax. *J Zhejiang Univ Sci B*. 2010;11(10):735-744. [CrossRef]
2. Wong A, Galiabovitch E, Bhagwat K. Management of primary spontaneous pneumothorax: a review. *ANZ J Surg*. 2019;89(4):303-308. [CrossRef]
3. El Sonbaty MR, Bitar ZI, Marafie AA, Sharma PN. Primary spontaneous pneumothorax in Arabs: does its frequency differ from elsewhere? *J Clin Epidemiol*. 2000;53(6):631-633. [CrossRef]
4. Al-Qudah A. Treatment options of spontaneous pneumothorax. *Indian J Chest Dis Allied Sci*. 2006;48(3):191-200.
5. Tschopp JM, Rami-Porta R, Noppen M, Astoul P. Management of spontaneous pneumothorax: state of the art. *Eur Respir J*. 2006;28(3):637-650. [CrossRef]
6. Aljehani Y, Niaz R, Almajid F, Elbawab H. Influence of meteorological factors on the onset of primary spontaneous pneumothorax. *Ann R Coll Surg Engl*. 2018;100(8):1-6. [CrossRef]
7. Yoon J, Sivakumar P, O'Kane K, Ahmed L. A need to reconsider guidelines on management of primary spontaneous pneumothorax? *Int J Emerg Med*. 2017;10(1):9. [CrossRef]
8. MacDuff A, Arnold A, Harvey J, BTS Pleural Disease Guideline Group. Management of spontaneous pneumothorax: British Thoracic Society pleural disease guideline 2010. *Thorax*. 2010;65(suppl 2):ii18-ii31. [CrossRef]
9. Mendis D, El-Shanawany T, Mathur A, Redington AE. Management of spontaneous pneumothorax: are British Thoracic Society guidelines being followed? *Postgrad Med J*. 2002;78(916):80-84. [CrossRef]
10. Ismail T, Anshar MF, How SH, Hashim CW, Mohamad WH, Katiman D. A survey on the initial management of spontaneous pneumothorax. *Med J Malaysia*. 2010;65(3):187-191.
11. Almalki M, Fitzgerald G, Clark M. Health care system in Saudi Arabia: an overview. *East Mediterr Health J*. 2011;17(10):784-793. [CrossRef]
12. Sihoe AD, Yim AP, Lee TW, et al. Can CT scanning be used to select patients with unilateral primary spontaneous pneumothorax for bilateral surgery? *Chest*. 2000;118(2):380-383. [CrossRef]
13. Baumann MH, Strange C, Heffner JE, et al. Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. *Chest*. 2001;119(2):590-602. [CrossRef]
14. Rhea JT, DeLuca SA, Greene RE. Determining the size of pneumothorax in the upright patient. *Radiology*. 1982;144(4):733-736. [CrossRef]
15. Brown SGA, Ball EL, Perrin K, et al. Conservative versus interventional treatment for spontaneous pneumothorax. *N Engl J Med*. 2020;382(5):405-415. [CrossRef]
16. So SY, Yu DY. Catheter drainage of spontaneous pneumothorax: suction or no suction, early or late removal? *Thorax*. 1982;37(1):46-48. [CrossRef]
17. Weissberg D, Refaely Y. Pneumothorax: experience with 1,199 patients. *Chest*. 2000;117(5):1279-1285. [CrossRef]
18. Miller AC, Harvey J. Pneumothorax: what's wrong with simple aspiration? *Chest*. 2001;120(3):1041-1042. [CrossRef]
19. Ayed AK, Chandrasekaran C, Sukumar M. Aspiration versus tube drainage in primary spontaneous pneumothorax: a randomised study. *Eur Respir J*. 2006;27(3):477-482. [CrossRef]
20. Devanand A, Koh MS, Ong TH, et al. Simple aspiration versus chest-tube insertion in the management of primary spontaneous pneumothorax: a systematic review. *Respir Med*. 2004;98(7):579-590. [CrossRef]
21. Herrmann D, Klapdor B, Ewig S, Hecker E. Initial management of primary spontaneous pneumothorax with video-assisted thoracoscopic surgery: a 10-year experience. *Eur J Cardiothorac Surg*. 2016;49(3):854-859. [CrossRef]
22. Soulsby T. British Thoracic Society guidelines for the management of spontaneous pneumothorax: do we comply with them and do they work? *J Accid Emerg Med*. 1998;15(5):317-321. [CrossRef]

Thorac Res Pract. 2023; 24(2): 103-108 DOI: 10.5152/ThoracResPract.2023.22087

Original Article

Treatment Results of Multidrug-Resistant Tuberculosis Patients in the Aegean Region

Onur Karaman, Yelda Varol, Tülay Akarca, Çağrı Atasoy, Can Biçmen, Diğdem Özbakır, Mustafa Şevket Dereli

Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, University of Health Science, Izmir, Turkey

Cite this article as: Karaman O, Varol Y, Akarca T, et al. Treatment results of multidrug-resistant tuberculosis patients in the aegean region. *Thorac Res Pract.* 2023;24(2):103-108.

Abstract

OBJECTIVE: We aimed to evaluate 109 rifampicin-resistant or multidrug-resistant tuberculosis patients who are treated in Izmir Chest Diseases MDR Tuberculosis Centre.

MATERIAL AND METHODS: The patient profile, side effects, treatment success, and mortality of rifampicin-resistant or multidrug-resistant tuberculosis patients who were followed up and treated in our hospital's tuberculosis service between 2010 and 2018 were analyzed retrospectively.

RESULTS: Of the rifampicin-resistant or multidrug-resistant tuberculosis patients, 83 (76.1%) were male and the mean age was 46.3 ± 16.3 years. Of the cases 13 (11.9%) had rifampicin resistance without isoniazid. Since 5 out of 109 patients diagnosed with multidrug-resistant tuberculosis emigrated to other countries, the treatment results of 104 patients were evaluated. As a result of the treatment, the cure was achieved in 81 (77.9%) patients and treatment was completed in 13 (12.5%). Treatment success was found as 90.4%. No patient experienced recurrence. The mortality rate was determined as 9.6%. The cure rate of patients treated with ≥6 drugs (90.9%) was statistically significantly ($P = .029$) higher than the group treated with ≤5 drugs (71.8%).

CONCLUSIONS: Multidrug-resistant tuberculosis treatment is a long-term, financially burdensome practice that may cause serious side effects and complications, and it requires strict discipline. The fight against tuberculosis can be successful with tuberculosis control programs that are pursued with determination.

KEYWORDS: Tuberculosis, treatment, mortality, multidrug-resistant tuberculosis

Received: *April 27, 2022* ***Accepted:*** *October 31, 2022* ***Publication Date:*** *March 28, 2023*

INTRODUCTION

Multidrug-resistant tuberculosis (MDR-TB) is a globally important public health problem. Rifampicin-resistant (RR) and MDR-TB strains are more difficult to treat than drug-susceptible tuberculosis (TB) and threaten global progress toward End-TB Strategy targets.[1] Multidrug-resistant tuberculosis is multifactorial. It feeds on mistakes made in treatment and difficulties in drug supply.[2] In addition, the coronavirus disease 2019 (COVID-19) pandemic has adversely affected the fight against TB.[3-5]

Multidrug-resistant tuberculosis is resistant to both isoniazid (INH) and rifampicin. There may also be other drug resistance together. Rifampicin is the most important drug in the treatment of TB; once resistance develops, treatment of patients with TB becomes difficult. Rifampicin-resistant/multidrug-resistant tuberculosis requires treatment with second-line drugs.[6] In the treatment of MDR-TB, less effective drugs are used when compared to the treatment of drug-susceptible TB. It is more toxic, long-lasting, and expensive. Success rates are lower.[7,8]

Therefore, with this study, we aimed to evaluate the demographic, clinical data, resistance rates, and treatment results of RR/MDR-TB patients diagnosed and followed up in our hospital.

MATERIALS AND METHODS

Patient Data

Rifampicin-resistant/multidrug-resistant tuberculosis patients diagnosed and treated in the Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital between 2010 and 2018 were analyzed retrospectively in terms of demographic, clinical, side effects, treatment success, and mortality. Informed consent for clinical treatment was obtained from all patients taken to the study. For this study, 22/07/2020 dated approval was obtained from the Ethics Committee of the Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital with the number 16. Data from the patients were analyzed through hospital archive records.

Chest x-rays and, if available, thorax computed tomography of the cases recorded in the hospital imaging system were examined. The radiological extent was evaluated under 2 groups as one-lung and two-lung involvement.

Corresponding author: Onur Karaman, e-mail: karaman.onur@hotmail.com

Copyright@Author(s) - Available online at thoracrespract.org. Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Microbiological Data

For each sample, acid-resistance staining with standard fluorochrome and/or Kinyoun method, culture on BACTEC 960 (MGIT) (Becton Dickinson, Sparks, Md, USA) system, and Löwenstein–Jensen medium were performed. The susceptibility test of patient samples was performed using the BACTEC 960 (MGIT) system in accordance with the manufacturer's recommendations. Drug resistance in new cases was defined as drug resistance observed in patients who had not used TB drugs before or had used them for less than a month. In treated cases, drug resistance was defined as resistance to a drug that the patient had previously used for more than 1 month.[9,10]

Treatment and Follow-Up Data

The drugs were classified according to the recommendations of the World Health Organization (WHO) and the National Tuberculosis Guidelines, which were up-to-date in the time period (between 2010 and 2018) of the patients we included in the study.[11] At least 5 active drugs, 1 parenteral and 1 quinolone, were included in the treatment regimen of the MDR-TB patient. Drugs that were sensitive in the drug sensitivity test but had never been used before were regarded as active drugs, whereas drugs that had been used in the past yet were sensitive in the test were seen as suspicious drugs. Drugs that were resistant and that had previously been used were both accepted as inactive. While creating the treatment regimen of the MDR-TB patient, the drugs were added step by step from the first group to the fifth group.

Grouping Antituberculosis Agents

Group 1

First-line oral agents: Isoniazid (H); rifampicin (R); ethambutol (E); pyrazinamide (Z); rifabutin (Rfb)

Group 2

Injectable agents: Kanamycin (Km); amikacin (Am); capreomycin (Cm); streptomycin (S)

Group 3

Fluoroquinolones: Moxifloxacin (Mfx); levofloxacin (Lfx); ofloxacin (Ofx)

Group 4

Oral bacteriostatic second-line agents: Ethionamide (Eto); protionamide Pto); cycloserine (Cs); terizidone (Trd); p-aminosalicylic acid (PAS)

Group 5

Agents with unclear efficacy (not recommended by WHO for routine use in MDR-TB patients): Clofazimine (Cfz); linezolid (Lzd); amoxi cilli n/cla vulan ate (Amx/Clv); thioacetazone (Thz); imipenem/cilastatin (Ipm/Cln); high-dose isoniazid (high-dose H); clarithromycin (Clr).

MAIN POINTS

- In the treatment of multidrug-resistant tuberculosis, less effective drugs are used when compared to the treatment of drug-susceptible tuberculosis. It is more toxic, long-lasting, and expensive. Success rates are lower.
- High treatment success rates are possible in patients with rifampicin-resistant or multidrug-resistant tuberculosis treated under direct observation.
- The fight against multidrug-resistant tuberculosis should be continued with determination without compromising the foreseen program, despite all obstacles, including the coronavirus disease 2019 pandemic era.

For MDR-TB, a regimen consisting of at least 5 active drugs from 5 groups of drugs was applied according to the guideline recommendation. In this treatment, amikacin, capreomycin, moxifloxacin, ofloxacin, linezolid, cycloserine, prothionamide, para-aminosalicylic acid, and thioacetazone were used by choosing according to susceptibility and side effects. For the MDR-TB treatment initiation period, a regimen consisting of at least 5 drugs and parenteral drugs was used for at least 6 months until sputum smear and cultures were consistently negative. Drugs were given regularly by a directly observed treatment (DOT) program. For the treatment of 13 RR-TB patients, the regimen using first-option drugs recommended in the same guideline was applied. In addition, special treatment consisting of first-option drugs was administered to 8 MDR-TB patients who did not accept the second-option drug treatment specified in the guideline. Amikacin was preferred as the parenteral drug in the second-option drug treatment, and capreomycin was used according to culture in 2 patients. Moxifloxacin was preferred as quinolone. Ofloxacin was used in 11 patients. The treatment was administered under direct observation. The treatment period was applied for 24 months after the culture became negative. The updated WHO 2020 guidelines recommend an all-oral bedaquiline (Bdq)-based shorter regimen in place of the previously recommended injectable-based shorter regimen, with one of the key eligibility criteria being that patients are not resistant to the fluoroquinolones. The shorter regimen comprises (6 Bdq plus 4-6 Lfx/Mfx-Cfz-Eto-)-Hh-E-Z/5 Lfx/Mfx-Cfz-E-Z. The WHO 2020 guidelines also recommend a 6- to 9-month regimen that comprises a new medicine, pretomanid, together with Bdq and linezolid (i.e., the BPaL regimen) for the treatment of MDR-TB with additional resistance to fluoroquinolones; however, this regimen is to be used under operational research conditions only. However, in the time period during which our study was undergoing, Bdq-based shorter regimen was not reached because there were no resources available for this course of treatment.[12]

For the sputum conversion period, the date of the first negativity was used when the smear and cultures of 2 groups of sputum taken at least 30 days apart were negative. In patients who completed treatment without evidence of treatment failure criteria, 3 or more consecutive negative cultures that were taken at least 30 days apart after the baseline period were defined as cure. Patients who completed the treatment without any signs of failure but did not show 3 or more consecutive negative cultures that were taken at least 30 days apart after the initial period were considered to be treatment completion. The sum of the cases with cure and treatment completion was taken as treatment success.

Statistical Analysis

Statistically descriptive analyses were performed with Statistical Package for the Social Sciences software version 25.5 software (IBM Corp.; Armonk, NY, USA). Results were presented as median (min-max), number and percentage (%). Shapiro–Wilk and Kolmogorov–Smirnov tests of

normality were used to determine whether the parameters used in the comparison of the groups were normally distributed. Mann–Whitney U-test and Student's *t*-test were used to compare continuous variables, and chi-square and Fisher's exact tests were used to compare categorical data. Results were presented as median (min-max), mean ± SD, and number and percentage (%). $P < .05$ was considered statistically significant.

RESULTS

In our center, 109 patients were diagnosed with RR/MDR-TB. The mean age of 109 patients was determined as 46.3 ± 16.3 (17-81). Of 109 patients, 83 (76.1%) were male and 26 (23.9%) were female. Eight patients (7.3%) were foreign nationals (Table 1). Human immunodeficiency virus (HIV) was positive in 2 patients (1.8%). Of 109 (2.7%) patients, 3 had extrapulmonary TB. These were 1 pleurisy, 1 skin, and 1 lymphadenitis TB patient. In the radiological appearance of the lesions, involvement was detected in 1 lung in 26 patients (23.9%) and in 2 lungs in 83 patients (76.1%) (Table 2). There was additional disease in 33 (30.3%) patients. The most common comorbidities were diabetes mellitus 15.6%, cardiovascular 5.5%, and chronic renal failure 4.6%. Of 109 patients, 13 (11.9%) had RFM resistance not accompanied by INH. Amikacin resistance was studied in 71 (65.1%) patients, and resistance was detected in 8 (11.2%) patients. Moxifloxacin resistance was studied in 65 patients (59.6%), and resistance was found in 3 (4.6%) patients. Linezolid resistance was studied in 57 patients (52.2%), and resistance was detected in 2 (3.5%) patients. Pyrazinamide resistance was studied in 77 (70.6%) patients, and resistance was detected in 29 (37.6%) patients. Two patients had resistance to 9 drugs, and 8 patients had resistance to 8 drugs.

Table 1. Demographic Properties

	Patients (n = 109)
Properties	**n (%)**
Age, years, mean ± SD (min-max)	46.3 ± 16.3 (17.0-81.0)
Sex	
Female	26 (23.9)
Male	83 (76.1)
Educational status	
Illiterate	1 (0.9)
Primary education	47 (43.1)
High school	59 (54.2)
University	2 (1.8)
Marital status	
Married	79 (72.5)
Single	30 (27.5)
Profession	
Unemployed	36 (33.0)
Employed	53 (48.6)
Retired	20 (18.3)

Table 2. Clinical Properties

	Patients (n = 109)
Properties	**n (%)**
Smoking history	
Never smoked	26 (23.9)
Active smoker	69 (63.3)
Quit	14 (12.8)
Family history of MDR-TB	4 (3.7)
Comorbidity	
Diabetes mellitus	17 (15.6)
Cardiovascular	6 (5.5)
Chronic renal impairment	5 (4.6)
Malignancy	4 (3.6)
COPD	3 (2.7)
Chronic liver disease	1 (0.9)
Schizophrenia	1 (0.9)
Silicosis	1 (0.9)
Resistance history	
Drug resistance in new cases	46 (42.2)
Drug resistance in treated cases	63 (57.8)
Radiological involvement	
Single lung	26 (23.9)
Bilateral	83 (76.1)

COPD, chronic obstructive pulmonary disease; MDR-TB, multidrug-resistant tuberculosis.

Treatment

Since 5 out of 109 patients diagnosed with RR/MDR-TB emigrated to other countries, the treatment results of 104 patients were evaluated. The mean time between admission to the hospital and initiation of the treatment was 26.7 ± 30.4 (1.0-120.0) days (Table 3). The mean duration of the treatment initiation period was 5.8 ± 2.5 (1.0-14.0) months. The mean culture conversion time was 2.3 ± 1.6 (1.0-12.0) months. The duration of hospitalization was 6.4 ± 6.2 (0.0-36.0) months. The total treatment time was 21.1 ± 6.6 (8.0-30.0) months. Drug side effects were

Table 3. Treatment Characteristics

Duration (days) between admission and treatment initiation, mean ± SD (min-max)	26.7 ± 30.4 (1.0-120.0)
Initial period durations (months), mean ± SD (min-max)	5.8 ± 2.5 (1.0-14.0)
Culture conversion (months), mean ± SD (min-max)	2.3 ± 1.6 (1.0-12.0)
Duration of hospitalization (months), mean ± SD (min-max)	6.4 ± 6.2 (0.0-36.0)
Total treatment duration (months), mean ± SD (min-max)	21.1 ± 6.6 (8.0-30.0)
Patients underwent surgery	0 (0.0)

Table 4. Drug Side Effect

	Patients (n = 104)
	n (%)
No side effect	44 (42.3)
Side effect present	60 (57.7)
Hepatotoxicity	20 (19.2)
Ototoxicity	18 (17.3)
Psychiatric disorder	13 (12.5)
Hypothyroidism	12 (11.5)
Visual impairment	11 (10.6)
Nephrotoxicity	7 (6.7)
Hematological disorder	5 (4.8)
Neurotoxicity	4 (3.8)
Allergic reactions	2 (1.9)

observed in 60 patients (57.7%). The most common side effects were hepatotoxicity 19.2% and ototoxicity 17.3%. In 29 (27.9%) patients who experienced side effects, the drug was withdrawn from the treatment regimen (Table 4). No patient underwent surgical treatment.

As a result of the treatment, cure was achieved in 81 (77.9%) patients and treatment was completed in 13 (12.5%) (Table 5). Treatment success was found to be 94 (90.4%). All patients were followed up starting from the end of the treatment within the study period. No recurrence was detected in any patient. Ten patients (9.6%) died. Eight of the deaths were due to TB and 2 were due to non-tuberculous causes (malignancy, ruptured aortic aneurysm). The data were evaluated in terms of factors affecting the treatment outcome. Seventy-one (68.3%) patients treated with 5 or fewer drugs and 33 (31.7%) patients treated with 6 or more drugs were compared. The cure rate (90.9%) of the patients treated with 6 or more drugs was found to be higher than the other group (71.8%). This value was statistically significant ($P = .029$).

DISCUSSION

Treatment for multidrug-resistant tuberculosis is more expensive, carries a higher risk of adverse effects, and lasts longer than therapy for drug-susceptible TB. Therefore, it is the cause of increased mortality and morbidity and the treatment success rate is lower. However, successful treatments are possible with disciplined practices. In our study, there was no case with treatment failure or out of follow-up; 77.9% cure, 12.5% treatment completion rate was achieved, and

Table 5. Treatment Outcome

	Patients (n = 104)
	n (%)
Cured	81 (77.9)
Treatment completed	13 (12.5)
Treatment success	94 (90.4)
Treatment failed	0 (0.0)
Died	10 (9.6)
Recurrence	0 (0.0)

treatment success is 90.4%. No recurrence was detected during the 9-year follow-up. In one of the different RR/MDR-TB studies conducted in different centers, in the study of Törün et al.[13] 77.6% treatment success was reported. Karagöz et al[14] reported a cure rate of 86.4%, Arpağ et al[15] reported a cure rate of 84.4%, and Ünsal et al[16] reported a cure rate of 53.1% in their studies. The treatment success rate of RR/MDR-TB was reported as 57% in the World Health Organization Global Tuberculosis 2020 Report.[6] Brode et al[17] found treatment success as 83.9%. Singh et al[18] reported a 74.5% cure. The treatment success of our center is similar to or even higher than many other centers. Compared to the results of other studies, we attribute this high success rate to treatment with long-term hospitalization and treatment under direct observation.

In our study, the mortality rate was 9.6%. Karagöz et al[14] reported a mortality rate of 7.8%, Ünsal et al[16] reported a mortality rate of 3.7%, and Arpağ et al[15] reported a mortality rate of 7.8%. Singh et al[18] found a mortality rate of 10.2% in the study, and Xu et al[19] found a mortality rate of 8.6%. The results of the study were found to be similar to other studies. In addition, HIV positivity is one of the reasons that increase mortality in RR/MDR-TB patients. There was no HIV infection in 104 patients whom we gave the result of treatment, so a comparison could not be performed. After diagnosis, 5 patients for whom we did not present treatment results left to complete their treatment in their country or region (not evaluated case) and 2 of these patients were HIV-positive. In the study population, HIV-positive RR/MDR-TB comorbidity was observed in 2 foreign patients. Therefore, no data could be presented in our study on HIV infection and RR/MDR-TB comorbidity mortality.

In the radiology of our patients, 76.1% had involvement in both lungs. Karagöz et al[14] reported the rate of involvement in both lungs as 61.2% and Singh et al[18] as 94.9%. The fact

Table 6. Treatment Outcomes of Patients Treated in Accordance with the Drug Regime

	Cured Completed (n)	Treatment Follow-Up (n)	Lost to (n)	Died (n)
	n (%)	n (%)	n (%)	n (%)
First-line drugs (n = 21)	11 (52.3)	9 (42.8)	-	1 (4.7)
Second-line drugs (≤5 drugs) (n = 50)	40 (80.0)	3 (6.0)	-	7 (14.0)
Second-line drugs (≥6 drugs) (n = 33)	30 (90.9)	1 (3.0)	-	2 (6.0)

that most of the patients had extensive disease is a finding consistent with the literature.

Mean sputum conversion (culture conversion) was found as 2.3 ± 1.6 months. Arpağ et al[15] reported the mean sputum conversion 1.9 ± 1.03 months. Li et al[20] found an average of 85 days for sputum conversion (culture conversion) in 359 MDR-TB patients. As it is seen, our culture conversion rates are similar to other literature results.

The mean duration of hospitalization was 6.4 ± 6.2 months. Arpağ et al[15] reported the mean duration of hospitalization as 162.7 days and stated that long-term hospitalization increases the chance of treatment success. Olaru et al[21] reported the mean duration of hospitalization as 128 days. In our study, the mean total treatment duration was found as 21.6 ± 6.6 months. In the study by Olaru et al,[21] this period was reported as 19.5 months on average. The length of the hospitalization is higher in our study compared to other studies; we think that a longer duration of hospitalization increases the chance of DOT and increases the rate of coping with complications and side effects. We believe that the long duration of hospitalization has an effect on our high treatment success rates. Although the length of duration of hospitalization may have increased the cost, there is a need for studies on this subject.

Side effects were observed in 57.7% of the cases in this study. The most common side effect was hepatotoxicity with 19.2%. Ototoxicity was observed with a rate of 17.3%, and psychiatric disorders with a rate of 12.5%. The drug was withdrawn from the regimen in 27.9% of the cases. Törün et al[13] evaluated 263 MDR-TB cases in terms of side effects and found side effects at a rate of 69%, and the most common side effect was ototoxicity at a rate of 41.8%. Treatment changes were performed in 55% of patients who experienced adverse effects. Karagöz et al[14] found side effects at a ratio of 37.9%, Ünsal et al[16] 60.9%, and Arpağ et al[15] 45.5%. In a meta-analysis by Wu et al[22] in which 5346 MDR-TB patients were evaluated in terms of side effects, 57.3% of the patients were found to have experienced at least 1 side effect. The 3 most common adverse events were gastrointestinal disorders at a rate of 32.1%, ototoxicity at a rate of 14.6%, and psychiatric disorders at a rate of 13.2%. They found that MDR-TB treatment should be changed in 70.4% of the patients who developed side effects. Also in our study, side effects were observed in 1 of every 2 patients. Surgical treatment may be helpful in addition to medical treatment in the treatment of MDR-TB. In our study, no patient underwent surgical treatment. Karagöz et al[14] did not find a statistically significant difference between the groups with and without treatment success in terms of adjunctive surgical treatment. There are studies reporting that surgical resection increases the chance of treatment success.[23-25]

Although Karagöz et al[14] did not find a significant ratio between the number of drugs and treatment success in their study, an average of 5.3 ± 0.8 drugs were used in the treatment of MDR-TB in our study. The cure rate of patients who used 6 or more drugs in the treatment was found to be higher than the patients who used 5 drugs or less, and it was found to be statistically significant. (P = .029). Patients who used 6 or more drugs stayed at the hospital longer, but similar side effects and death rates were observed. We believe that these treatment regimens should be given a chance in patients who can tolerate 6 or more drugs, although they have achieved acceptable success rates with 5 drugs (Tables 6 and 7).

Table 7. Comparison of Treatment Characteristics According to Drug Groups in MDR-TB Patients

	Treatment with ≤5 Drugs	Treatment with ≥6 Drugs	
	n = 71	n = 33	
	n (%)	n (%)	*P*
Total duration of treatment (months) median (min-max)	18.0 (1.0-29.0)	25 (11.0-30.0)	.001
Duration of hospitalization (months) median (min-max)	4.0 (0.0-23.0)	8.0 (0.5-36.0)	.002
Side effect	37 (52.1)	23 (69.7)	.091
Cure	51 (71.8)	30 (90.9)	.029[+]
Treatment completion	12 (16.9)	1 (3.0)	.047
Treatment success	63 (88.7)	31 (93.9)	.402
Died rate	8 (11.3)	2 (6.1)	.402

MDR-TB, multidrug-resistant tuberculosis.
[+]Statistically significant.

In our study, 13 RR-TB and 8 MDR-TB patients were treated with first-line drugs. This is because in the national TB guideline recommendations between the years 2010 and 2018 when our study was conducted, first-line drugs were recommended to RR-TB patients. Eight MDR-TB patients are patients treated in the first years of this period, and major treatment was started until the results of resistance appear. Resistance tests were completed in 1 or 2 months. The first-line pharmacological therapy that the patients received during this time period was successful from a clinical, radiological, and laboratory aspect, and they refused the second-line therapy. Therefore, they completed their treatment with first-line drugs. Treatment success was achieved in these patients, and no recurrence was detected. There are other studies in the literature that applied major treatment in MDR-TB patients in the same years.[26,27] However, in the following years, as a result of the more frequent use of molecular rapid resistance tests in our hospital, the recommendations of the WHO and the new national TB guideline[9] and literature data, the diagnosis of RR/MDR-TB was made faster and second-line treatment was applied to each RR/MDR-TB patient.

CONCLUSION

Our study results showed that high treatment success rates are possible in patients with RR/MDR-TB treated under direct observation. The fight against TB is an important public health war. We believe that the fight against MDR-TB should be continued with determination without compromising the foreseen program, despite all obstacles, including the COVID-19 pandemic era.

Ethics Committee Approval: The study was approved by the medical ethics committee of the Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital with the number 16.

Informed Consent: Informed consent for clinical treatment was obtained from all patients taken to the study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – O.K., Y.V., T.A., Ç.A., M.Ş.D.; Design – C.B., D.Ö.; Supervision – Y.V., M.Ş.D.; Materials – O.K., T.A., C.B., D.Ö., M.Ş.D.; Data Collection and/or Processing – O.K.,T.A., Ç.A., C.B., D.Ö.; Analysis and/or Interpretation – O.K., Y.V., C.B.; Literature Review – O.K., Y.V., C.B.; Writing Manuscript – O.K., Y.V.; Critical Review – O.K., Y.V.

Declaration of Interests: The authors have no conflict of interest to declare.

Funding: This study received no funding.

REFERENCES

1. World Health Organization. *WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment*. Geneva; 2019. Available at: https://apps.who.int/iris/handle/10665/311389.
2. World Health Organization. *Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis*. Geneva: WHO/HTM/TB; 2014. Available at: https://apps.who.int/iris/handle/10665/130918.
3. Ong CWM, Goletti D. Impact of the global COVID-19 outbreak on the management of other communicable diseases. *Int J Tuberc Lung Dis*. 2020 May 1;24(5):547-548. [CrossRef]
4. Vilbrun SC, Mathurin L, Pape JW, Fitzgerald D, Walsh KF. Case report: multidrug-resistant tuberculosis and COVID-19 coinfection in Port-au-Prince, Haiti. *Am J Trop Med Hyg*. 2020;103(5): 1986-1988. [CrossRef]
5. Tiberi S, Vjecha MJ, Zumla A, Galvin J, Migliori GB, Zumla A. Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. *Int J Infect Dis*. 2021;113(suppl 1): S96-S99. [CrossRef]
6. World Health Organization. *Global Tuberculosis Report 2020*. Geneva; 2020. Available at: https://www.who.int/publications/i/item/9789240013131.
7. Ding P, Li X, Jia Z, Lu Z. Multidrug-resistant tuberculosis (MDR-TB) disease burden in China: a systematic review and spatio-temporal analysis. *BMC Infect Dis*. 2017;17(1):57. [CrossRef]
8. Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. *Eur Respir J*. 2014;43(2):554-565. [CrossRef]
9. Bakanlığı S. *Tüberküloz Tanı ve Tedavi Rehberi, 1129*. Ankara: Mayıs; 2019. Available at: https://hsgm.saglik.gov.tr/depo/birimler/tuberkuloz_db/haberler/Tuberkuloz_Tani_Ve_Tedavi_Rehberi_/Tuberkuloz_Tani_ve_Tedavi_Rehberi.pdf.
10. World Health Organization. *Anti-Tuberculosis Drug Resistance in the World. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance*. Fourth Global Report. Geneva: WHO/HTM/TB; 2008. Available at: http://apps.who.int/iris/bitstream/handle/10665/43889/WHO_HTM_TB_2008.394_eng.pdf?sequence=1.
11. Sağlık Bakanlığı. *Tüberküloz Tanı ve Tedavi Rehberi, 862*. Ankara; 2011. Available at: https://toraks.org.tr/site/sf/documents/pre_migration/0843354699a1757b76dde91155e96a9f72d0604ec89c5ed967e4db07dc77ad02.pdf 9
12. World Health Organization. *Meeting Report of the WHO Expert Consultation on the Definition of Extensively Drug-Resistant Tuberculosis, 27-29 October 2020*. Geneva: World Health Organization; 2021. Available at: https://www.who.int/publications/i/item/meeting-report-of-the-who-expert-consultation-on-the-definition-of-extensively-drug-resistant-tuberculosis.
13. Törün T, Güngör G, Ozmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis*. 2005;9(12):1373-1377. Available at: https://pubmed.ncbi.nlm.nih.gov/16468160/.
14. Karagöz T, Duman YD, Pazarlı P, Moçin YÖ. Treatment results of multi-drug resistant tuberculosis patients whose treatments were managed by a single center and with an indirect observation during whole treatment [in Turkish]. *Solunum*. 2009;11(1): 1-6. Available at: https://www.journalagent.com/eurasianjpulmonol/pdfs/SOLUNUM_11_1_1_6.pdf.
15. Arpağ H, Yalçınsoy M, Güngör S, Kuyucu T, Atilla N. Treatment outcomes of pulmonary multidrug-resistant tuberculosis; 10 year follow up study. *Med J*. 2021;3(1):26-30. [CrossRef]
16. Ünsal E, Güler M, Ofluoglu R, Capan N, Cimen F. Factors associated with treatment outcome in 64 HIV negative patients with multidrug resistant tuberculosis. *J Thorac Dis*. 2013;5(4):435-439. [CrossRef]
17. Brode SK, Varadi R, McNamee J, et al. Multidrug-resistant tuberculosis: treatment and outcomes of 93 patients. *Can Respir J*. 2015;22(2):97-102. [CrossRef]
18. Singh A, Prasad R, Kushwaha RAS, et al. Treatment outcome of multidrug-resistant tuberculosis with modified DOTS-plus strategy: a 2 years' experience. *Lung India*. 2019;36(5):384-392. [CrossRef]
19. Xu C, Pang Y, Li R, et al. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. *J Infect*. 2018;76(4):348-353. [CrossRef]
20. Li Q, Lu M, Hsieh E, et al. Time to sputum culture conversion and its predictors among patients with multidrug-resistant tuberculosis in Hangzhou, China: a retrospective cohort study. *Med (Baltim)*. 2020;99(50):e23649. [CrossRef]
21. Olaru ID, Lange C, Indra A, Meidlinger L, Huhulescu S, Rumetshofer R. High rates of treatment success in pulmonary multidrug-resistant tuberculosis by individually tailored treatment regimens. *Ann Am Thorac Soc*. 2016;13(8):1271-1278. [CrossRef]
22. Wu S, Zhang Y, Sun F, et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. *Am J Ther*. 2016;23(2):e521-e530. [CrossRef]
23. Orki A, Kosar A, Demirhan R, Saygi A, Arman B. The value of surgical resection in patients with multidrug resistant tuberculosis. *Thorac Cardiovasc Surg*. 2009;57(4):222-225. [CrossRef]
24. Kir A, Inci I, Torun T, Atasalihi A, Tahaoglu K. Adjuvant resectional surgery improves cure rates in multidrug-resistant tuberculosis. *J Thorac Cardiovasc Surg*. 2006;131(3):693-696. [CrossRef]
25. Harris RC, Khan MS, Martin LJ, et al. The effect of surgery on the outcome of treatment for multidrug-resistant tuberculosis: a systematic review and meta-analysis. *BMC Infect Dis*. 2016;16:262. [CrossRef]
26. Saka D, Aydoğdu M, Çalışır HC, Çimen F, Öğretensoy M. The treatment results of retreatment pulmonary tuberculosis patients in our clinic [in Turkish]. *Tuberk Toraks*. 2011;59(2):111-119. [CrossRef]
27. Saravia JC, Appleton SC, Rich ML, Sarria tM, Bayona J, Becerra MC. Retreatment management strategies when first-line tuberculosis therapy fails. *Int J Tuberc Lung Dis*. 2005;9(4):421-429. Available at: https://pubmed.ncbi.nlm.nih.gov/15830748/.

Thorac Res Pract. 2023; 24(2): 109-112 DOI: 10.5152/ThoracResPract.2023.22075

Case Report

An Important Clinical Condition in Differential Diagnosis of Coronavirus Disease 2019: Crack Lung

Işıl Kibar Akıllı[1], Müge Bilge[2], Ekrem Bilal Karaayvaz[3]

[1]Department of Pulmonary Disease, University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey
[2]Department of Internal Medicine, University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey
[3]Department of Cardiology, İstanbul University, İstanbul Faculty of Medicine, İstanbul, Turkey

Cite this article as: Kibar Akıllı I, Bilge M, Karaayvaz EB. An important clinical condition in differential diagnosis of coronavirus disease 2019: Crack lung. *Thorac Res Pract.* 2023;24(2):109-112.

Abstract

Crack cocaine has been associated with a variety of pulmonary manifestations. We report a 44-year-old man been diagnosed with severe acute respiratory syndrome coronavirus 2 infection, presenting shortness of breath, non-productive cough, chest pain, headache, dizziness, and fever lasting for 2 days. At first, all findings of our patient called for an impression of coronavirus disease 2019. During admission, he presented with acute respiratory symptoms, patchy ground-glass opacities, and laboratory abnormalities, such as elevated acute phase response and lymphopenia. After, the presence of transient lung infiltrations in the follow-up triggered the cause for a re-evaluation of the diagnosis of coronavirus disease 2019. After a detailed inquiry, it was revealed that he had had a history of intense inhaled cocaine use 2 days before hospitalization. We speculate that the crack lung should also be considered in the differential diagnosis in patients with suspected coronavirus disease 2019 pneumonia.

KEYWORDS: Thorax CT, crack lung, crack cocaine, patchy ground-glass opacity, acute pulmonary injury
Received: *April 10, 2022* ***Accepted:*** *October 6, 2022* ***Publication Date:*** *March 28, 2023*

INTRODUCTION

Cocaine is one of the most widely used illegal drugs in the world. Because of its great propensity for addiction, it is a common cause of drug-related death. When cocaine hydrochloride combines with sodium bicarbonate and is extracted with ether, it is heated and smoked to generate crack cocaine. Crack cocaine has been linked to a range of pulmonary symptoms when inhaled. Crack lung states an acute syndrome of diffuse alveolar damage and hemorrhagic alveolitis that appears within 48 hours of smoking crack and it is a rare type of cocaine-related respiratory illness with distinct radiographic features. These radiographic features are nonspecific and include diffuse alveolar infiltrations and ground-glass opacities that usually go away once the drug is discontinued.[1,2]

In patients with coronavirus disease 2019 (COVID-19) pneumonia, crack lung should be considered in the differential diagnosis due to the similarity of its clinical, laboratory, and radiological findings.

CASE REPORT

A 44-year-old man was admitted to emergency department of Prof. Dr. Murat Dilmener Emergency Hospital with a history of shortness of breath, non-productive cough, chest pain, headache, dizziness, and fever lasting for 2 days. On examination, he was found to have tachypnea and tachycardia (respiratory rate was 24 bpm, pulse rate 100 bpm) with fever (37.7°C). On admission, his peripheral blood oxygen saturation (SpO_2) was 90% at room air. Peripheral blood oxygen saturation was measured as >93%, after starting with 5L/min oxygen by nasal cannula. He had no hemoptysis. During auscultation, in addition to diffuse expiratory rhonchi, inspiratory crackles were also detected in the bilateral basal fields. Physical examination did not reveal any other abnormality. There was no known history of any chronic disease. As a long-distance driver by profession, he had a cigarette smoking history of 40 packs a year and a moderate level of alcohol consumption. His electrocardiogram showed sinus tachycardia, but his echocardiography was normal. Complete blood count and comprehensive metabolic panel analyses were performed. Most of the laboratory findings were significantly high, such as C-reactive protein (478 mg/L), procalcitonin (3.28 ng/mL), D-dimer (2.49 µgFEU/mL), fibrinogen (684 mg/dL), troponin I (36 ng/mL), ferritin (4380 µg/L), aspartate transaminase (343 U/L), alanine transaminase (98 IU/L), gamma-glutamyl transpeptidase (52 U/L), lactate dehydrogenase (1171 U/L), and creatine phosphokinase (11357 U/L), suggesting COVID-19. Additionally, he had hyponatremia (125 mmol/L), lymphopenia (0.47 cells/mL), and low eosinophil (0.01 cells/mcL) count. At the admission, arterial blood gases analysis showed respiratory alkalosis and hypoxemia. Serologic testing for autoimmune antibodies and vasculitis consist of rheumatoid factor, antinuclear antibodies, antibodies to double-stranded DNA, cytoplasmic antineutrophil cytoplasmic autoantibodies, perinuclear antineutrophil cytoplasmic autoantibodies, anti-cyclic citrullinated peptide antibodies, and serum complement components C3 and C4 levels

Corresponding author: Işıl Kibar Akıllı, e-mail: isilkibar@yahoo.com

Copyright@Author(s) - Available online at thoracrespract.org. Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.




Figure 1. (A) Chest computed tomography (CT) on admission. Consolidation in the left upper and middle zone. (B-D) Chest CT scan on admission, showing diffuse ground-glass opacities containing air bronchograms in the left lung upper lobe, multifocal and patchy ground-glass opacities with nodular infiltration in the left lung lower lobe, left-sided minimal pleural effusion (13 mm), and ground-glass opacities in the anterior segment of the right lung lower lobe. (E) Control chest x-ray demonstrating consolidations with patchy bilateral ground-glass opacities on the fifth day.

yielded negative results. Viral hepatitis, HIV antigens, and a series of sputum for acid-fast bacilli smear and culture were also negative.

A computed tomography (CT) scan of the patient's chest revealed diffuse ground-glass opacities containing air bronchograms, predominantly perihilar in the left lung upper lobe, multifocal and patchy ground-glass opacities with nodular infiltration in the left lung lower lobe, left-sided minimal pleural effusion (13 mm), and ground-glass opacities in the anterior segment of the right lung lower lobe (Figure 1A-D).

The patient has been treated with a presumed diagnosis of COVID-19 and/or atypical pneumonia based on clinical, laboratory, and radiological findings, and after that, a real-time polymerase chain reaction (PCR) sample was requested under pandemic conditions. In accordance with the guideline of the Turkish Health Ministry's COVID-19 treatment protocol, he was started favipravir (1.6 g twice daily on day 1, followed by 600 mg twice daily for 4 days), low-molecular-weight heparin (LMWH, enoxaparin sodium 4000 U/0.4 mL/day, subcutaneous) and parenteral methylprednisolone (1 mg/kg methylprednisolone for 5 days) was implemented due to acute hypoxemic respiratory failure.[3] Additionally, he was given an empirical antibiotic (moxifloxacin 400 mg/day for 5 days), and oxygen support by nasal cannula (5 L/min).

Despite the decrease in his complaints in the following days, his oxygen support continued. Control chest x-ray scan showed a marked regression of the infiltration in the left lung and the emergence of new infiltrations in the middle and lower zones of the right lung on the fifth day (Figure 1E). A decrease in acute phase response with an increase in transaminases and D-dimer (3.9 µgFEU/mL) values were observed in the subsequent laboratory results. Pulmonary CT angiography was performed in order to exclude the possibility of any pulmonary embolism on the eighth day following admission. No filling defect was observed but parenchymal imaging showed a significant reduction in left lung opacities, while new ground-glass opacities were appearing in the lower lobe of the right lung similar to that in the chest x-ray scan (Figure 2). After that, real-time PCR remained negative on 2 occasions. The patient was re-evaluated due to the rapidly changing radiological findings with clinical suspicion. After a detailed inquiry, it was revealed that he had a history of heavy inhaled cocaine use 2 days before hospitalization. He was a regular crack smoker at least for 5 years, but he had no complaints regarding the pulmonary system in the past. Also, he had smoked cannabis for 10 years. Afterward, his urine toxicology was found to be positive for cocaine. Considering all these findings, we thought that the diagnosis is crack lung.

Although there are no specific clinical or laboratory findings for crack lung which can help for its discrimination from COVID-19 pneumonia, treatment protocols are similar for these conditions. During the follow-up, his dyspnea was recovered and SpO_2 was found 98% at room air. His laboratory findings and his radiologic findings returned to normal within 10 days. He was discharged with a follow-up appointment and referred to a psychiatry clinic.

MAIN POINTS

- Cocaine is one of the most widely used illegal drugs in the world. Because of its great propensity for addiction, it is a common cause of drug-related death. Crack cocaine has been linked to a range of pulmonary symptoms when inhaled.
- Crack lung states an acute syndrome of diffuse alveolar damage and hemorrhagic alveolitis that appears within 48 hours of smoking crack. Crack lung is a rare type of cocaine-related respiratory illness with distinct radiographic features. These radiographic features are nonspecific and include diffuse alveolar infiltrations and ground-glass opacities that usually go away once the drug is discontinued.
- There are no specific differentiable clinical, laboratory, and radiological findings for crack lung which can help for its discrimination from coronavirus disease 2019 pneumonia.
- Most of the drug abusers deny cocaine use. Crack lung should also be considered within the differential diagnosis of patients presented with acute hypoxemic respiratory failure and bilateral pulmonary infiltrates.

DISCUSSION

"Crack lung" has been defined as an acute pulmonary syndrome that occurs after smoking crack cocaine.[1,4] Smoked cocaine leads to acute and chronic pulmonary complications including pulmonary edema, alveolar hemorrhage, eosinophilic pneumonia, bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, alveolar hemorrhage, pneumothorax, barotrauma, bullous lung disease, thromboembolic disease, and pulmonary hypertension. Diagnosis can be difficult due to nonspecific clinical features




Figure 2. (A-G) Pulmonary computed tomography angiography on the eighth day. The left lung opacities regressed significantly, while new ground-glass opacities developed in the lower lobe of the right lung. (H) Complete radiological resolution, chest x-ray 10 days following presentation.

including acute pulmonary syndrome and chest imaging in crack lung.[1,2,5,6] Suspicion, a detailed history, and physical examination are required to obtain a diagnosis.

At first, all clinical and laboratory findings of our patient suggested COVID-19. During admission, he presented with acute respiratory symptoms, patchy ground-glass opacities, and laboratory abnormalities, such as elevated acute phase response and lymphopenia. Interestingly, most laboratory findings that have been reported in the crack lung are similar to COVID-19, including elevated troponin,[7] liver enzymes,[8] C-reactive protein,[9] and lymphopenia.[10] Empirical antibiotics were given to the patient before the sputum test results because of probable bacterial etiology. A recently reported meta-analysis showed that high procalcitonin levels are associated with severe COVID-19[11]; however, increased procalcitonin levels were also reported in amphetamine and sympathomimetic drug overdose.[12] In addition to that, another recent meta-analysis showed that procalcitonin levels are not sensitive enough to direct the decision of antibiotic usage in patients with community-acquired pneumonia.[13]

Our patient's consecutive real-time PCR tests were negative, and CT images were compatible with radiological findings of COVID-19. However, the presence of transient lung infiltrations in the follow-up prompted us to re-evaluate the diagnosis of COVID-19. Previous studies on crack lung and thorax CT findings reported that pathological findings such as consolidation, ground-glass opacities, cavitations, and airspace nodules were usually found bilaterally and in the upper lobes. The chronological association between crack cocaine usage and the symptoms observed at the beginning and the rapid resolution of pulmonary lesions discontinued after drug use enabled us to diagnose "crack lung".[2,6]

The treatment approach for crack lung primarily consists of the use of supplemental oxygen, bronchodilators, supportive fluid treatment, and ventilatory support if required.[1] Administration of LMWH is necessary for the thromboembolism prophylaxis of COVID-19, as well as in the treatment of cocaine-induced in situ thrombosis.[14] There were reports about steroid benefits in severe cases.[4] However, steroid usage is controversial.[15]

In our COVID-19 treatment protocol, the use of corticosteroids was recommended for patients who needed oxygen support, which is why corticosteroids were used in this patient.[3] Rapid clinical improvement may be associated with corticosteroid therapy and/or cessation of drug use.

Finally, there are no specific pathognomonic clinical, laboratory, or radiological findings for crack lung which can help for its discrimination from COVID-19 pneumonia or other pathologies such as pneumonia, cryptogenic organized pneumonia or BOOP, eosinophilic pneumonia, and cardiogenic pulmonary edema. As information about recreational drugs is poorly transferred, a structured approach to taking a medication history would be of utmost importance when this condition is among the differential diagnosis. When a ground-glass opacity pattern is seen at a chest CT scan, crack lung should also be taken into consideration for a differential diagnosis.

Informed Consent: Written informed consent for publication concerning all photographic materials for this case report was received.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – I.K.A., M.B.; Design – I.K.A., M.B.; Supervision – I.K.A., M.B.; Materials – I.K.A., M.B.; Data Collection and/or Processing – I.K.A., M.B.,E.B.K.; Analysis and/or Interpretation – I.K.A., M.B.; Literature Review – I.K.A., M.B.,E.B.K.; Writing – I.K.A., M.B.; Critical Review – I.K.A., M.B.

Acknowledgments: The authors wish to thank Prof. Dr. Ahmet Ademoğlu for his help with the interpretation of the data.

Declaration of Interests: The authors have no conflict of interest to declare.

Funding: This study received no funding.

REFERENCES

1. Forrester JM, Steele AW, Waldron JA, Parsons PE. Crack lung: an acute pulmonary syndrome with a spectrum of clinical and histopathologic findings. *Am Rev Respir Dis*. 1990;142(2):462-467. [CrossRef]
2. Almeida RR de, Zanetti G, Souza Jr AS, et al. Cocaine-induced pulmonary changes: HRCT findings. *J Bras Pneumol*. 2015;41(4):323-330. [CrossRef]
3. Republic of Turkey Ministry of Health. COVID-19 (SARS-CoV-2 infection) guide. Available at: https://covid19.saglik.gov.tr/TR-66926/eriskin-hasta-tedavisi.html. Accessed March 21, 2022.
4. Devlin RJ, Henry JA. Clinical review: major consequences of illicit drug consumption. *Crit Care*. 2008;12(1):202. [CrossRef]
5. Restrepo CS, Carrillo JA, Martínez S, Ojeda P, Rivera AL, Hatta A. Pulmonary complications from cocaine and cocaine-based substances: imaging manifestations. *RadioGraphics*. 2007;27(4):941-956. [CrossRef]
6. Mançano A, Marchiori E, Zanetti G, Escuissato DL, Duarte BC, Apolinário L de A. Complicações pulmonares após uso de crack: achados na tomografia computadorizada de alta resolução do tórax. *J Bras Pneumol*. 2008;34(5):323-327. [CrossRef]
7. Riley ED, Hsue PY, Vittinghoff E, et al. Higher prevalence of detectable troponin I among cocaine-users without known cardiovascular disease. *Drug Alcohol Depend*. 2017;172:88-93. [CrossRef]
8. Pateria P, de Boer B, MacQuillan G. Liver abnormalities in drug and substance abusers. *Best Pract Res Clin Gastroenterol*. 2013;27(4):577-596. [CrossRef]
9. Meng Q, Lima JA, Lai H, et al. Elevated C-reactive protein levels are associated with endothelial dysfunction in chronic cocaine users. *Int J Cardiol*. 2003;88(2-3):191-198. [CrossRef]
10. Jankowski MM, Ignatowska-Jankowska B, Glac W, Swiergiel AH. Cocaine administration increases CD4/CD8 lymphocyte ratio in peripheral blood despite lymphopenia and elevated corticosterone. *Int Immunopharmacol*. 2010;10(10):1229-1234. [CrossRef]
11. Ji P, Zhu J, Zhong Z, et al. Association of elevated inflammatory markers and severe COVID-19: a meta-analysis. *Medicine*. 2020;99(47):e23315. [CrossRef]
12. Lovas A, Ágoston Z, Késmárky K, Hankovszky P, Molnár Z. Extreme procalcitonin elevation without proven bacterial infection related to amphetamine abuse. *Case Rep Crit Care*. 2014;2014:179313. [CrossRef]
13. Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. *Clin Infect Dis*. 2020;70(3):538-542. [CrossRef]
14. Sharma T, Kumar M, Rizkallah A, Cappelluti E, Padmanabhan P. Cocaine-induced thrombosis: review of predisposing factors, potential mechanisms, and clinical consequences with a striking case report. *Cureus*. 2019;11(5):e4700. [CrossRef]
15. Haim DY, Lippmann ML, Goldberg SK, Walkenstein MD. The pulmonary complications of crack cocaine. A comprehensive review. *Chest*. 1995;107(1):233-240. [CrossRef]

Thorac Res Pract. 2023; 24(2): 113-116 DOI: 10.5152/ThoracResPract.2023.22012

Case Report

Pseudoaneurysm as an Etiological Cause of Hemoptysis in Extensive Tuberculosis

Martina Mikanović[1], Ivona Markelić[2], Zagorka Boras[2], Vesna Trkeš[2], Ana Hećimović[2,3], Ante Marušić[2,3], Andrea Vukić Dugac[2,3]

[1]Department of for Lung Ddiseases, Hospital for Lung Diseases and Tuberculosis Klenovnik, Klenovnik, Croatia
[2]Clinic for Respiratory Diseases Jordanovac, University Hospital Center Zagreb, Zagreb, Croatia
[3]University of Zagreb, School of Medicine, Zagreb, Croatia

Cite this article as: Mikanović M, Markelić I, Boras Z, et al. Pseudoaneurysm as an etiological cause of hemoptysis in extensive tuberculosis. *Thorac Res Pract.* 2023;24(2):113-116.

Abstract

Hemoptysis is a life-threatening emergency and a possible first sign of pulmonary tuberculosis. Minor hemoptysis, as a possible clinical aspect of adult tuberculosis, usually has limited course and in most cases, is resolved with antitubercular therapy. However, massive hemoptysis is a life-threatening condition associated with a mortality rate of >50% in the absence of well-timed and proper handling. Hence, prompt diagnosis and early interventions are essential. In this study, we present a rare case of pseudoaneurysm causing massive hemoptysis in a patient with pulmonary tuberculosis.

KEYWORDS: Pseudoaneurysm, tuberculosis, hemoptysis
Received: *January 25, 2022* ***Accepted:*** *October 18, 2022* ***Publication Date:*** *February 6, 2023*

INTRODUCTION

Tuberculosis is still a major threat to public health in the world.[1] It represents diagnostic and therapeutic challenges as it can present numerous forms of complications that may involve the lung parenchyma, airways, pleura, or pulmonary vessels.[1] Cavitation, bronchiectasis, and pleural disease are the most seen and described complications that are opposite to the vascular complications which are rare sequelae of pulmonary tuberculosis. However, the latter has a very high mortality rate.[1]

Pseudoaneurysm is a rarity caused by the weakening of the pulmonary artery wall from adjacent cavitary tuberculosis. Progressive weakening of the arterial wall occurs as granulation tissue replaces both the adventitia and the media. The granulation tissue in the vessel wall is then gradually replaced by fibrin, resulting in thinning of the arterial wall, pseudoaneurysm formation, and subsequent rupture.

The aim of this study is to emphasize the importance of early identification of pseudoaneurysm as a cause of potentially life-threatening bleeding in pulmonary tuberculosis.

CASE PRESENTATION

A 51-year-old male, a salesman by profession, a long-term smoker, with a history of diabetes mellitus, gastritis, and severe sideropenic anemia, was hospitalized due to serious conditions, massive hemoptysis and acute respiratory failure.

He complained of a productive cough that lasted for months with severe hemoptysis that had occurred 7 days before hospitalization. Additionally, he reported recent night sweats, progressive fatigue, shortness of breath, and weight loss.

The physical examination showed dyspnea at rest and diffuse auscultatory wet rales but stable vital signs. In the initial laboratory investigation, we find microcytic anemia, leukocytosis, elevated C-reactive protein, hypokalemia, hyponatremia, and hypoalbuminemia. The classic chest x-ray showed inhomogeneous shading of the upper lung lobe on the right with a large round soft tissue shadow of 7.7 cm in diameter located in the middle lung lobe on the right with bilateral spotted infiltrates (Figure 1). Written informed consent was obtained from the patient for publication of his medical data, including images.

The patient underwent flexible bronchoscopy as an initial procedure to investigate massive hemoptysis because it has potential diagnostic as well as therapeutic benefits. But the procedure was interrupted before bronchoscopic sampling was even started because of the intolerance of the patient.

Upon stabilization of the patient, we performed a computed tomography (CT) scan which showed a completely morphologically altered upper lung lobe to the right with wide bronchial spaces and volume reduction and destruction.

Corresponding author: Andrea Vukić Dugac, e-mail: adugac71@gmail.com

Copyright@Author(s) - Available online at thoracrespract.org. Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.




Figure 1. Inhomogeneous shading of the upper lung lobe on the right with a large round soft tissue shadow of 7.7 cm in diameter located in the middle lung lobe on the right with bilateral spotted infiltrates.

Diffuse bilateral varicose and cylindrical bronchiectasis of markedly thickened bronchial walls with mucoid impacts were also shown. Furthermore, it showed a large consolidation in the anterior segment of the lower lung lobe on the right and within the consolidation foci of destruction with pseudoaneurysm sizes of 23 and 26 mm. Lymphadenopathy of the mediastinum and a lower group of paratracheal and subcarinal lymph nodes were also described (Figure 2).

Acid-resistant bacilli were recorded in the sputum by direct microscopy, with a subsequent positive culture for *Mycobacterium tuberculosis*. The QuantiFERON test was negative. The patient was diagnosed to have extensive pulmonary tuberculosis with pseudoaneurysm within the inflammatory consolidation of the right lower lobe.

Conservative treatment of hemoptysis was performed due to the stable vital signs of patient. It included strict bed rest, cough suppressant, tranexamic acid, and blood transfusion. Further, we started the first-line antituberculous therapy (isoniazid, rimactane, ethambutol, pyrazinamide, and streptomycin). *The patient's clinical condition gradually improved, and there was no need for bronchial artery embolization (BAE) or urgent surgical procedures.*

MAIN POINTS

- Tuberculosis is still a major threat to public health in the world, and hence, it requires prompt diagnosis and an early treatment plan.
- Pseudoaneurysm could be a cause of life-threatening bleeding in pulmonary tuberculosis
- Comprehensive awareness and knowledge of atypical tuberculosis manifestations as well as extremely rare tuberculosis-related pulmonary vascular complications are crucial.




Figure 2. Consolidation in the anterior segment of the lower lung lobe on the right and within the consolidation foci of destruction with pseudoaneurysm sizes of 23 and 26 mm.

A control chest x-ray performed after 3 weeks showed that the infiltrate of the anterior segment of the lower right lobe is in the partial regression and the infiltrate of the right apical is stationary with a smaller amount of gas inclusion (Figure 3). Also, control CT pulmonary angiography after 3 weeks showed complete regression of the previously described pseudoaneurysm *as well as partial regression of the consolidation* (Figure 4). *The patient's follow-up period was 2 years.*

DISCUSSION

Hemoptysis in the presence of tuberculosis can be due to varied etiopathologies like bronchiectasis, aspergillomas, bronchiolitis, scar carcinoma, chronic bronchitis, microbial colonization within a cavity, and vascular abnormalities such as pseudoaneurysms.

The infection has been associated with pseudoaneurysms in the systemic circulation but is seen less commonly in the pulmonary circulation. We need to mention that there are also a few non-infectious as well as iatrogenic cases that could possibly be associated with pseudoaneurysm formation.[2]




Figure 3. Infiltrate of the anterior segment of the lower right lobe is in the partial regression and the infiltrate of the right apical is stationary size with a smaller amount of gas inclusion.




Figure 4. Complete regression of the previously described pseudoaneurysm in the consolidation of the anterior segment of the lower lobe to the right, which is regressive in size.

In our case, pseudoaneurysm was a very rare complication of pulmonary tuberculosis. These pseudoaneurysms, which were first described in 1868 by Fritz Valdemar Rasmussen, can originate in the bronchial vasculature (most frequently, in up to 90% of cases), non-bronchial systemic arteries, or pulmonary artery branches.[3]

Aneurysmal dilatation of the pulmonary artery adjacent to the cavity (Rasmussen's pseudoaneurysm) is one of these vascular complications which are estimated to occur in 0.25% of patients with pulmonary tuberculosis. It usually presents clinically by massive hemoptysis thus carrying an extremely high mortality rate that exceeds 38%.[4]

The pulmonary artery pseudoaneurysm associated with tuberculosis is thought to be caused by contiguous spread from the tuberculous cavity, which leads to tissue destruction from the outer vessel wall toward the lumen. The affected vessel wall is prone to break down, leading to rupture and pseudoaneurysm formation.[5] Computed tomography angiography is the preferred diagnostic modality for pulmonary artery pseudoaneurysm. In the literature, the prevalence of pulmonary artery pseudoaneurysm ranges from 5% to 11% in patients with tuberculosis presenting with hemoptysis.[6]

Since hemoptysis is a life-threatening condition, early intervention with diagnostic and therapy plans in patients with respiratory or hemodynamic compromise not responding to the conservative treatment is mandatory. The treatment of choice is BAE or if it is further required surgery, either urgent or planned – delayed, which mainly depends on the patients' clinical status. The risk of mortality in patients who underwent urgent surgery was higher versus planned-delayed surgery; therefore, it is impelling to accomplish preoperative optimization.[7]

Previous similar case presentations have revealed that the treatment of choice was BAE with only 1 case report in which surgery was conducted.[8-11]

Comprehensive knowledge of atypical tuberculosis manifestations as well as extremely rare tuberculosis-related pulmonary vascular complication is crucial since early antituberculosis treatment introduction could contribute to conservative treatment of hemoptysis.

Informed Consent: Written informed consent was obtained from the patient.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – A.V.D., I.M.; Design – A.V.D., M.M.; Supervision – A.V.D., Z.B.; Materials – Vesna Trkeš, M.M.; Data Collection and/or Processing – M.M., I.M.; Analysis and/or Interpretation – A.H., A.M.; Literature Review – M.M., I.M.; Writing – M.M., I.M.; Critical Review – A.V.D.

Declaration of Interests: The authors have no conflict of interest to declare.

Funding: The authors declared that this study has received no financial support.

REFERENCES

1. *Global Tuberculosis Report 2020*. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
2. Nguyen ET, Silva CI, Seely JM, Chong S, Lee KS, Müller NL. Pulmonary artery aneurysms and pseudoaneurysms in adults: findings at CT and radiography. *AJR*. 2007;188(2):W126-W134. [CrossRef]
3. Håkanson E, Konstantinov IE, Fransson SG, Svedjeholm R. Management of life-threatening haemoptysis. *Br J Anaesth*. 2002;88(2):291-295. [CrossRef]
4. Ivković S, Milosavljević T, Ivković A. MDCT with angiography in Rasmussen aneurysms. *Eur Respir J*. 2014;44(suppl 58):P2631.
5. Bartter T, Irwin RS, Nash G. Aneurysms of the pulmonary arteries. *Chest*. 1988;94(5):1065-1075. [CrossRef]
6. Chen Y, Gilman MD, Humphrey KL, et al. Pulmonary artery pseudoaneurysms: clinical features and CT findings. *AJR Am J Roentgenol*. 2017;208(1):84-91. [CrossRef]
7. Peghini Gavilanes E, López Yepes LA, Peñalver Paolini CL, Morales Ruiz R. Rasmussen's pseudoaneurysm in a patient with a history of pulmonary tuberculosis. *Arch Bronconeumol*. 2015;51(2):96-97. [CrossRef]
8. Pekçolaklar A, Çitak N, Aksoy Y, Erdoğu V, Sayar A, Metin M. Surgery for life-threatening massive hemoptysis; does the time of performed surgery and the timing of surgery affect the rates of complication and mortality? *Indian J Surg*. 2022;84(1):149-156. [CrossRef]

9. Jaber JF, Innabi A, Patel DC. Rasmussen's aneurysm: a rare and potentially fatal cause of hemoptysis. *Adv Respir Med*. 2021. [CrossRef]
10. Albogami S, Touman AA. Rasmussen's pseudoaneurysm- case report. *Respir Med Case Rep*. 2018;25:150-153. [CrossRef]
11. Rajamannar KV, Kilaru H, Aravelly S, Gudipati AR, Kilaru SC. Massive hemoptysis from Rasmussen's aneurysm in active pulmonary tuberculosis; A case report of successful treatment with bronchial artery embolization. *Respir Med Case Rep*. 2017;22:277-279. [CrossRef]